IL127871A - PHARMACEUTICAL COMPOSITIONS CONTAINING CRF ANTAGONIST 3-ARYL-PYRAZOLO (AND 1,2,3-TRIAZOLO) [1,5-a]-1,3,5-TRIAZINE DERIVATIVES AND SOME NEW SUCH DERIVATIVES - Google Patents

Description

127871 ,7-n I 453328 τηκ i iTXTD- -iN-S ηπ^ιη arw CRF πλυ οι17·ο»π mnpn •'Tuon Π^ΪΟ munn rmVin nasi riN o-S^ -ta-S J ^Tx a-S^,!-!) PHARMACEUTICAL COMPOSITIONS CONTAINING CRF ANTAGONIST 3-ARYL-PYRAZOLO (AND l,2,3-TRIAZOLO)[l,5-a]-l,3,5-TRIAZINE DERIVATIVES AND SOME NEW SUCH DERIVATIVES DUPONT PHARMACEUTICALS COMPANY C33053 FIELD OF THE INVENTION This invention relates to the use of compounds for the manufacture of a medicament for treatment of psychiatric disorders and neurological diseases including major depression, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress. The aforesaid compounds include certain pyrazolo-[l,5-a]-l,3,5-triazines, l,2,3-triazolo-[l,5-a]-l,3,5-triazines, pyrazolo-[l,5-a]-pyrimidines and l,2,3-triazolo-[l,5-o]-pyrimidines. This invention also relates to some novel such compounds.

BACKGROUND OF THE INVENTION Corticotropin releasing factor (herein referred to as CRF), a 41 amino acid peptide, is the primary physiological regulator of proopiomelanocortin(POMC) -derived peptide secretion from the anterior pituitary gland [J. Rivier et al., Proc. Nat. Acad. Sci. (USA) 80:4851 (1983); W. Vale et al., Science 213: 1394 (1981)]. In addition to its endocrine role at the pituitary gland, immunohistochemical localization of CRF has demonstrated that the hormone has a broad extrahypothalamic distribution in the central nervous system and produces a wide spectrum of autonomic, electrophysiological and behavioral effects consistent with a neurotransmitter or neuromodulator role in brain [W. Vale et al., Rec. Prog. Horm. Res. 39:245 (1983); G.F. Koob, Persp. Behav. Med. 2:39 (1985); E.B. De Souza et al., J.

Neurosci. 5:3189 (1985) ] . There is also evidence that CRF plays a significant role in integrating the response of the immune system to physiological, psychological, and immunological stressors [J.E. Blalock, Physiological Reviews 69:1 (1989); J.E. Morley, Life Sci . 41:527 (1987) ] .

Clinical data provide evidence that CRF has a role in psychiatric disorders and neurological diseases including depression, anxiety-related disorders and feeding disorders. A role for CRF has also been postulated in the etiology and pathophysiology of Alzheimer' s disease, Parkinson's disease, Huntington's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis as they relate to the dysfunction of CRF neurons in the central nervous system [for review see E.B. De Souza, Hosp. Practice 23:59 (1988)] .

In affective disorder, or major depression, the concentration of CRF is significantly increased in the cerebral spinal fluid (CSF) of drug-free individuals [C.B. Nemeroff et al . , Science 226:1342 (1984) ; CM. Banki et al . , Am. J. Psychiatry 144:873 (1987) ; R.D. France et al., Biol. Psychiatry 28:86 (1988) ; M. Arato et al., Biol Psychiatry 25:355 (1989) ] . Furthermore, the density of CRF receptors is significantly decreased in the frontal cortex of suicide victims, consistent with a hypersecretion of CRF [C.B. Nemeroff et al., Arch. Gen. Psychiatry 45:577 (1988)] . In addition, there is a blunted adrenocorticotropin (ACTH) response to CRF (i.v. administered) observed in depressed patients [P.W. Gold et al., Am J. Psychiatry 141:519 (1984); F. Holsboer et al., Psychoneuroendocrinology 9:147 (1984) ; P.W. Gold et al., New Eng. J. Med. 314:1129 (1986) 3. Preclinical studies in rats and non-human primates provide additional support for the hypothesis that hypersecretion of CRF may be involved in the symptoms seen in human depression [R.M. Sapolsky, Arch. Gen. Psychiatry 46:1047 (1989)]. There is preliminary evidence that tricyclic antidepressants can alter CRF levels and thus modulate the numbers of CRF receptors in brain [Grigoriadis et al., Neuropsychopharmacology 2:53 (1989)].

There has also been a role postulated for CRF in the etiology of anxiety-related disorders. CRF produces anxiogenic effects in animals and interactions between benzodiazepine / non-benzodiazepine anxiolytics and CRF have been demonstrated in a variety of behavioral anxiety models [D.R. Britton et al., Life Sci. 31:363 (1982); C.W. Berridge and A.J. Dunn Regul. Peptides 16:83 (1986)]. Preliminary studies using the putative CRF receptor antagonist a-helical ovine CRF (9-41 ) in a variety of behavioral paradigms demonstrate that the antagonist produces "anxiolytic-like" effects that are qualitatively similar to the benzodiazepines [C.W. Berridge and A.J. Dunn Horm. Behav. 21:393 (1987), Brain Research Reviews 15:71 (1990)]. Neurochemical, endocrine and receptor binding studies have all demonstrated interactions between CRF and benzodiazepine anxiolytics providing further evidence for the involvement of CRF in these disorders. Chlordiazepoxide attenuates the "anxiogenic" effects of CRF in both the conflict test [ .T. Britton et al., Psychopharmacology 86:170 (1985); .T. Britton et al., Psychopharmacology 94:306 (1988)] and in the acoustic startle test [N.R. Swerdlow et al., Psychopharmacology 88:147 (1986)] in rats. The benzodiazepine receptor antagonist (Ro 15- 1788), which was without behavioral activity alone in the operant conflict test, reversed the effects of CRF in a dose- 150163/3 dependent manner while the benzodiazepine inverse agonist (FG7142) enhanced the actions of C F [K.T. Britton et al., Psychopharmacology 94:306 (1988)].

The mechanisms and sites of action through which the standard anxiolytics and antidepressants produce their therapeutic effects remain to be elucidated. It has been hypothesized however, that they are involved in the suppression of the CRF hypersecretion that is observed in these disorders. Of particular interest is that preliminary studies examining the effects of a CRF receptor antagonist (a - h elical CRFc)_4 ] ) in a variety of behavioral paradigms have demonstrated that the CRF antagonist produces "anxiolytic-like" effects qualitatively similar to the benzodiazepines [for review see G.F. Koob and K.T. Britton, In: Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide, E.B. De Souza and C.B. Nemeroff eds., CRC Press p221 (1990)].

Several publications describe corticotropin releasing factor antagonist compounds and their use to treat psychiatric disorders and neurological diseases. Examples of such publications include DuPont Merck PCT application US94/1 1050, Pfizer WO 95/33750, Pfizer WO 95/34563, Pfizer WO 95/33727 and Pfizer EP 0778 277 Al.

Insofar as is known, pyrazolo-[l,5-a]-l,3,5-triazines, l,2,3-triazolo-[l,5-a]-1 ,3,5-triazines, pyrazolo-[l,5-fl]-pyrimidines and l,2,3-triazolo-[l,5-o]-pyrimidines, have not been previously reported as corticotropin releasing factor antagonist compounds useful in the treatment of psychiatric disorders and neurological diseases. However, there have been publications which teach some of these compounds for other uses.

For instance, EP 0 269 859 (Ostuka, 1988) discloses pyrazolotriazine compounds of the formula where R1 is OH or alkanoyl, R2 is H, OH, or SH, and R3 is ar. unsaturated heterocyclic group, naphthyl or. substituted phenyl, and states that the compounds have xanthine oxidase inhibitory activity and are useful for treatment of gout.

EP 0 594 149 (Ostuka, 1994) discloses pyrazolotriazine and pyrazolopyrimidine compounds of the formula where A is CH or N, R° and R3 are H or alkyl, and R1 and R2 are H, alkyl, alkoxyl, alkylthio, nitro, etc., and states that the compounds inhibit androgen and are useful in treatment of benign prostatic hypertrophy and prostatic carcinoma.

US 3,910,907 (ICI, 1975) discloses pyrazolotriazines of the formula: where Rl is CH3, C2H5 or C6H5, X is H, C6H5, m-CH3C6H4, CN, COOEt, CI, I or Br, Y is H, CeH5, o-CH3C6H4, or p- CH3C6H4, and Z is OH, H, CH3, C2H5, C6H5, n-C3H7, 1-C3H7, SH, SCH3, NHC4H9 , or N(C2H5) 2, and states that the compounds are c-AMP phosphodiesterase inhibitors useful as bronchodilators .

US 3,995,039 discloses pyrazolotriazines of the formula: where R1 is H or alkyl, R2 is H or alkyl, R3 is H, alkyl, alkanoyl, carbamoyl, or lower alkylcarbamoyl, and R is pyridyl, pyrimidinyl, or pyrazinyl, and states that the compounds are useful as bronchodilators.

US 5,137,887 discloses pyrazolotriazines of the formula wh.^re R is lower alkoxy, and teaches that the compounds are xanthine oxidase inhibitors and are useful for treatment of gout.

US 4,692,576 discloses pyrazolotriazines of the formula where X is 0 or S, Ar is a phenyl, naphthyl, pyridyl or thienyi group, R6-Re ar« H, alkyl, etc., and R9 is H, alkyl, phenyl, etc. The patent states that the compounds are useful as herbicides and plant growth regulants .

US 5,484,760 and WO 92/10098 discloses herbicidal compositions containing, among other things, a herbicidal compound of the formula 127871/2 where A can be N, B can be CR3, R3 can be phenyl or substituted phenyl, etc., R is -N(R )S02R5 or -S02N(R5)R7 and R]_ and R2 can be taken together to form z Y z Y x D Nr=c c=r=z:c or N C N c where X, Y and Z are H, alkyl, acyl , etc. and D is 0 or US 3,910,907 and Senga et al . , J. Med. Chem., 1982, 25, 243-249, disclose pyrazolotriazines cAMP phosphodiesterase inhibitors of the formula where Z is H, OH, CH3/ C2H5( C6H5, n-C3H7, iso-C3H7, SH, SCH3, NH(n-C4H9), or N(C2H5)2, R is H or CH3 , and Rx is CH-3 or C2H5. The reference lists eight therapeutic areas where inhibitors of cAMP phosphodiesterase could have utility: asthma, diabetes mellitus, female fertility control, male infertility, psoriasis, thrombosis, anxiety, and hypertension .

W095/35298 (Otsuka, 1995) discloses pyrazolopyrimidines and states that they are useful as analgesics. The compounds are represented by the formula where Q is carbonyl or sulfonyl, n is 0 or 1, A is a single bond, alkylene or alkenylene, R1 is H, alkyl, etc., R2 is naphthyl, cycloalkyl, heteroaryl, substituted phenyl or phenoxy, R3 is H, alkyl or phenyl, R4 is H, alkyl, alkoxycarbonyl , phenylalkyl, optionally phenvlthio-substituted phenyl, or halogen, R5 and R6 are H or alkyl .

EP 0 591 528 (Otsuka, 1991) discloses antiinflammatory use of pyrazolopyrimidines represented by the formula R3 where Ri, R2/ 3 and R4 are H, carboxyl, alkoxycarbonyl, optionally substituted alkyl, cycloalkyl, or phenyl, R5 is SRg or R7 R8 , R6 is pyridyl or optionally substituted phenyl, and R7 and Rs are H or optionally substituted phenyl .

Springer et al, J. Med. Chem., 1976, vol. 19, no. 2, 291-296 and Springer U.S. patents 4021,556 and 3,920,652 disclose pyrazolopyrimidines of the formula where R can be phenyl, substituted phenyl or pyridyl, and their use to treat gout, based on their ability to inhibit xanthine oxidase.

Joshi et al., J. Prakt . Chemie, 321, 2, 1979, 341-344, discloses compounds of the formula where R1 is CF3, C2F5, or C 6H4 F , and R2 is CH3, C2H5, CF3, or CgK4F. 127871/2 Maquestiau et al . , Bull. Soc. Belg., vol. 101, no. 2, 1992, pages 131-136 discloses a pyrazolo [1, 5-a] pyrimidine of the formula Ibrahim et al., Arch. Pharm. (Weinheim) 320, 487-491 (1987) discloses pyrazolo [ 1, 5-a] pyrimidines of the formula where R is NH2 or OH and Ar is 4-phenyl-3-cyano-2-aminopyrid-2-yl .

Other references which disclose azolopyrimidines include EP 0 511 528 (Otsuka, 1992), US 4,997,940 (Dow, 1991), EP 0 374 448 (Nissan, 1990), US 4,621,556 (ICN, 1997), EP 0 531 901 (Fujisawa, 1993), US 4,567,263 (BASF, 1986), EP 0 662 477 (Isagro, 1995), DE 4 243 279 (Bayer, 1994), US 5,397,774 (Upjohn, 1995), EP 0 521 622 (Upjohn, 1993), WO 94/109017 (Upjohn, 1994), J. Med. Chem. , 24, 610-613 (1981), and J. Het. Chem., 22, 601 (1985).

SUMMARY OF THE INVENTION In accordance with one aspect, the present invention provides novel compounds, and pharmaceutical compositions which may be used in the treatment of affective disorder, anxiety, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, gastrointestinal disease, anorexia nervosa or other feeding disorder, drug or alcohol withdrawal symptoms, drug addiction, inflammatory disorder, fertility problems, disorders, the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, or a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic, phobias, obsessive-compulsive disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; fatigue syndrome; stress-induced headache; cancer, human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases such as ulcers, irritable bowel syndrome, Crohn's disease, spastic colon, diarrhea, and post operative ilius and colonic hypersensitivity associated with psychopathological disturbances or stress; hemorrhagic stress; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiarrhetic hormone (ADH); obesity; head traumas; spinal cord trauma; ischemic neuronal damage (e.g., cerebral ischemia such as cerebral hippocampal ischemia); excitotoxic neuronal damage; epilepsy; cardiovascular and heart related disorders including hypertension, tachycardia and congestive heart failure; stroke; immune dysfunctions including stress induced immune dysfunctions (e.g., stress induced fevers, porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, and dysfunctions induced by confinement in chickens, shearing stress in sheep or human-animal interaction related stress in dogs); muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multi infarct dementia; amyotrophic lateral sclerosis; chemical dependencies and addictions (e.g., dependencies on alcohol, cocaine, heroin, benzodiazepines, or other drugs); osteoporosis; psychosocial dwarfism and hypoglycemia in a mammal.

According to another aspect, the present invention provides novel compounds of Formulae (1) and (2) (described below) which are useful as antagonists of the corticotropin releasing factor. The compounds of the present invention exhibit activity as corticotropin releasing factor antagonists and appear to suppress CRF hypersecretion. The present invention also includes pharmaceutical compositions containing such compounds of Formulae (1) and (2), and methods of using such compounds for the suppression of CRF hypersecretion, and/or for the treatment of anxiogenic disorders.

According to yet another aspect of the invention, the compounds provided by this invention (and especially labelled compounds of this invention) are also useful as standards and reagents in determining the ability of a potential pharmaceutical to bind to the CRF receptor.

NOTICE UNDER COMMISSIONER'S CIRCULAR NO. (P)23 Portions of the present specification that fall outside the scope of the claims do not relate directly to the present invention. This Notice is not meant to disclaim any legitimate rights to which the Patentee is legally entitled, especially any rights in accordance with Section 49 of the Law.

DETAILED DESCRIPTION OF INVENTION •[1] The present invention comprises the use of compounds in the preparation of medicaments for treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRP, including but not limited to disorders induced or facilitated by CRP, in mammals said medicaments suited for administration to the mammal a therapeutically effective amount of a compound, of Formulae (1) or (2): (1) (2) and isomers thereof, stereoisomeric fonns thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof, wherein: 127871/3 A is N Z is N or CR2; Ar is selected from phenyl, naphthyl, pyridyl, pyrimidinyl , triazinyl, furanyl, thienyl, benzothienyl , benzofuranyl , 2 , 3-dihydrobenzofuranyl, 2, 3-dihydrobenzothienyl, indanyl, 2H-l-benzopyranyl, 3 , -dihydro-2H-l-benzopyranyl , and tetralinyl, each Ar optionally substituted with 1 to 5 R4 groups; R1 is selected from H, Ci-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halo, CN, Ci-C4 haloalkyl, Ci-C12 hydroxyalkyl , C2- Ci2 alkoxyalkyl, C2-Ci0 cyanoalkyl, C3-C6 cycloalkyl, C4-Ci0 cycloalkylalkyl, NR9R10, Ci-C4 alkylene-NR9R10, NR9COR10, OR11, SH or S (0) nR12; R2 is selected from H, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, Ci-C4 hydroxyalkyl, halo, CN, NR6R7, NR9COR10, NR6S(0)nR7, S(0)nNR6R7, Ci-C4 haloalkyl, OR7, SH or S(0)nR12; R3 is selected from: -CrC]o alkyL C2-C]0 alkenyl, C2-C]0 alkynyl, C3-C3 cycloalkyi, Cj-Cg cycloalkenyl, Q-C]2 cycloalkylalkyl or C6-C]0 cycloalkenylalkyL each optionally substituted with 1 to 3 substituents independent!)' selected at each occurrence from C]-Cs alkyl, C3-C6 cycloalk}']. halo, C]-C4 haloalkyl, cyano OR15, SH, S(0)nR13, COR15, CO2R15, OC(0)R13, ]\¾SCOR 53 N(COR15)2;. NRsCONR16R15, N 8C02R13, NR16Ri5; CONR16R15, aryl, heteroaryi and heterocyclyl, or -H: OR7, SH, S(0)nR13, COR7, CO2R7, OC(0)R13, NR8COR7, (COR7)2, NRsCONR6R7, NR8C02R13; NR6aR7 , N(OR7)R6, CONR6R7,. aryl, heteroaryi and heterocyclyl; is independently selected at each occurrence from: Cj-Cio alkyl. C2-C10 alkenyl, C2~C]0 alkynyl. C3-C6 cycloalkyi, C4-C12 cycloalkylalkyl, N02, halo, CN, C1-C4 haloalkyl, NR6R7, R8COR7, NR8C02R7, COR7, OR7, CO R6R7, CO( OR9)R7, CO2R7, or S(0)nR7, where each such Q-Cio alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C6 cycloalkyi and C4-C12 eye] oalkyl alkyl are optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C4 alkyl, O2, halo, CN, NR6R7. NRsCOR7 NRsCO?R7 COR7, OR7, CONR6R7 CO2R7, C0( 0R9)R7, or S(0)nR7; R^ and R7. R°a and R7a are independently selected at each occurrence from: (a) -Cj-Cio alkyl, C3-C10 alkenyl, C3-C10 alkynyl, C]-C]o haloalkyl with 1-10 halogens, C2-Cg alkoxyalkyk C3-C6 cycloalk)'!, C4-C12 cycloalkylalkyl, C5-C10 cycloalkenyl, or 5-C14 cycioalkenylalkyl, each optionally substituted with 1 to 3 substituents independent!}' selected at each occurrence from C1-C6 alky c3-c6 cycloalkyi halo, C1-C4 haloalkyl, cyano, OR15, SH, S(0)fiR13, COR15, C02R15, OC(0)R13, NRsCOR15, N(COR15)2,-NR8CONR16R15, NR8C02R13, NR16R] 5: CONR16R15, aryl, heteroary] or heterocyclyl, (b) -H, -aryl, alkyl). heteroaryi. heteroaiyl(Ci-C4 alkyl), heterocyclyl or heterocyc]yl(Ci-C4 alkyl); alternatively, R^R and R^aR7a are independent]}' piperidino, pyrrolid o, piperazino, - N-methylpiperazino, morpholino or thiomoipholino, each optionally substituted with 1-3 C1-C4 alio,'] groups; R8 is independent])' selected at each occurrence from H or C]-C4 alkyl; R9 and R1^ are independent]}' selected at each occurrence from H. C1-C4 alkyl, or C3-C6 cycloalk}'!: R11 is selected from H, C1-C4 alk)'l, C1-C4 haloalkyl, or C3-C6 cycloalk)'!; R12 is C-J-C4 alkyl or C1-C4 haloalkyl; R13 is selected from C1-C4 alkyl, C]-C4 haloalkyl, C2-C alkoxyalky], C3-C6 cycloalkyl, C4-C12 cycloalkylalky], aryl, aiyl(C]-C4 alkyl)-. heteroary! or heteroary!(C]-C4 alkyl)-: R14 is selected from (a) C]-C]0 alkyl, C3-C10 alkenyL C3-C10 alkynyl. C3-Cg cycloalkyl. or C4-C12 cycloalkylallcyl, ■ each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C]-C6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR15, SH, S(0)nR] 5, COR15, CO2R15, OC(0)R15, NR8COR15, N(COR15)2, NR8CONR16R15, NR8C02R15, R]6R15. CO R16R1 and (b) C\-C$ alkylthio, C\-CQ alkylsulfinyl and Cj-Cg alkylsulfonyl; R15 and R1^ are independently selected at each occurrence from H, Cj-Cg allyl, C3-C10 cycloalkyl, C4-C16 cycloalkylallcyl, except that for S(0)nR15, R15 can ot be H: aryl is phenyl or naphthyl, each optionally substituted with 1 to 5 substituents independent!}' selected at each occurrence from Ci-Cg allcyl, C3-C6 cycloalkyl, halo, Q-C4 haloalkyl, cyano, OR15. SH, S(0)nR]5, COR15, CO2R15, OC(0)R15, NRsCOR15, (COR15)2, NR8CONR36R15, NRsC02R]5, R16R15;and CONR16R15: heteroaiyl is pyridyl. pyrimidinyl, triazinyl. furanyl, pyranyl. quinolinyl. isoquinolinyl. thien)'l, imidazolyl, thiazolyl, indolyl, pjirolyl. oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, isoxazolyl, pyrazolyl.2.3-dihydrobenzothienyl or 2,3-dihydrobenzofurany], each being optionally substituted with 1 to 5 substituents independently selected at each occurrence from C]-C6 alkyl, C3-C6 cycloalkyl halo, C1-C4 haloalk-yl, cyano, OR15, SH, S(0)nR15, -COR15, CO2R15, OC(0)R15, NR8COR15, (CQR15)2, NRsCO R16R15, R8C02R15, NR16R15, and CONR36R35: heterocycly] is saturated or partially saturated heteroaryl. optionally substituted with 3 to 5 substituents independently selected at each occurrence from C]-C6 alkyl. C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR15, SH, S(0)DR35, COR35, CO2R15, OC(0)R15, NR8COR15, N(COR]5)2,NR8CONR16R15,NR8C02R]5,NR15R16, and CONR36R35; and n is independently at each occurrence 0, ] or 2, 127871/3 with the provisos that: (a) when R1 is -(CrC2 alkylene)-0-(CrC2 alkyl) or -(C|-C2 alkylene)-OH, then at least one of the following conditions (i), (ii) and (iii) is true: (i) the compound is a compound of formula (2); (ii) Ar is selected from optionally substituted naphthyl, optionally substituted triazinyl, optionally substituted furanyl, optionally substituted thienyl, optionally substituted benzothienyl, optionally substituted benzofuranyl, optionally substituted 2,3-dihydrobenzofuranyl, optionally substituted 2,3-dihydrobenzothienyl, optionally substituted indanyl, optionally substituted 2H-1- benzopyranyl, optionally substituted 3,4-dihydro-2H-l-benzopyranyl, and optionally substituted tetralinyl; (iii) R3 is selected from H, SH, S(0)„R13 wherein n > 1, C02R7, OC(0)R13, NR8COR7, N(COR7)2, NR CONR6R7, NR8C02R13, N(OR7)R6, CONR6R7, aryl other than optionally substituted phenyl, heteroaryl other than (a) optionally substituted pyrazinyl, (b) optionally substituted pyrimidyl or (c) optionally substituted pyridazinyl, or heterocyclyl; (b) when R3 is C5-C8 cycloalkenyl or C6-Ci0 cycloalkenylalkyl, then at least one of the following conditions (i). (ii) and (iii) is true: (i) the compound is a compound of formula (2); (ii) Ar is selected from optionally substituted naphthyl, optionally substituted triazinyl, optionally substituted furanyl, optionally substituted thienyl, optionally substituted benzothienyl, optionally substituted benzofuranyl, optionally substituted 2,3-dihydrobenzofuranyl, optionally substituted 2,3-dihydrobenzothienyl, optionally substituted indanyl, optionally substituted 2H-l-benzopyranyl, optionally substituted 3,4-dihydro-2H-l-benzopyranyl, and optionally substituted tetralinyl; (iii) R1 is selected from C -C4 alkenyl, C2-C4 alkynyl, CN, Ci-C4 haloalkyl, C3-Ci2 hydroxyalkyl, C - C12 alkoxyalkyl other than -(Ci-C2 alkylene)-0-(CrC2 alkyl), C2-C,0 cyanoalkyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, NR9R16, C,-C4 alkylene-NR9R10,: NR9COR16, OR1 1, SH or S(0)nR12; and (c) when Z is CR2, R1 is H, R2 is H, and Ar is unsubstituted pyridyl or unsubstituted pyrimidinyl, then R3 is not -NH2, -NR8COR7 wherein R7 is C,-C5 alkyl, NR8CONR6R7 wherein R6 is H or C,-C5 alkyl, or -NR6aR7a wherein R6a and R7a are each independently selected from H and CrC5 alkyl; in the preparation of a medicament for treating a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in a mammal, substantially as described in the specification. [2] Preferred compositions of the present invention are compositions wherein the compound of Formulae (1) or (2), Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, each optionally substituted with 1 to 4 R4 substituents. [3] Further preferred compositions of the above invention are compositions wherein, in the compound of Formulae (1) or (2), A is Ν,.Ζ is CR2, Ar is 2,4-dichlorophenyl, 2,4-dimethylphenyl or 2,4,6-trimethylphenyl, R1 and R2 are CH3, and R3 is NR6aR7a. [4] The present invention comprises compounds of Formulae (1 ) or (2): Ar Ar (1) (2) and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and phannaceutically acceptable salt or pro-dmg forms thereof wherein: 127871/3 A is N; Z is N or CR2: Ar is selected from phenyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, benzothienyl, benzofuranyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, indanyl, 2H-l -benzopyranyl, 3,4- dihydro-2H-l-benzopyranyl, tetralinyl, each Ar optionally substituted with 1 to 5 R4 groups; R1 is selected from H, C,-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halo, CN, C,-C4 haloalkyl, C,-Ci2 hydroxyalkyl, C2-C12 alkoxyalkyl, C2-Ci0 cyanoalkyl, C3-C6 cycloalkyl, C4-C,o cycloalkylalkyl, NR9R10, C,-C4 alkylene-NR R10, NR9COR10, OR", SH or S(0)„R12; R" is selected from H, Ci-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C6 cycloalkyl, C4-Ci0 cycloalkylalkyl, C,- C4 hydroxyalkyl, halo, CN, -NR6R7, NR'COR10, -NR6S(0)„R7, S(0)„NR6R7, C,-C4 haloalkyl, -OR7, SH or -S(0)nR12; R3 is selected from: (a) -C|-Cio alkyl, C2-Ci0 alkenyl, C2-Ci0 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C4-Ci2 cycloalkylalkyl or C6-Cio cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C,-C6 alkyl, C3-C6 cycloalkyl, halo, CrC haloalkyl, cyano, OR15, SH, S(0)nR13, COR15, C02R15, OC(0)R13, NR8C0R", N(COR15)2, NR8C0NR16R15, NR8C02R13, NR16R", C0NRI 6R15, aryl, heteroaryl and heterocyclyl, or (b) -H, OR7, SH, S(0)nR13, COR7, C02R7, OC(0)R13, NR8COR7, N(COR7)2, NR8CONR6R7, NR8C02R'3, NR6aR7a, N(OR7)R6, CONR6R7, aryl, heteroaryl and heterocyclyl; R" is independently selected at each occurrence from: C -ClQ alkyl, C2-Ci0 alkenyl, C2-Ci0 alkynyl, C3-C6 cycloalkyl, C4-C,2 cycloalkylalkyl, N02, halo, CN, C,-C4 haloalkyl, NR6R7, NR8COR7, NR8C02R7, COR7, OR7, CONR6R7, CO(NOR9)R7, C02R7, or S(0)nR7, where each such C,-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-Q cycloalkyl and C -Ci2 cycloalkylalkyl are optionally substituted with 1 to 3 substituents independently selected at each occurrence from CrC4 alkyl, N02, halo, CN, NR6R7, NR8C0R7, NR8C02R7, COR7, OR7, CONR6R7, C02R7, CO(NOR9)R7, or S(0)„R7; R6 and R7, R6a and R7a are independently selected at each occurrence, from: (a) -CrC|0 alkyl, C3-C|0 alkenyl, C3-Ci0 alkynyl, Ci-Qo haloalkyl with 1-10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C -C|2 cycloalkylalkyl, C5-Ci0 cycloalkenyl, or C6-C|4 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C]-Cs alkyl, C3-Q5 cycloalkyl. halo. C1-C4 haloalkyl, cyano. OR1 S(0)n 13, COR15, C02R] 5, OC(0)R13, NR8COR15, (COR15)2, NR8CONPJ 6R15, R8C02R13, NR36R15, CONR16Ri5, aryl, heteroaryl or heterocyclyl, (b) -H, -aryl, aryl(C] -C4 ally]), heteroaryl, heteroaryl(G]-C4 alio,']), heterocyclyl or heterocyclyl(C]-C4 alkyl), alternatively, NR^R^ and E^ r^a are independently piperidino, pyiTolidino, piperazino, N-methylpiperazino, morpholino or tliiomorpholino;, each optionally substituted with 1 alkyl groups: is independent!}' selected at each occurrence from H or C1-C4 alkyl; R9andRlO are independently selected at each occurrence from H, C1-C4 alkyl, or C3-C6 cycloalkyl; R13 is selected from H, C1-C4 alkyl, C31-C4 haloalkyl, or C3-C6 cycloalkyl; R12 is C1-C4 alky] or C1-C4 haloalkyl; R j is selected from C1-C4 alkyl, C1-C4 haloalkyl, C-2-Cg alkoxyalkyl, C3-C6 cycloallyl, C4-C 12 cycloalkylalkyl. -.aryl, aryl(C ] -C4 alkyl)-, heteroaryl or heteroaryl(C \ -C4 alkyl)-: R14 is selected from C\-C\Q alkyl, C3-C10 alkenyl, C3-C10 alkynyl, C3-Cg cycloalkyl, or G4-C12 cycloalkylalkyl, each optional]}' substituted with 1 too substituents independently selected at each occurrence from C]-C6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano. OR15, SH, S(0)nR15, COR15, CO2R15, OC(0)R]5, NR8COR15, N(COR]5)2, NR8CONR16R15, NR8C02R15, NR16R15, C02\T 36R15, and C]-C6 aDcylthio, Cj-C6 alkylsulfiny] and C]-C6 alkylsulfonyl: R 5 and R1^ are independently selected at each occurrence from H, C]-C6 alkyl. C3-C]0 cycloalkyl, 'C4-C16 cycloalkylalkyl, except that for S(0)nR15; R15 cannot be H; ary] is phenyl or naphtbyl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from C]-C6 alkyl, C3-C0 cycloalkyl, halo. Q-C4 haloalkyl, cyano, OR15, SH, S(0)nR15, COR15, C02R15, OC(0)R1≤, R8COR15, (COR]5)2; NR8CONR16R15, NR8C02 15, N 16R 15 , an d CONR 36R 15 ; heteroaryl is pyridyl, pyrimitiiny], triaziny], furanyl, pyranyl, quinolinyl, isoquinolinyl, thienyj, i nidazolyl, thiazolyl. indolyl, pj'rrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, isoxazo3yl, pyrazoly], 2,3-dibydrobenzothienyl or 2,3-dihydrobenzofuranyl;' each being optionally substituted with 1 to 5 substituents independently selected at each occurrence from C] -C6 alky], C3 -C0 cycloalkyl, halo, C3 -C4 haloalkyl, cyano, OR1 5, SH, S(0)D 1 5, -COR1 5, CO2R3 5, OC(0)R15, NR8COR1 5, N(COR15)2, NR8CONR1 6R1 5, NK8C02K 1 5, NR] 6R1 5: and CO R] 6R1 5; heterocycly] is saturated or partially saturated heteroaryl, optionally substituted with ] to 5 substituents independently selected at each occuiTence from C\ -Cs alkyl, C3-C6 cycloalkyl, halo, C3 -C4 haloalkyl, cyano, OR35, SH, S(Oy 35, COR15, C02R15, OC(0)R15, RsCOR15, N(COR35)2, NR¾ONR36R35, NR£C02R35, M 15R36, and CONR36R15; n is independently at each occurrence 0, 1 or 2, with the provisos that: (1 ) when Z is CR2, R2 is H, R3 is -OR7 or -OCOR13, and R7 is H, then R1- is not H, OH or SH: (2) when Z is CR2, R! is CH3 or C2% R2 is H, and R3 is OH, H, CH3, C2H5, C6H5, 11-C3H7, i-C3H7, SH, SCH3, HC4H9, or N(C2H5)2> then Ar is not phenyl or m-CH3-pheny]; (3) ^ hen Z is. CR2. R3 is H, R2 is H,_and AT is unsubstiruted pyridyl or unsubstiruted pyrimidinyl then R3 is not -NH2) -NRBCOR7 wherein R7 is C C5 alkyl, RsCONR6R7 wherein R6 is H or Q-C5 alkyl, or -]\¾6¾¾ wherein R6a and R7a are each independent!}7 selected from H and Q-C5 alkyl; (4) when Z is CR2 and R2 is -NR6S02R7 or -SO? R6R7, then R3 is not OH or SH; (5) when Z is CR2, R] is H, SH, SC¾, methyl or ethyl, R2 is H. and R3 is H, OH. CH3: C2¾ C6H5: n-C3H7, iso-C3H7, SH, SCH3, NH(n-C4H9), or N(C2H5)2, then Ar is not unsubstiruted phenyl, m-ch!orophenyl or m-metbylpheny]; (6) when R! is -(CRC2 alky!ene)-0-(C]-C2 alky!) or -(Q-C? alkylene)-OH, then at least one of the following conditions (i), (ii) and (iii) is true: (i) the compound is a compound of formula (2); (ii) Ar is selected from optionally substituted naphthyl. triazmyl. furanyl, thienyl, benzotliienyl. benzoforanyl. 2.3 -dihydrobenzo furanyl, 2 -dibydrobenzothienyj. indanyl. . 2H-benzopyranyL 3:4-dibydro- 2H-benzopyranyl„ and tetralinyl: (iii) R3 is selected from H, SH; S(0)ER33 wherein n > I, CO2R7; OC(0)R]3; RsCOPv7, N(COR7)2, NRsCONR6R7J NR8C02R13, N(OR )R6, CON ^7, aryl other than optionally substituted phenyl; heteroaryl other than (a) optionally substituted pyrazinyl, (b) optionally substituted pynmidyl or (c) optionally substituted pyridazuryl. or heterocyclyh when R3 is C5-C2 cycloalken}'! or C6-C]0 cylcoalkenylalkyl. then at least one of the following conditions (i), (ii) and (iii) is true: (i) the compound is a compound of formula (2): (ii) Ar is selected from optional!}' substituted naphihyl. triazmyl. furanyl. thieiryL benzotliienyl. benzomran.}"!. 2.3-dihydrobenzofuran)rl. 2.3-d ydjobenzothienyl. indanyl, 2H-benzopyranyl, 3;4-dihyciro— 2H-benzopyranyl, and tetralinyl; (iii) R1 is selected from C2-C4 aikerryt C2-Q alkynyL C : Q-C4 haloalkyL C3-C;2 hydroxya]- kyLGs-C], aikoxyalkyl other than -(C-,-C2 alkylene)-0-(C Ci alky])/ C2-C;0 cyanoalkyL C3-C6 cycloaLkyL C4-C-l0 cycloatt lalkyl, NR'R16, C C4 alkyl- R'Ri 0= NR5COR36: OR33, SH or S(0)BR32; when Z is CR2. R* is H, R2 is CH3. and Ar is unsubstiruted pyridyl or uiisubsiiruted pyricnidiny], then R3 is not - HC(C¾);. [5] Preferred compounds of the above invention are compounds of Formulae (1) and (2) and isomers thereof, stereoisomeric forms thereof, or • mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof with the additional provisos that: (1) when A N, R1 is H, C1-C4 alkyl, halo, CN, C1-C12 hydroxyalkyl, C1-C4 alkoxyalkyl or S02(C} -C4 alkyl), R3 is NR^aR^a and R6a is unsubstituted C1-C4 alkyl, then R7a is not phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, furanyl, benzofuranyl, benzothiazoJyl, indolyl or C3-C6 cycJoaUcyl; and (2) A is N, Rl is H, C1-C4 alkyl, halo, CN, C1-C12 hydroxyalkyl, C1-C4 alkoxyalkyl or S02(Ci-C4 alkyl), R3 is NR6aR7a and R7a is unsubstituted C1-C4 alkyl, then R6a is not phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, furanyl, benzofuranyl, benzothiazolyl, indolyl or C3-C6 cycloalkyl. [6] Preferred compounds of the above invention also include compounds of Formulae (1) and (2) and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, each optionally substituted with 1 to 4 R^ substituents. [7]. Preferred compounds of the above invention also include compounds of Formulae (1) and (2) and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein A is N, Z is CR2, Ar is 2,4-dichlorophenyl, 2,4-dimethylphenyl or 2,4,6-trimethylphenyl, R1 and R2 are CH3, and R3 is NR6aR7a. [8] More preferred compounds of the above invention are compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein A is N. [9] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof.

[10] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R.4 substituents.

[11] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R3 is NR6aR7a or OR7.

[12] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R4 substituents, and R3 is NR6aR7a 0r OR?

[13] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Z is CR2.

[14] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R.4 substituents.

[15] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R3 is R6aR7a 0rOR7.

[16] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^a is independently selected from: -H, -Ci-Cio alkyl, C3-Cio alkenyl, C3-C10 alkynyl, C1-C10 haloalkyl with 1-10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4- C12 cycloalkylalkyl, C5-C10 cycloalkenyl, or C6-C14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C3- C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR15, SH, S(0)nR13, CORl5, C02R15, OC(0)R13, NR8COR15, N(COR15)2, NR8CO R16R15, NR8C02R13, NR^R*5, CONR16R15 ary}3 heteroaryl or heterocyclyl, 127871/3 -aryl, aryl(Ci-C4 alkyl)-, heteroaiyl, heteroaryl(Ci- C4 alkyl)-, heterocyclyl or heterocyclyl(Ci-C4 alkyl)-; and R^A is independently selected at each occurrence from: -H, -C5-C10 alkyl, C3-C10 alkenyl, C3-C10 alkynyl, C1-C10 haloalkyl with 1-10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyl, C5-C10 cycloalkenyl, or C6-C14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C3- C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR1 5, SH, S(0)NR!3; COR1 5, CO2R15, OC(0)R13, R^COR1 5, N(COR15)2, NR8CONR1 6R1 5, NR8C02R13, NR^R15, CO R^R1 5, aryl, heteroaryl or heterocyclyl. -aryl, aryl(Cl-C4 alkyl), heteroaryl, heteroaryl(Ci-C4 alkyl), heterocyclyl or heterocyclyl (C1-C4 alkyl); alternatively, NR6R7 and N ^aR7a ^ independently piperidino, pyrrolidino, piperazino, N-methylpiperazino, morpholino or thiomorpholino, each optionally substituted with 1-3 C1-C4 alkyl groups.

[17] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R6a and R7A are identical and are selected from: -C 1-C4 alkyl or C3-C6 cycloalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from Ci-C6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR15, SH, S(0)nR13, -COR15, CO2RI5, 0C(0)R13, NR8COR15, N(C0R15)2, NR8CONR16R15, NR8CO2R13, NR16R15, CONR16R15, aryl, heteroaryl or heterocyclyl, and -aryl or heteroaryl.

[18] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R6a is selected from: -H, -Ci-C 10 alkyl, C3-C10 alkenyl, C3-C10 alkynyl, C1 -C10 haloalkyl with 1-10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4- C12 cycloalkylalkyl, C5-C10 cycloalkenyl, or C6-C1 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C3- C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR 5, SH, S(O)nR13, COR15, CO2R15, OC(O)R13, NR8COR15, N(COR15)2, NR8CONR16R15, NR8CO2R13, NR16R155 CONR 15 , aryl, heteroaryl or heterocyclyl, -aryl, aryl(Ci-C4 alkyl), heteroaryl, heteroaryl(Ci-C4 alkyl), heterocyclyl or heterocyclyl(Ci-C4 alkyl); R7a is selected from: -C 1 -C4 alkyl and each such C1-C4 alkyl is substituted with 1-3 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR35, SH, S(O)nRi3, cORl5, C02R 5, 0C(0)R13, NR8COR15, N(C0R15)2, NR8CONR16R15, NR8C02R13, R16R159 CONR16R15, αΓγ1, heteroaryl or heterocyclyl.

[19] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein one of R6a and R?a is selected from: -C3-C6 cycloalkyl, each such C3-C6 cycloalkyl optionally substituted with 1-3 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, ORi5, SH, S(0)nRi3, CORi5, C02R15, 0C(0)R13, NR8COR15, N(C0R15)2, R8CONR16R15, NR8C02R13, NR16R15, CONR16R15, aryl, heteroaryl or heterocyclyl, -aryl, -heteroaryl or -heterocyclyl, and the other of R6 and R7¾ is unsubstituted C1-C4 alkyl.

[20] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R >a and R7a are independently H or C] -Cio alkyl, each such C1-C10 alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR1 5, SH, S(O)nR13, COR15, CO2R15, OC(0)R13, NR8COR15, N(COR15)2, R8CONRi 6R15, NR8C02R1 3, R1 6R15, CONR16Rl5, aryl, heteroaryl or heterocyclyl.

[21] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2.3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R4 substituents, and R3 is NR6aR7a 0r OR?

[22] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^a is independently selected from: -H, -Ci-Cio alkyl, C3-Cio alkenyl, C3-Cio aU ynyl, Q-Cio haloalkyl with 1 -10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4- C12 cycloalkylalkyl, C5-C10 cycloalkenyl, or C6-C14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C 1 -C6 alkyl, C3- C6 cycloalkyl, halo, C 1 -C4 haloalkyl, cyano, OR15, SH, S(O)nR13, COR 5, CO2R15, OC(O)R13, NR8C0R1 5, N(COR15)2, NR8CO Rl6R15, NR8CO2R13, NR16R15, CONR^R^, aryl, heteroaryl or heterocyclyl, -aryl, aryl(C] -C4 alkyl)-, heteroaryl, heteroaryl(Ci-C4 alkyl), heterocyclyl or heterocyclyl(Ci-C4 alkyl); 127871/3 R a is independently selected at each occurrence from: -H, -C5-C10 alkyl, C3-C10 alkenyl, C3-C10 alkynyl, C1 -C10 haloalkyl with 1-10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4-Q 2 cycloalkylalkyl, C5-C] 0 cycloalkenyl, or C6-Q4 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from Cj -Cg alkyl, C3- Cft cycloalkyl, halo, Ci -C4 haloalkyl, cyano, OR1 5, SH, S(0)nR13, COR1 5, C02 1 5, OC(0)R13, NR8COR1 5, N(COR1 5)2, NR8CONR1 6R15, NR8C02R13, NR1 6R15, CONR! 6R15; heteroaryl or heterocyclyl, -aryl, aryl(Ci-C4 alkyl), heteroaryl, heteroaryl(Ci-C4 alkyl), heterocyclyl or heterocyclyl(Ci-C4 alkyl), alternatively, NR^R? and ^aR7a are independently piperidino, pyrrolidino, piperazino, N-methylpiperazino, morpholino or thiomo holino, each optionally substituted with 1 -3 C1-C4 alkyl groups.

[23] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drag forms thereof wherein R6a and R7a are identical and are selected from: -C1-C4 alkyl or C3-C6 cycloalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, ORIS, SH, S(0)nR13, -COR15, C02R]5, 0C(0)R13, R8COR15, N(C0R15)2, NR8CONR16R15, NR8CO2R13, NR16R155 C0NR16R155 aryl I heteroaryl or heterocyclyl, and -aryl or heteroaryl.

[24] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R6a and R7a are identical and are -C 1 -C4 alkyl, each such C 1 -C4 alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C\-Ce alkyl, C3-C6 cycloalkyl, halo, Ci-C4 haloalkyl, cyano, ORi5, SH, S(0)nR] 3, -COR^, CO2RI5, OC(O)Rl3, NR8COR15, N(C0R15)2, NR8CONR16R15, NR8C02 13, R16R15, CO R16R15, aryl, heteroaryl or heterocyclyl.

[25] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R6a is selected from: -H, -C1-C10 alkyl, C3-C10 alkenyl, C3-C10 alkynyl, Cl-Cio haloalkyl with 1-10 ns, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4- C12 cycloalkylalkyl, C5-C10 cycloalkenyl, or C6-C 14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C3- C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR1 5, SH, SCO^R13, COR! 5, CO2R1 5, OC(0)R«, NR^COR1 5, N(COR] 5)2, R8CONR1 6R15, NR8CO2R13, NR16R1 5, CON ^ ^ aryl, heteroar l or heterocyclyl, -aryl, aryl(C] -C4 alkyl), heteroaryl, heteroaryl(C] -C4 alky 1), heterocyclyl or heterocyclyl(C ] -C4 alkyl); R7a is: -C 1 -C4 alkyl and each such C1-C4 alkyl is substituted with 1-3 substituents independently selected at each occurrence from Ci-Ce alkyl, C3-C6 cycloalkyl, halo, Ci-C4 haloalkyl, cyano, OR] 5, SH, S(O)nRl3, COR15, CO2R15, OC(O)Rl3, NR8CORl5, N(CORi5)2, NR8CONR16R15, NR8CO2R13, NR16R15, CONR16R15, aryl, heteroaryl or heterocyclyl .

[26] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein one of R6a and R7a is selected from: -C3-C6 cycloalkyl, each such C3-C6 cycloalkyl optionally substituted with 1-3 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, ORi5, S¾ S(O)nRi3, CORi5, CO2RI5, OC(O)Ri3, NR8COR15, N(CORi5)2, NR8CONR16R15, NR8CO2R13, NR16R15, CONR16R15, aryl, heteroaryl or heterocyclyl, -aryl, -heteroaryl or -heterocyclyl, and the other of R6a and R?a is unsubstituted C1-C4 alkyl.

[27] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R6A and R7A are independently H or C]-Cio alkyl, each such Ci-Cio alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR15, SH, S(0)NR13, COR15, CO2R1 5, OC(0)Rl3, NR8COR155 N(COR15)2, R8CONR16R15, R8CO2R1 3, R16R155 CONR16R15, aryl, heteroaryl or heterocyclyl.

[28] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein -Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R^ substituents, -R3 is NR6aR7a OR OR7 and -R1 and R^ are independently selected from H, C1-C4 alkyl, C3-C6 cycloalkyl, C4-C 10 cycloalkylalkyl.

[29] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^A is independently selected from: -H, -Ci-Cio alkyl, C3-C10 alkenyl, C3-C10 alkynyl, C1-C10 haloalkyl with 1-10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4- C12 cycloalkylalkyl, C5-C10 cycloalkeny1 , or C6-C14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C3- C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR15, SH, S(0)NR13, COR15, CO2R15, OC(0)R13, NR8COR15, N(COR15)2, RSCON 1 SR15 , NR8C02R13, NR16R15, CONR16R15, aryl, heteroaryl or heterocyclyl, , aryl(Ci-C4 aikyl)-, heteroaryl, heteroaryl (Ci-C4 alkyl), heterocyclyl or heterocyclyl ( C1-C4 aikyl) s independently selected at each occurrence from: -C5-C10 alkyl, C3-C10 alkenyl, C3-C10 alkynyl, Cl-Cio haloalkyl with 1-10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4- C12 cycloalkylalkyl, C5-C10 cycloalkenyl , or C6-C14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C3- C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR15, SH, S(0)NR13f COR15, CO2R15, OC(0)R13, NR8COR15, N(COR15)2, RSCONR16R15 F NR8C02R13, NR16R15, CONR16R15, aryl, heteroaryl or heterocyclyl, -aryl, aryl(Ci~C4 alkyl), heteroaryl, heteroaryl (C1-C4 alkyl), heterocyclyl or heterocyclyl (C1-C4 alkyl), 127871/3 alternatively, N 6R7 and NR6aR7a we independently piperidino, pyixolidino, piperazino, N-methylpiperazino, morpholino or thiomorpholino, each optionally substituted with 1 -3 Ci -C4 alkyl groups.

[30] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric fonns thereof, or mixtures of stereoisomeric forais thereof, and pharmaceutically acceptable salt or pro-drug fonns thereof wherein R6a and R7a are identical and are selected from: -C1 -C4 alkyl or C3-C6 cycloalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C\ -C(, alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, ORI S, SH, S(0)nR13, -COR15, C02R! 5, 0C(0)R13, NRSCOR15, N(C0R15)2, NR8CONR16R15, NR8CO2R1 3, R16R15, CONR16R15, aryl, heteroaryl or heterocyclyl, and -aiyl or heteroaryl.

[31] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R6a and R7a are identical and are, -C1 -C4 alkyl, each such C1 -C4 alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR15, SH, S(0)nRl3, -COR15, CO2R1 5, 0C(0)R13, NR8COR15, N(C0R15)2, R8CONR16R15, NR8CO2R13, NR16R15; C0NR16R15; aryl, heteroaryl or heterocyclyl.

[32] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drag forms thereof wherein R6a is selected from: -H, -Ci-C]O alkyl, C3-Cio alkenyl, C3-Cio alkynyl, Ci-Cio haloalkyl with 1-10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4- Cl2 cycloalkylalkyl, C5-C10 cycloalkenyl, or C6-C14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C3- Ce cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR15, SH, S(0)nR13, COR15, CO2R15, OC(O)R13, R8COR15, N(COR15)2, NR8CONRl6R15, NR8CO2R13, NR16R15, CONR 1 15 , aryl, heteroaryl or heterocyclyl, -aryl, aryl(Ci-C4 alkyl), heteroaryl, heteroaryl(Ci -C4 alkyl), heterocyclyl or heterocyclyl(Ci-C4 alkyl); R7a is: -C 1 -C4 alkyl and each such C1-C4 alkyl is substituted with 1 -3 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, halo, Ci-C4 haloalkyl, cyano, OR^, SH, S(O)nRi3, COR15, CO2R15, OC(O)Rl3, NR8CORl5, N(CORi5)2, NR8CO R16R15, NR8CO2R13, NR16R15, CONR16R15, aryl, heteroaryl or heterocyclyl.

[33] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein one of R6¾ and R?a is selected from: -C3-C6 cycloalkyl, each such C3-C6 cycloalkyl optionally substituted with 1 -3 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR15, SH, S(0)nRi3, COR15, CO2R15, OC(O)Ri3, NR8COR15, N(COR15)2, NR8CONR16R15, NR8CO2R'3, NR16R15, CONR16R15, aryl, heteroary] or heterocyclyl, -aryl, -heteroaryl or -heterocyclyl, and the other of R6» and R?a is unsubstituted C1-C4 alkyl.

[34] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R6a and R7a are independently H or Ci-Cio alkyl, each such C]-C}0 alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR15, SH, S(0)nR13, COR1 5, CO2R15, OC(O)R13, NR8COR1 5, N(CORL5)2, R8CONR16R15, NR8CO2R13, NRl6R15, CONR16R15, aryl, heteroaryl or heterocyclyl.

[35] Specifically preferred compounds of the above invention are compounds of Formula (50) and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceu ically acceptable salt or pro-drug forms thereof, selected from the group consisting of: a compound of Formula (50) wherein is -NHCH (n-Pr) 2, R R4a is CI, ,4b is H, is CI R4d is H and R e is H; compound of Formula (50) wherein RJ is -N(Et) (n-Bu) t R a is CI, R b is H, R c is CI, R4d is H and R e is compound of Formula (50) wherein R3 is -(n- Pr) (CH2cPr), R4a is C1/ R4b is ^ R4c ig Qlf R4d is H and R4e is H; compound of Formula (50) wherein R^ is - (CH2CH20Me) 2, R4a is CI, R4b is H, R c is CI, R4d is H and R e is H; a compound of Formula (50) wherein R^ is -NHCH(Et) (n- Bu), R4a is CI, R4b is H, R4c is CI, R d is H and R e is H; a compound of Formula (50) wherein ^ is -NHCH(Et) (CH2OMe) , R R4b is H> R4c ig M&f R4D is H and R E is H; compound of Formula (50) wherein R3 IS -OCH (Et) (CH2OMe) , R4A is Me, R4B is H, R4C is Me, R D is H and R4E is H; compound of Formula (50) wherein R3 is -N(n- Pr) (CH2cPr), R4A IS ME , R B is H, R4C is Me, R D is H and R4E is H; compound of Formula (50) wherein R3 IS -NHCH(Me) (CH2N(Me)2) , R4A is Me, R B is H, R4C is Me, R4D is H and R4E is H; compound of Formula (50) wherein R3 IS -N(cPr) (CH2CH2CN) , R4a is Me, R4B is H, R C is Me, R4D is H and R4E is H; compound of Formula (50) wherein R is -N(n- Pr) (CH2CH2CN) , R4a is Me, R4B is H, R4C is Me, R4D is H and R is H; a compound of Formula (50) wherein R3 is -N(n- Bu) (CH2CN) , R4a is Me, R b is H, R c is Me, R4d is H and R4e is H; a compound of Formula (50) wherein R3 IS -NHCH(Et) (CH2OMe), R4a is Me, R b is H, R c is Me, R4d is H and R4e is Me ; a compound of Formula (50) wherein R3 is -N.HCH(Et)2, R4a is Me, R b is H, R c is Me, R4d is H and R e is Me; a compound of Formula (50) wherein R3 is - (CH2CH2OMe) 2 , R R44aa is Me, R4b is H, R4c is Me, R d is H and R e is Me; a compound of Formula (50) wherein R3 is R4a is Br, R4 is H, R4c is OMe, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -NHCH(Et)(CH2OMe), R4a is Br, R4b is H, R4c is OMe, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -N(Et)23 R4a is Me, R4b is H, R4c is Me, R4d is H and R4e is Me; a compound of Formula (50) wherein R3 is -NHCH(CH2OEt)2, R4a is Me, R b is H, R4c is Me, R4d is H and R4e is Me; a compound of Formula (50) wherein R3 is -NHCH(CH2CH2OMe)(CH2OMe)5 R4a js Me, R4b is ¾ R4c is Me, R4d is H and R4e is Me; a compound of Formula (50) wherein R3 is morpholino3 js j¾4b js R4c js Me, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -N(CH2CH2OMe)2, R4a js Br, R4b is H, R4c is OMe, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -NHCH(Et)2, R4a is Br, R4b is H, R4c is OMe, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -N(Ef)23 R4a js Br, R4b is H, R4c is OMe, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -NH(c-Pr)5 R4a js Me, R4b is H, R4c is Me, R d is H and R4e is H; a compound of Formula (50) wherein R3 is -NHCH(CH2OMe)2, R4a is CN, R4b is H, R4c is OMe, R4d is H and R4e is H; a compound of Formula (50) wherein is -NHCH(CH2O e) (CH2CH2OMe) , R4a is He> R4b ig R> R4c is Br, R d is H and R e is H; a compound of Formula (50) wherein R3 is -NHCH (CH20Me) 2, R4A is Me, R B is H, R4C is OMe, R4d is Me and R4e is H ; a comoound of Formula (50) wherein ^ is -N (CH2CH20Me) 2 R4a . is Me, R4b is H, R4c is OMe, R d is Me and R4e is K; compound of Formula (50) wherein R^ is -NHCH (Et ) 2 , R4a is Me, R B is H, R4C is OMe, R D is Me and R4E is H; compound of Formula (50) wherein a compound of Formula (50) wherein R3 is -N(Et)2, R A is Me, R4B is H, R4C is OMe, R D is Me and R E is H; a compound of Formula (50) wherein R^ is -NHCH (CH20Me) 2 R R44a is CI, R4b is H, R4c is Me, R4d is H and R e is H; compound of Formula (50) wherein R3 is -NHCH(Et) (CH2OMe) , R4a is Cl, R4b is H, R4c is Me, R4d is H and R4e is H; compound of Formula (50) wherein R^ is -N (CH2CH20Me) 2 , R a is Cl, R4 is H, R4c is Me, R4d is H and R4e is H; compound of Formula (50) wherein R IS -NHCH(CH20Me) (CH2CH20Me) , R4a is Cl, R4b is H, R c is Me, R4 is H and R4e is H; a compound of Formula (50) wherein R^ is -N(c- P Prr)) ((CCHH22CCHH22CCNN)) f R4¾ is Me> R4b is Hf R4c is 0Me> R4d is Me and R4e is H; a compound of Formula (50) wherein R^ is -N(c- Pr) (CH2CH2CN), R4a is cl R4b ig H> R4c is R4d is H and R4e is H; a compound of Formula (50) wherein R3 is (S)- NHCH (CH2OMe) (CH2CH2OMe) , R4a is CI, R4b is H, R4c is CI, R4d is H and R e is H; compound of Formula (50) wherein R3 is -NHCH (CH2OMe) (CH2CH2OMe) , R4a is Cl, R b is H, is Ci, R d is H and R4e is H; compound of Formula (50) wherein R3 is -NHCH(Et)2, is Me, R b is H, R c is Br, R d is H and R e is a compound of Formula (50) wherein R3 is -N (CH2CH2OMe) 2/ R is Me, RHU is H, R4 is Br, R a is H and R e is H; a compound of Formula (50) wherein R3 is -NH(CH2OMe) (CH2-iPr) , R4a is Me> R4b ig ^ R4c is Me, R4d is H and R e is H; a compound of Formula (50) wherein R3 is -N (CH2CH2OMe) 2/ R R a is Me, R4b is H, R4c is H, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -N (CH2CH2OMe) 2 , R4a is Me, R b is H, R4c is NMe2, R4d is H and R e is H; a compound of Formula (50) wherein R3 is -NHCH(CH2OMe) (n-Pr) , R4a is Me, R4b is H, R4c is Me, R d is H and R4e is H a compound of Formula (50) wherein R3 IS -NHCH (CH20Et ) (Et), R4a is Me, R4b is H, R4c is Me, R4d is H and R e is H a compound of Formula (50) wherein R3 s -NHCH (CH2OMe ) (CH2CH2OMe) , R4a is Me, R4b is H, R c is NMe2, R d is H and R e is H; a compound of Formula (50) wherein R3 is -N(Et)2, R a is Me, R4b is H, R c is Cl, R d is H and R e is H; a compound of - Formula (50) wherein R3 is -NHCH (Et) 2, R4a is Me, R b is H, R4c is Cl, R d is H and R e is H; a compound of Formula (50) wherein is - (CH2CH20Me) 2 R4A is Me, ,4b is H, R¾ is CI, R4D is H and R4E is H; a compound of Formula (50) wherein R^ is -NHCH (CH20Me) ? R4A is Me, R4B is H, R¾T- is CI, R4d is H and R e is K; compound of Formula (50) wherein R^ is -N(Et)2, is Me, R4B is H, R4C is Br, R4D is H and R4E is a compound of Formula (50) wherein R^ is -N(Et)2, R4a is Ci, R b is H, R4C is Me, R d is H and R e is H; a compound of Formula (50) wherein R^ is -NHCH (Et ) 2 , R4a is CI, R4b is H, R4C is Me, R4d is H and R4e is H; a compound of Formula (50) wherein R^ is -NHCH (Et ) 2 , R4a is Me, R B is H, R4c is NMe2 , R4D is H and R4e is H; a compound of Formula (50) wherein R3 is (S)- NHCH(CH2OMe) (CH2CH2OMe) , R4^ IS ME, R4B IS H, R C is Me, R D is H and R4e is H; a compound of Formula (50) wherein R^ is -NHCH(CH2OMe) (CH2CH2OMe) , R4 is Me, R4B is H, R4C is Me, R D is H and R E is H; a compound of Formula (50) wherein R^ is (S)- NHCH (CH2OMe) (CH2CH2OMe) , R4a is Me, R B is H, R4C is CI, R4D is H and R E is H; a compound of Formula (50) wherein 3 IS -NHCH (CH20Me) (CH2CH2OMe) , R4a is Me, R4B is H, R4C is CI, R4D is H and R E is H; a compound of Formula (50) wherein R^ is -N(c- Pr) (CH2CH2CN) , R4a is Me, R4B is H, R4C is CI, R4D is H and R4E is H; a compound of Formula (50) wherein R^ is -NH(Et) (CH2CN) R R44a is Me, R4b is H, R c is CI, R4d is H and R4E is H; compound of Formula (50) wherein R3 is -N(Et)2/ R4A i< Me, R B is Me, R4C is OMe, R4D is H and R E is H; compound of Formula (50) wherein R^ is -N(CH2CH2OMe) (CH2CH2OH) , R^a is c^ R4b .g ^ R4c is CI, R4D is H and R E is H; compound of Formula (50) wherein R^ is -N (CH2CH2OMe) 2 , R4A is Me, R4B is Me, R4C is OMe, R4D is H and R e is H a compound of Formula (50) wherein R^ is . -NHCH (Et ) 2 , R4a iiss Me, R4b is Me, R c is OMe , R4d is H and R4e is H; a compound of Formula (50) wherein R^ is -N(CH2c-Pr) (n- Pr) . R4a is Me, R4b is H, R c is CI, R d is H and R e is H a compound of Formula (50) wherein R^ is -N(c-Pr) (CH2CH2CN), R4a is Me, R4b is Me, R c is OMe, R d is H and R4e is H; a compound of Formula (50) wherein R^ is -NHCH (Et)2, R4a s CI, R4b is H, R4c is OMe, R4d is H and R4e is H; a compound of Formula (50) wherein R^ is -N(Et)2, R4a is CI, R4b is H, R4c is OMe, R4d is H and R e is H; compound of Formula (50) wherein R^ is -N (CH2CH2OMe) 2, R4a is CI, R4b is H, R c is OMe, R d is H and R e is H; compound of Formula (50) wherein R3 IS -NHCH(Et) (CH2OMe) , R4a is Cl, R4b is H, R4c is OMe, R4d. is H and R4e is H compound of Formula (50) wherein is -N(Et)2, 4a is Cl, R b is H, R4c is CN, R4d is H and R e is H compound of Formula (50) wherein R3 is - ( c- Pr) (CH2CH2CN) , R^a is clf R4b is H^ R4c ig 0Μβ/ R4d is H and R4e is H 127871/2 a compound of Formula (50) wherein R^ is -NHCH(CH20H)2, R4a is CI, R4b is H, R4c is CI, R4d is H and R4e is H; and a compound of Formula (50) wherein R^ is (CH2CH20Me)2, R4a is Me, R4b is H, R4c is OMe, R4d is H and R ^ is H.

[39] More specifically preferred is 4-(bis-(2-methoxyethyl)amino)-2,7- dimethyl-8-(2-methyl-4-inethoxyphenyl)-pyrazolo-[ 1 ,5-a]- 1 ,3,5-triazine and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric fonns thereof, and pharmaceutically acceptable salt or pro-drug fonns thereof.

[40] More specifically preferred is 4-(bis-(2-methoxyethyl)amino)-2,7- dimethyl-8-(2,5-dimethyl-4-methoxyphenyl)-pyrazolo-[l,5-a]-l,3,5-triazine and isomers thereof, stereoisomeric fonns thereof, or mixtures of stereoisomeric fonns thereof, and pharmaceutically acceptable salt or pro-drug fonns thereof.

[41] More preferced are compounds of the above invention are compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein A is CR.

[42] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric fonns thereof, or mixtures of stereoisomeric fonns thereof, and pharmaceutically acceptable salt or pro-drug forms thereof.

[43] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2 , 3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R4 substituents . [4~j More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R3 is NR6aR7a Cr OR7.

[45] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2 , 3-dihydrobenzofuranyl , and each Ar is optionally substituted with 1 to 4 R4 substituents, and R3 is NR6aR7a or OR7.

[46] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Z is CR2.

[47] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2 , 3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R4 substituents.

[48] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R3 is NP,6aR7a or OR7. [4 ; More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or -"mixtures' of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2 , 3-dihydrobenzofuranyl , and each Ar is optionally substituted with 1 to 4 R^ substituents, and 3 is NR6aR a or OR7.

[50] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R6a and R7a are independently H or Ci-Cio alkyl, and each such Ci-Cio alkyl is optionally substituted with 1 to 3 substituents independently selected at each occurrence from Ci~C6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR15, SH, S(0)nR13, COR15, C02R15, OC(0)R13, NR8COR15, N(COR15)2, R8CONR16R15, NR8C02R13, NR16R15, CO R^R15, aryi heteroaryl or heterocyclyl .

[51] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein -Ar is phenyl, pyridyl or 2 , 3-dihydrobenzofuranyl , and each Ar is optionally substituted with 1 to A substituents, -R3 is R6aR7a or OR7 and -R and R2 are independently selected from H, C3.-C4 alkyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl .

[52] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^a and R a are independently H or C1-C10 alkyl, and each such C1-C10 alkyl is optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, halo, C3.-C4 haloalkyl, cyano, OR15, SH, S(0)nR13, COR15, C02R15, OC(0)R13, NR8COR15, N(COR15)2, R8CONR16R15, NR8C02R13, NR16R15, CO R^-^ 15, aryl, heteroaryl or heterocyclyl .

[53] Specifically preferred compounds of the above invention are compounds of Formula (51) FORMULA (51) and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof selected from the group consisting of: a compound of Formula (51) wherein R- is -NHCH (n-Pr) 2 , R4a is Me, R b is H, R4c is Me, R4d is H and R4e is H; a compound of Formula (51) wherein R^ is -NHCH (CH20Me) 2, R4a is Me, R4b is H, R4c is Me, R d is H and R e is H; a compound of Formula (51) wherein R^ is -N (CH2 H20Me) 2, R4a is Me, R4b is H, R4c is Me, R4d is H and R e is H; a com R4d a compound of Formula (51) wherein R^ is -N (CH2CH20 e) 2 R R44a is CI, R4b is H, R4c is Me, R4d is H and R e is H; a compound of Formula (51) wherein R3 is -NHCH (CH20Me) 2, R R4a is CI, R4b is H, R4c is Me, R d is H and R e is H; a compound of Formula (51) wherein is -NHCH(Et)? R4A is CI, R b is H, R4c is Me, R d is H and R e is H; compound of Formula (51) wherein R-3 is -N(Et) is Me, R b is H, R4c is Me, R4d is H and R e a compound of Formula (51) wherein R is -N(n- Pr) (CH2CH2CN), R«a ig Me> R4b ig H> R4c ig M^ R4d is H and R¾c is H; compound of Formula (51) wherein R^ is -N(n- Bu) (CH2CH2CN), R4a is Me> R4b ig ^ R4c -s ^ R4d is H and R E is H; compound of Formula (51) wherein R^ is -NHCH(n- Pr) (CH2OMe), R4a is Me, R B is H, R4C is Me, R D is H and R E is H; compound of Formula (51) wherein R^ is -NHCH(Et)2 R4a is Me, R B is H, R C is OMe, R4D is H and R4E is H; compound of Formula (51) wherein R^ is -NHCH (CH2OMe) 2, R4A is Me, R4B is H,' R4C is OMe, R4D is H and R4 is H; compound of Formula (51) wherein R3 is (S) -NH(CH2CH2OMe)CH2OMe, R4 is Me? R4b .g ^ R4c ig Me, R D is H and R E is H; compound of Formula (51) wherein R IS -NH(CH2CH2OMe)CH2OMe, R4a is Me^ R4b is Hf R4c ig Me, R4D is H and R E is H; compound of Formula (51) wherein ^ is -N (CH2CH2OMe) 2, R A is Me, R B is H, R4C is CI, R is H and R E is H; a compound of Formula (51) wherein R^ is -NH(Et), R4a is Me, R b is H, R4c is Me, R d is H and R4e is H; a compound of Formula (51) wherein R^ is -NHCH (n-Pr) 2, R R4a is Me, R b is H, R4c is CI, R4d is H and R4e is H; compound of Formula (51) wherein R3 is -NHCH (CH20Me) 2 R R44a is Me, R4b is H, R4c is CI, R4d is H and R e H; a compound of Formula (51) wherein R3 is (S) -NH(CH2CH2OMe)CH2OMe, R4 is Me, R4b is H, R4c is CI, R4d is H and R4e is H; compound of Formula (51) wherein R^ is -NH(CH2CH20Me)CH2OMe, R^ ig Me> R4b .g ^ R4c is CI, R4d is H and R4e is H; compound of Formula (51) wherein R^ is -N(n- Pr) (CH2CH2CN), R4.a .s MQi R4b .g ^ R4c .g 0Μ^ R4d is H and R4e is H; compound of Formula (51) wherein R3 is -N(Et)2, R4A is Me, R i) is H, R4c is OMe, R4D is H and R4E is K; compound of Formula (51) wherein R^ is (S) -NH(CH2CH2OMe)CH2OMe, R4a is Q1/ R4b .g ^ R4c ig Me, R D is H and R E is H; compound of Formula (51) wherein is -NH(CH2CH2OMe)CH2OMe, R4a ig C1 R4b ig H> R4c .g Me, R4D is H and R4E is H; a compound of Formula (51) wherein R^ is -N(Et)2, R4A is CI, R4B is H, R C is Me, R4D is H and R4E is H; a compound of Formula (51) wherein R3 is -N(c- Pr) (CH2CH2CN), R4a ig Μβ/ R4b ig H/ R4c ig 0Μθ> R4d is H and R E is H a compound of Formula (51) wherein R^ is -N(c- Pr) (CH2CH2CN), R4a ig cl/ R4b ig Hf R4c ig Me> R4d is H and R E is H; a compound of Formula (51) wherein R3 is -NHCH (n— Pr) (CH2OMe), R4a is Me, R4B is H, R C is OMe, R D is H and R E is H a compound of Formula (51) wherein R^ is -NHCH (n- Pr) (CH20Me), R4a is CI, R B is H, R4C is Me, R D is H and R4E is H; compound of Formula (51) wherein R-3 is -NHCH (E ) 2 iiss Br, R4b is H, R4c is OMe, R4d is O e and R e is H; compound of Formula (51) wherein R^ is '-NHCH (Et) 2, R a is Br, R4b is H, R c is OMe, R d is H and R e is H; compound of Formula (51) wherein is -N (CH2CH20Me) 2, R4a is Br, R4b is H, R c is OMe, R d is H and R4e is H; ompound of Formula (51) wherein R^ is -NHCH (CH20Me ) 2 ,4c R R aa iis Br, R b is H, is OMe, R4U is H-. and R 4e is H; a compound of Formula (51) wherein R^ is -N(Et)2, R4a is Me, R4b is H, R4c is CI, R d is H and R4e is H; a compound of Formula (51) wherein R^ is -N(Et)2, R4a is CI, R4b is H, R c is OMe, R4d is OMe and R4e is H a compound of Formula (5\) wherein R3 is -NHCH (Et ) 2 , R4a is CI, R4b is H, R c is OMe, R d is OMe and R e is H; a compound of Formula (51) wherein R^ is -N (CH2CH20Me) 2, R4a is CI, R b is H, R4c is CI, R4d is H and R e is H; a compound of Formula (51) wherein R3 is -NHCH (CH20 e ) 2 , R4a is CI, R b is H, R4c is CI, R d is H and R4e is H; a compound of Formula (51) wherein R3 IS -N(Pr) (CH2CH2CN) , R4a is CI, R b is H, R c is CI, R4d is H and R e is H; a compound of Formula (51) wherein R3 is -N(Bu) (Et), R4 s CI, R4b is H, R4c is CI, R4d is H and R e is H a compound of Formula (51) wherein R3 is -NHCH(Et)CH2OMe, R4a is CI, R b is H, R4c is CI, R is H and R e is H; a compound of Formula (51) wherein R3 is -NHCH(Et)2, R4a is CI, R4b is H, R4c is CI, R4d is H and R e is H; a compound of Formula (51) wherein R3 is -NHCH(Et)2, R4a is Me, R b is H, R4c is Me, R4d is H and R4e is H; a compound of Formula (51) wherein R3 is -NHCH(Et)2 R4a is CI, R4b is H, R4c is Me, R4d is H and R4e is H; a compound of Formula (51) wherein R3 is -NHCH(Et)2, R4a is Me, R4b is H, R c is CI, R4d is H and R4e is H; a compound of Formula (51) wherein R3 is -NEt2 R4a is Me, R4b is H, R4c is OMe, R4d is H and R4e is H; and a compound of Formula (51) wherein R3 is -N(Pr)(CH2CH2CN), R4a is Me, R4b is H, R4c is OMe, R4d is H and R4e is H.

[54] More specifically preferred is 7-(3-pentylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl)-pyrazolo[l,5-a]pyrimidine and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof.

[55] More specifically preferred is 7-(diethylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl-pyrazolo[l,5-a]pyrimidine and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof.

[56] More specifically preferred is 7-(N-(3-cyanopropyl)-N-propylamino)-2,5-dimethyl-3-(2,4-dimethylphenyl)-pyrazolo[l,5-a]pyrimidine and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and 127871/2 pharmaceutically acceptable salt or pro-drug fonns thereof.

The present invention also provides pharmaceutical compositions comprising compounds of Formulae (1) and (2) and a pharmaceutically acceptable canier.

Many compounds of this invention have one or more asymmetric centers or planes. Unless otherwise indicated, all chiral (enantiomeric and diastereomeric) and racemic fonns are included in the present invention. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds, and all such stable isomers are contemplated in the present invention. The compounds may be isolated in optically active or racemic fonns. It is well known in the art how to prepare optically active fonns, such as by resolution of racemic forms or by synthesis from optically active starting materials. All chiral, (enantiomeric and diastereomeric) and racemic forms and all geometric isomeric fonns of a structure are intended, unless the specific stereochemistry or isomer form is specifically indicated.

The tenn "alkyl" includes both branched and straight-chain alkyl having the specified number of carbon atoms. Commonly used abbreviations have the following meanings: Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl. The prefix "n" means a straight chain alkyl. The prefix "c" means a cycloalkyl. The prefix "(S)" means the S eriantiomer and the prefix "(/?)" means the R enantiomer. "Alkenyl" includes hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, and the like. "Alkynyl" includes hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl, propynyl and the like. "Haloalkyl" is intended to include both branched and straight-chain alkyl having the specified number of carbon atoms, substituted with 1 or more halogen; "alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge; "cycloalkyl" is intended to include saturated ring groups, including mono-,bi- or poly-cyclic ring systems, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and so forth. "Halo" or "halogen" includes fluoro, chloro, bromo, and iodo.

The term "substituted", as used herein, means that one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substitent is keto (i.e., =0) , then 2 hydrogens on the atom are replaced.

Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By "stable compound" or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

The term "appropriate amino acid protecting group" means any group known in the art of organic synthesis for the protection of amine or carboxylic acid groups. Such amine protecting groups include those listed in Greene and Wuts, "Protective Groups in Organic Synthesis" John Wiley & Sons, New York (1991) and "The Peptides: Analysis, Synthesis, Biology, Vol. 3, Academic Press, New York (1981), the disclosure of which is hereby incorporated by reference. Any amine protecting group known in the art can be used. Examples of amine protecting groups include, but are not limited to, the following: 1) acyl types such as formyl, trifluoroacetyl , phthalyl, and p-toluenesulfonyl ; 2) aromatic carbamate types such as benzyloxycarbonyl (Cbz) and substituted benzyloxycarbony Is , 1- (p-biphenyl) -1- ethylethoxycarbonyl, and 9- iuorenylmethyloxycarbony1 (Fmoc) ; 3) aliphatic carbamate types such as tert-butyloxycarbonyl (Boc) , ethoxycarbony1 , diisopropylmethoxycarbonyi , and allyloxycarbonyl ; 4) cyclic alkyl carbamate types such as cyclopentyloxycarbonyl and adamantyloxycarbonyl; 5) alkyl types such as triphenylmethyl and benzyl; 6) trialkylsilane such as trimethylsilane ; and 7) thiol containing types such as phenylthiocarbonyl and dithiasuccinoyl .

The term "pharmaceutically acceptable salts" includes acid or base salts of the compounds of Formulae (1) and (2) . Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.

Pharmaceutically acceptable salts of the compounds of the invention can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington ' s Pharmaceutical Sciences. 17th ed. , Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.

"Prodrugs" are considered to be any covalently bonded carriers which release the active parent drug of formula (I) or (II) in vivo when such prodrug is administered to a mammalian subject. Prodrugs of the compounds of formula (I) and (II) are prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds . Prodrugs include compounds wherein hydroxy, amine, or sulfhydryl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino, or sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds Of formulas (I) and (II); and the like.

The term "therapeutically effective amount" of a compound of this invention means an amount effective to antagonize abnormal level of CRT or treat the symptoms of affective disorder, anxiety or depression in a host .

Syntheses Some compounds of Formula (1) may be prepared from intermediate compounds of Formula (7), using the procedures outlined in Scheme 1 : SCHEME 1 Ar Ar (7) Y = 0 (8) (1) A = N Compounds of Formula (7) (where Y is 0) may be treated with a halogenating agent or sulfonylating agent in the presence or absence of a base in the presence or absence of an inert solvent at reaction temperatures ranging from -80°C to 250°C to give products of Formula (8) (where X is halogen, alkanesulfonyloxy, arylsulfonyloxy or haloalkane-sulfonyloxy) . Halogenating agents include, but are not limited to, SOCI2, POCI3, PCI3, PCI5, POBr3, PBr3 or PBrs. Sulfonylating agents include, but are not limited to, alkanesulfonyl halides or anhydrides (such as methanesulfonyl chloride or methanesulfonic acid anhydride), arylsulfonyl halides or anhydrides (such as p-toluenesulfony1 chloride or anhydride) or haloalkylsulfonyl halides or anhydrides (preferably trifluoromethanesulfonic anhydride) . Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride) , alkali metal alkoxides ( 1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide) , alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di- isopropylamide) , alkali metal bis (trialkylsilyl ) amides (preferably sodium bis ( trimethylsilyl ) amide ) , trialkyl amines (preferably N, N-di-isopropyl-N-ethy 1 amine or triethylamine) or aromatic amines (preferably pyridine) Ir. rt solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile ) , dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1, -dioxane) , N, N-dialkylformamides (preferably dimethylformamide ) , N, N-dialkylacetamides (preferably dimethylacetamide ) , cyclic amides (preferably N-methy lpyrrolidin-2-one ) , dialkylsulfoxides (preferably dimethylsulfoxide ) , aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane ) .

Preferred reaction temperatures range from -20°C to 100°C.

Compounds of Formula (8) may be reacted with compounds of Formula R3H (where R^ is defined as above except R3 is not SH, COR7, CO2 7, aryl or heteroaryl) in the presence or absence of a base in the presence or absence of an inert solvent at reaction temperatures ranging from -80 to 250°C to generate compounds of Formula (1) . Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide) , alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide) , alkali metal carbonates, alkali metal bicarbonates , alkali metal bis (trialkylsilyl ) amides (preferably sodium bis (trimethylsilyl) amide) , trialkyl amines (preferably , N-di-isopropyl-N-ethy i amine) or aromatic amines (preferably pyridine) . Inert solvents may include, but are not limited to, alkyl alcohols ( 1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile) , dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1 , 4 -dioxane ) , N, N-dialkylformamides (preferably dimethylformamide ) , N, N-dialkylacetamides (preferably dimethylacetamide ) , cyclic amides (preferably N-methylpyrrolidin-2-one) , dialkylsulfoxides (preferably dimethylsuifoxide) , aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane ) . Preferred reaction temperatures range from 0°C to 140°C.

Scheme 2 delineates the procedures for converting intermediate compounds of Formula (7) (where Y is S) to some compounds of Formula (1) .

SCHEME 2 Compounds of Formula (7) (where Y is S) may be treated with an alkylating agent R13X (where R13 is defined as above, except R13 is not aryl or heteroaryl) in the presence or absence of a base in the presence or absence of an inert solvent at reaction temperatures ranging from -80°C to 250°C. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide) , alkaline earth metal hydrides, alkali metal diaikylamides (preferably lithium di-isopropylamide) , alkali metal carbonates, alkali metal hydroxides, alkali metal bis (trialkylsilyl ) amides (preferably sodium bis (trimethylsilyl ) amide) , trialkyl amines (prefereably N, N-di- isopropyl-N-ethyl amine or triethyl amine) or aromatic amines (preferably pyridine) . Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile) , dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1 , -dioxane ) , N, N-dialkylformamides (preferably dimethylformamide ) , N, -dialkylacetamides (preferably dimethylacetamide ) , cyclic amides (preferably N- methylpyrrolidin-2-one) , diaikylsulfoxides (preferably dimethylsul foxide ) , aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane ) .

Preferred reaction temperatures range from -80°C to 100°C .

Compounds of Formula (12) (Formula (1) where R3 is SR13) may then be reacted with compounds of Formula R3H to give compounds of Formula (1), using the same conditions and reagents as were used for the conversion of compounds of Formula (8) to compounds of Formula (1) as outlined for Scheme 1 above. Alterna ively, compounds of Formula (12) (Formula (1) where R3 is SR13) may be oxidized to compounds of Formula (13) (Formula (1) where R3 is S(0)nR13' n is 1,2) by treatment with an oxidizing agent in the presence of an inert solvent at temperatures ranging from -80°C to 250°C. Oxidizing agents include, but are not limited to, hydrogen peroxide, alkane or aryl peracids (preferably peracetic acid or m-chloro-perbenzoic acid), dioxirane, oxone, or sodium periodate. Inert solvents may include, but are not limited to, alkanones (3 to 10 carbons, preferably acetone), water, alkyl alcohols (1 to 6 carbons), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane ) or combinations thereof.

The choices of oxidant and solvent are known to those skilled in the art (cf. Uemura, S., Oxidation of Sulfur, Selenium and Tellurium, in .Syn hesis , Trost, B.M. ed., (Elmsford, NY: Pergamon Press, 1991), 7, 762-769) . Preferred reaction temperatures range from -20°C to 100°C. Compounds of Formula (13) (Formula (1) where R3 is S(0)nR13< n is 1,2) may then be reacted with compounds of Formula R3H to give compounds of Formula (1) , using the same conditions and reagents as were used for the conversion of compounds of Formula (S) to compounds of Formula (1) as outlined for Scheme (1) above.

Compounds of Formula (1), where R3 may be -NR8COR7, -N(COR7)2, -NR8CONR6R7, -NR8C02R13, -NR6R7, -NR8S02R7, may be prepared from compounds of Formula (7), where Y is NH, by the procedures depicted in Scheme 3.

SCHEME 3 ( 7 ) Y = NH (1) A = N; R3 = NR6R7, NR8COR7, N( COR7) 2 , NReCONR6R7, eC02Ri3 Reaction of compounds of Formula (7) , where Y is NH, with alkylating agents, sulfonylating agents or acylating agents or sequential reactions with combinat ions thereof, in the presence or absence of a base in an inert solvent at reaction temperatures ranging from -80°C to 250°C may afford compounds of Formula (1), where R3 may be -NR8COR7, -N(COR7)2, -NR8CONR6R7, -NR8C02R13, -NR6R7' -NR8S02R7. Alkylating agents may include, but are not limited to, Ci-Cio alkyl -halides, -tosylates, -mesylates or -triflates Ci-Cio haloalkyld - 10 halogens ) -halides , -tosylates, -mesylates or -triflates; C2-C8 alkoxyalkyl-halides , -tosylates, -mesylates or -triflates; C3-C6 cycloalkyl- haiides, -tosylates, -mesylates or -triflates; C4- C12 cycloalkylalkyl-halides , -tosylates, -mesylates or -triflates; aryl (C1-C4 alkyl) -halides, -tosylates, -mesylates or -triflates; heteroaryl (C1-C4 alkyl)- halides, -tosylates, -mesylates or -triflates; or heterocyclyl (C1-C4 alkyl) -halides, -tosylates, -mesylates or -triflates. Acylating agents may include, but are not limited to, C1-C10 alkanoyl halides or anhydrides, C1-C10 haloalkanoyl halides or anhydrides with 1 - 10 halogens, C2~CQ alkoxyalkanoyl halides or anhydrides, C3-C6 cycloalkanoyl halides or anhydrides, C4-C12 cycloalkylalkanoyl halides or anhydrides, aroyl halides or anhydrides, aryl(Ci~C4) alkanoyl halides or anhydrides, heteroaroyl halides or anhydrides, heteroaryl (C1-C4 ) alkanoyl halides or anhydrides, heterocyclylcarboxylic acid halides or anhydrides or heterocyclyl (C1-C4 ) alkanoyl halides or anhydrides.

Sulfonylat ing agents include, but are not limited to, cl~c10 alkylsulfonyl halides or anhydrides, C1-C10 haloalkylsulfonyl halides or anhydrides with 1 - 10 halogens, C2-C8 alkoxyalkylsulfonyl halides or anhydrides, C3-C6 cycloalkylsulfonyl halides or anhydrides, C4-C12 cycloalkylalkylsulfonyl halides or anhydrides, arylsulfonyl halides or anhydrides, aryl(Ci~ C4 alkyl)-, heteroarylsulfonyl halides or anhydrides, heteroaryl (C1-C4 alkyl ) sulfonyl halides or anhydrides, hecerocyclylsulfonyl halides or anhydrides or heterocyclyl (C1-C4 alkyl ) sulfonyl halides or anhydrides. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride) , alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide) , alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di- isopropylamide ) , alkali metal carbonates, alkali metal bis (trialkylsilyl ) amides (preferably sodium b i s ( rimethylsily 1 ) amide) , trialkyl amines (prefereably di-isopropylethyl amine) or aromatic amines (preferably pyridine) . Inert solvents may include, but are not iimited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile ) , dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1 , 4-dioxane) , N, N-dialkylformamides (preferably dimethylformamide ) , N, N-dialkylacetamides (preferably dimethylacetamide ) , cyclic amides (preferably N-methylpyrrolidin-2-one ) , dialkylsulfoxides (preferably dimethylsulfoxide ) or aromatic hydrocarbons (preferably benzene or toluene) . Preferred reaction temperatures range from 0°C to 100°C.

Scheme 4 delineates procedures, which may be employed to prepare intermediate compounds of Formula (7), where Y is 0, S and Z is CR2.

SCHEME 4 (7) Y = 0, S; Z = OR2 Compounds of the formula ArCH2CN are reacted with compounds of the formula R2C0Rb, where R2 is defined above and Rb is halogen, cyano, lower alkoxy (1 to 6 carbons) or lower alkanoyloxy (1 to 6 carbons), in the presence of a base in an inert solvent at reaction temperatures ranging from -78°C to 200°C to afford compounds of Formula (3) . Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide) , alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide) , alkali metal carbonates, alkali metal hydroxides, alkali metal bis (trialkylsilyl) amides (preferably sodium bis (trimethylsilyl) mide) , trialkyl amines (preferably N, -di-isopropyl-N-ethyl amine) or aromatic amines (preferably pyridine) . Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol) , lower alkanenit riles (1 to 6 carbons, preferably acetonitrile) , water, dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1 , 4-dioxane ) , Ν',Ν- dialkylformamides (preferably dimethylformamide) , N,N- dialkylacetamides (preferably dimethylacetamide ) , cyclic amides (preferably N-methylpyrrolidin-2-one ) , dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene) . Preferred reaction temperatures range from 0°C to 100°C.

Compounds of Formula (3) may be treated with hydrazine-hydrate in the presence of an inert solvent at temperatures ranging from 0°C to 200°C, preferably 70°C to 150°C, to produce compounds of Formula (4) . Inert solvents may include, but are not limited to, water, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile) , cyclic ethers (preferably tetrahydrofuran or 1 , -dioxane ) , N, -dialkylformamides (preferably dimethylformamide), N, N-dialkylacetamides (preferably dimethylacetamide) , cyclic amides (preferably N-methylpyrrolidin-2-one ) , dialkylsulfoxides (preferably dimethylsul foxide ) or aromatic hydrocarbons (preferably benzene or toluene) . Compounds of Formula (4) may be reacted with compounds of Formula (5) (where Rc is alkyl (1-6 carbons)) in the presence or absence of an acid in the presence of an inert solvent at temperatures ranging from 0°C to 200°C to produce compounds of Formula (6) . Acids may include, but are not limited to alkanoic acids of 2 to 10 carbons (preferably acetic acid) , haloalkanoic acids (2 - 10 carbons, 1-10 halogens, such as trifluoroacetic acid),, arylsulfonic acids (preferably p-toluenesulfonic acid or benzenesulfonic acid) , alkanesulfonic acids of 1 to 10 carbons (preferably methanesulfonic acid) , hydrochloric acid, sulfuric acid or phosphoric acid. Stoichiometric or catalytic amounts of such acids may be used. Inert solvents may include, but are not limited to, water, alkanenitriles (1 to 6 carbons, preferably acetonitrile) , halocarbons of 1 to 6 carbons and 1 to 6 halogens (preferably dichioromethane or chloroform) alkyl alcohols of 1 to 10 carbons (preferably ethanol) , dialkyl ethers (4 to 12 carbons, preferably diethyl ether or di-isopropylether ) or cyclic ethers such as dioxan or tetrahydrofuran . Preferred temperatures range from ambient temprature to 100°C.

Compounds of Formula (6) may be converted to intermediate compounds of Formula (7) by treatment with compounds C=Y(Rd)2 (where Y is 0 or S and Rd is halogen (preferably chlorine), alkoxy (1 to 4 carbons) or alkylthio (1 to 4 carbons)) in the presence or absence of a base in an inert solvent at reaction temperatures from -50°C to 200°C. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide) , alkali metal carbonates, alkali metal hydroxides, trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine) . Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol) , lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), cyclic ethers (preferably tetrahydrofuran or 1, -dioxane) , N, N-dialkylformamides (preferably dimethylformamide ) , N, N-dialkylacetamides (preferably dimethylacetamide ) , cyclic amides (preferably N-methylpyrrolidin-2-one) , dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene) . Preferred temperatures are 0°C to 150°C.

Intermediate compounds of Formula (7) , where 2 is N, may be synthesized according the methods outlined in Scheme 5.

SCHEME 5 Ar (7) Y = O, S; Z =N Compounds of ArCH2CN are reacted with compounds of Formula RC1CH2N3 (where R¾ is a phenyl group optionally substituted by H, alkyl (1 to 6 carbons) or alkoxy (1 to 6 carbons) in the presence or absence of a base in an inert solvent at temperatures ranging from 0°C to 200°C to generate compounds of Formula (9) . Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide, sodium ethoxide or potassium t-butoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide ) , alkali metal carbonates, alkali metal hydroxides, alkali metal bis (trialkylsilyl ) amides (preferably sodium bis ( trimethylsilyl ) amide ) , trialkyl amines (preferably N, N-di-isopropyl-N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine) . Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile ) , dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1 , -dioxane ) , N, -dialkylformamides (preferably dimethylformamide ) , N, -dialkylacetamides (preferably dimethylacetamide ) , cyclic amides (preferably N-methylpyrrolidin-2-one ) , dialkylsulfoxides (preferably dimethylsulfoxide ) or aromatic hydrocarbons (preferably benzene or toluene) . Preferred reaction temperatures range from ambient temperature to 100°C.

Compounds of Formula (9) may be treated with a reducing agent in an inert solvent at -100°C to 100°C to afford products of Formula (10) . Reducing agents include, but are not limited to, (a) hydrogen gas in combination with noble metal catalysts such as Pd-on-carbon, PtC>2, Pt-on-carbon, Rh-on-alumina or Raney nickel, (b) alkali metals (preferably sodium) in combination with liquid ammonia or (c) eerie ammonium nitrate. Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol) , lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), water, dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1 , 4-dioxane) , N, -dialkylformamides (preferably dimethylformamide ) , N, N-dialkylacetamides (preferably dimethylacetamide ) , cyclic amides (preferably N-methylpyrrolidin-2-one) , dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene) . The preferred reaction temperatures are -50°C to 60°C. Compounds of Formula (9) are then converted to compounds of Formula (7) (where Z is N) via intermediates of Formula (11) using the reagents and reaction conditions outlined in Scheme 4 for the conversion of compounds of Formula (4) to compounds of Formula (7) (where Z is CR2 ) .

Compounds of Formula (1) may also be' prepared from compounds of Formula (7) (where Y is 0, S and Z is defined above) as outlined in Scheme 6: SCHEME 6 (7) Y = O, S; Z = N, CR (1) Compounds of Formula (7) may be reacted with compounds of Formula R3H in the presence of a dehydrating agent in an inert solvent at reaction temperatures ranging from 0°C to 250°C. Dehydrating agents include, but are not limited to, P2O5/ molecular sieves or inorganic or organic acids. Acids may include, but are not limited to alkanoic acids of 2 to 10 carbons (preferably acetic acid) , arylsulfonic acids (preferably p-toluenesulfonic acid or benzenesulfonic acid) , alkanesulfonic acids of 1 to 10 carbons (preferably methanesulfonic acid) , hydrochloric acid, sulfuric acid or phosphoric acid.

Inert solvents may include, but are not limited to, 127871/2 alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably glyme or diglyme), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylfonnamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or halocarbons of 1 to 10 carbons and 1 to 10 halogens (preferably chloroform). Preferred reaction temperatures range from ambient temperature to 150°C.

Some compounds of Formula (1) (where A is N) may also be prepared by the methods shown in Scheme 7: S CHEME 7 (1) A = N Intermediate compounds of Formula (14), where Z is defined above, may be reacted with compounds of Formula R3C(ORe)3, where Re may be alkyl (1 to 6 carbons) in the presence or absence of an acid in an inert solvent at temperatures ranging from 0°C to 250°C. Acids may include, but are not limited to alkanoic acids of 2 to 10 carbons (preferably acetic acid), arylsulfonic acids (preferably p-toluenesulfonic acid or benzenesulfonic acid), alkanesulfonic acids of 1 to 10 carbons (preferably methanesulfonic acid), hydrochloric acid, sulfuric acid or phosphoric acid. Stoichiometiic or catalytic amounts of such acids may be used. Inert solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile) , dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1, -dioxane) , N, N-dialkylformamides (preferably dimethylformamide) , N, -dialkylacetamides (preferably dimethylacetamide) , cyclic amides (preferably N- methylpyrrolidin-2-one) , dialkylsulfoxides (preferably dimethylsulfoxide ) , aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane ) .

Preferred reaction temperatures range from 50°C to 150°C.

Intermediate compounds of Formula (7) may also be synthesized by the reactions displayed in Scheme 8.

SCHEME 8 CR2, (7) X = Br, CI, I, B(OR"")2 Compounds of Formula (15), (where Y is OH, SH, NR6R7; Z is defined above, X is Br, CI, I, O3SCF3 or B(OR"")2 and R" " is H or alkyl (1 to 6 carbons)) may be reacted with a compound of Formula ArM (where M is halogen, alkali metal, ZnCl, ZnBr, Znl, MgBr, MgCl, Mgl, CeCl2, CeBr2 or copper halides) in the presence or absence of an organometallic catalyst in the presence or absence of a base in an inert solvents at temperatures ranging from -100°C to 200°C. Those skilled in the art will recognize that the reagents ArM may be generated in situ. Organometallic catalysts include, but are not limited to, palladium phosphine complexes (such as Pd(PPh3)_j), palladium halides or alkanoates (such as PdCl2(PPh3)2 or Pd(OAc)2> or nickel complexes (such as NiCl2 (PPh3) 2) · Bases may include, but are not limited to, alkali metal carbonates or trialkyl amines (preferably N, N-di-isopropy 1-N-ethyl amine or triethylamine ) . Inert solvents may include, but are not limited to, dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tet rahydrofuran or 1,4-dioxane) , N, N-dialkylformamides (preferably dimethylformamide) , N, -dialkylacetamides (preferably dimethylacetamide) , cyclic amides (preferably N-methylpyrrolidin-2-one) , dialkylsulfoxides (preferably dimethylsulfoxide) , aromatic hydrocarbons (preferably benzene or toluene) or water. Preferred reaction temperatures range from -80°C to 100°C.

The choices of M and X are known to those skilled in the art (cf. Imamoto, T., Organocerium Reagents in Comprehensive Organic Synthesis, Trost, B.M. ed., (Elmsford, NY: Pergamon Press, 1991), 1, 231-250; Knochel, P., Organozinc, Organocadmium and Organomercury Reagents in Comprehensive Organic Synthesis. Trost, B.M. ed., (Elmsford, NY: Pergamon Press, 1991), 1, 211-230; Knight, D.W., Coupling Reactions between sp2 Carbon Centers, in Comprehensive Organic Synthesis, Trost, B.M. ed., (Elmsford, NY: Pergamon Press, 1991), 3, 481-520) .

Compounds of Formula (1) may also be prepared using the methods shown in Scheme 9.

Compounds of Formula (16), where A, Z, R1 and R3 are defined above and X is Br, CI, I, O3SCF3 or B(0R"")2 and R"" is H or alkyl (1 to 6 carbons)) may be reacted with a compound of Formula ArM (where M is halogen, alkali metal, ZnCl, ZnBr, Znl, MgBr, MgCl, Mgl, CeCl2, CeBr2 or copper halides) in the presence or absence of an organometallic catalyst in the presence or absence of a base in an inert solvents at temperatures ranging from ■ -100°C to 200°C. Those skilled in the art will recognize that the reagents ArM may be generated in situ (see the above references in Comprehensive Organic Synthesis) . Organometallic catalysts include, but are not limited to, palladium phosphine complexes (such as Pd(PPh3)_j), palladium halides or alkanoates (such as PdCl2(PPh3)2 or Pd(0Ac)2) or nickel complexes (such as NiCl2 (PPh3) 2) · Bases may include, but are not limited to, alkali metal carbonates or trialkyl amines (preferably N, N-di-isopropyl-N-ethyl amine or triethylamine) . Inert solvents may include, but are not limited to, dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1,4- dioxane) , N, -dialkylformamides (preferably dimethylformamide) , N, N-dialkylacetamides (preferably dimethylacetamide) , cyclic amides (preferably N- methylpyrrolidin-2-one) , dialkylsulfoxides (preferably dimethylsulfoxide) , aromatic hydrocarbons (preferably benzene or toluene) or water. Preferred reaction temperatures range from -80°C to 100°C.

Intermediate compounds of Formula (7) (where Y is 0, S, NH, Z is CR2 and R1, R2 and Ar are defined as above) may be prepared as illustrated in Scheme 10.

SCHEME 10 Compounds of Formula (3) may be reacted with compounds of Formula H2 NH (C=Y) NH2, where Y is 0, S or NH, in the presence or absence of a base or acid in an inert solvent at temperatures from 0°C to 250°C to produce compounds of Formula (17). Acids may include, but are not limited to alkanoic acids of 2 to 10 carbons (preferably acetic acid) , arylsulfonic acids (preferably p-toluenesulfonic acid or benzenesulfonic acid) , alkanesulfonic acids of 1 to 10 carbons (preferably methanesulfonic acid) , hydrochloric acid, sulfuric acid or phosphoric acid. Stoichiometric or catalytic amounts of such acids may be used. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal bis (trialkylsilyl) amides (preferably sodium bis (trimethylsilyl) amide) , trialkyl amines (preferably N, -di-isopropyl-N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine) . Inert solvents may include, but are not limited to, alkyl alcohols (1 to 6 carbons), lower alkanenic ri les (1 to 6 carbons, preferably acetonitrile ) , dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1 , -dioxane ) , N, N-dialkyIformamides (preferably dimethylformamide) , N, -dialkylacetamides (preferably dimethylacetamide ) , cyclic amides (preferably N-methylpyrrolidin-2-one ) , dialkylsulfoxides (preferably dimethylsul foxide ) , aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane) .

Preferred reaction temperatures range from 0°C to 150°C. Compounds of Formula (17) may then be reacted with compounds of Formula R3C(ORe)3, where Re may be alkyl (1 to 6 carbons) in the presence or absence of an acid in an inert solvent at temperatures ranging from 0°C to 250°C. Acids may include, but are not limited to alkanoic acids of 2 to 10 carbons (preferably acetic acid) , arylsulfonic acids (preferably p-toluenesulfonic acid or benzenesulfonic acid) , alkanesulfonic acids of 1 to 10 carbons (preferably methanesulfonic acid) , hydrochloric acid, sulfuric acid or phosphoric acid.

Stoichiometric or catalytic amounts of such acids may be used. Inert solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile) , dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1, -dioxane) , N, N-dialkylformamides (preferably dimethylformamide) , N, N-dialkylacetamides (preferably dimethylacetamide) , cyclic amides (preferably N- methylpyrrolidin-2-one) , dialkylsulfoxides (preferably dimethylsulfoxide) , aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane ) .

Preferred reaction temperatures range from 50°C to 150°C.

In Scheme 11, the procedures which may be used to convert compounds of Formula (1) , where R3 is COR7, CO2R7, NR8COR7 and CONR6R7, to other compounds of Formula (1) , where R3 is CH(OH)R7, CH2OH, NR8CH2R7 and CH2NR6R7 by treatment with a reducing agent in an inert solvent at temperatures ranging from -80°C to 250°C.

SCHEME 11 CH2NR6R7 Reducing agents include, but are not limited to, alkali metal or alkaline earth metal borohydrides (preferably lithium or sodium borohydride) , borane, dialkylboranes (such as di-isoamylborane) , alkali metal aluminum hydrides (preferably lithium aluminum hydride) , alkali metal (trialkoxy) aluminum hydrides, or dialkyl aluminum hydrides (such as di-isobutylaluminum hydride) . Inert solvents may include, but are not limited to, alkyl alcohols (1 to 6 carbons), dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), aromatic hydrocarbons (preferably benzene or toluene) . Preferred reaction temperatures range from -80°C to 100°C.

In Scheme 12, the procedures are shown which may be used to convert compounds of Formula (1), where R3 is COR7 or CO2 R7 , to other compounds of Formula (1), where R3 is C(OH) (R7 ) 2 by treatment with a reagent of Formula R M in an inert solvent at temperatures ranging from -80°C to 250°C.

SCHEME 12 M is halogen, alkali metal, ZnCl, ZnBr, Znl, MgBr, MgCl, Mgl, CeCl2/ CeBr2 or copper halides. Inert solvents may include, but are not limited to, dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran) or aromatic hydrocarbons (preferably benzene or toluene) . Preferred reaction temperatures range from -80°C to 100°C.

Compounds of Formula (1), where R3 may be -NR8COR7, -N ( COR ) 2 , -NR8CONR6R7, -NR8C02R13, -NR6R7' -NR8S02R7, may be synthesized as depicted in Scheme 13.

SCHEME 13 (1) CR *JR6R7, NR8C N(COR7)2, NR8CONR6R7, NR8C02Ri3 Reaction of compounds of Formula (18), where R and R1 are defined above, with compounds of Formula ( 4 ) or (10) in the presence or absence of base in an inert solvent may produce compounds of Formula (19) at temperatures ranging from -50°C to 250°C. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (prefereably di-isopropylethyl amine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetomtrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1 ,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). Preferred reaction temperatures range from 0°C to 100°C.

Compounds of Formula (19) may then be reacted with alkylating agents, sulfonylating agents or acylating agents or sequential reactions with combinations thereof, in the presence or absence of a base in an inert solvent at reaction temperatures ranging from -80°C to 250°C affording compounds of Formula (1), where R3 may be -NR8COR7 -N(COR7)2, -NR8CONR6R7 -NR C02R13, - R6R7> - R8S02R7. Alkylating agents may include, but are not limited to, Ci-Cio alkyl -halides, -tosylates, -mesylates or -inflates; Ci-ClO haloalkyl(l - 10 halogens)-halides, -tosylates, -mesylates or -triflates; C2-C8 alkoxyalkyl-halides, -tosylates, -mesylates or -inflates; C3-C6 cycloalkyl-halides, -tosylates, -mesylates or -triflates; C4- Ci2 cycloalkylalkyl-halides , -tosylates, -mesylates or -triflates aryl (C1-C4 alkyl) -halides, -tosylates, ' -mesylates or -triflates; heteroaryl (C1-C4 alkyl) - halides, -tosylates, -mesylates or -triflates; or heterocyclyl (C1-C4 alkyl) -halides, -tosylates, -mesylates or -triflates. Acylating agents may include, but are not limited to, C1-C10 alkanoyl halides or anhydrides, C1-C10 haloalkanoyl halides or anhydrides with 1 - 10 halogens, C2-C8 alkoxyalkanoyl halides or anhydrides, C3-C6 cycloalkanoyl halides or anhydrides, C4-C12 cycloalkylalkanoyl halides or anhydrides, aroyl halides or anhydrides, aryi(Ci-C4) alkanoyl halides or anhydrides, heteroaroyl halides or anhydrides, heteroaryl (C1-C4 ) alkanoyl halides or anhydrides, heterocyclylcarboxylic acid halides or anhydrides or heterocyclyl (C1-C4 ) alkanoyl halides or anhydrides.

Sulfonylating agents include, but are not limited to, Cl-Cio alkylsulfonyl hali-des or anhydrides, C1-C10 haloalkylsulfonyl halides or anhydrides with 1 - 10 halogens, 2- Q alkoxyalkylsulfony 1 halides or anhydrides, C3-C6 cycloalkylsulfonyl _halides or anhydrides, C4-C12 cycloalkylalkylsulfonyl halides or anhydrides, arylsulfonyl halides or anhydrides, aryl(Ci~ C4 alkyl)-, heteroarylsulfonyl halides or anhydrides, heteroaryl (C1-C4 alkyl ) sulfonyl halides or anhydrides, heterocyclyls.ulfonyl halides or anhydrides or heterocyclyl (C1-C4 alkyl) sulfonyl halides or anhydrides. Bases may include, but are not limited to, alkali metal hydrides . (preferably sodium hydride) , alkali metal alkoxides (1 to 6 carbons) (preferably sodium me hoxide or sodium ethoxide) , alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide) , alkali metal carbonates, alkali metal bis (trialkylsilyl ) amides (preferably sodium bis (trimethylsilyl) amide) , trialkyl amines (prefereably di-isopropylethyl amine) or aromatic amines (preferably pyridine) . Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol) , lower alkanenitriles (1 to 6 carbons, preferably acetonitrile) , dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N, N-dialkylformamides (preferably dimethylformamide ) , N, N-dialkylacetamides (preferably dimethylacetamide) , cyclic amides (preferably N-methylpyrrolidin-2-one) , dialkylsulfoxides (preferably dimethylsulfoxide ) or aromatic hydrocarbons (preferably benzene or toluene) . Preferred reaction temperatures range from 0°C to 100°C.

Compounds of Formula (1), where A is CR and R is defined above, may be synthesized by the methods depicted in Scheme 14.

SCHEME 14 Compounds of Formula (4) or (10) may be treated with compounds of Formula (20) , where R1 and R3 are defined above in the presence or absence of base in an inert solvent at temperatures ranging from 0°C to 250°C to give compounds of Formula (1), where A is CR and R is defined above. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride) , alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide) , alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide) , alkali metal carbonates, alkali metal bis (trialkylsilyl) amides (preferably sodium bis (trimethylsilyl) amide) , trialkyl amines (preferably di-isopropylethyl amine) or aromatic amines (preferably pyridine) . Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile ) , dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1, 4-dioxane) , N, N-dialkylformamides (preferably dimethylformamide ) , N, N-dialkylacetamides (preferably dimethylacetamide ) , cyclic amides (preferably N-methylpyrrolidin-2-one) , dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene) . Preferred reaction temperatures range from 0°C to 100°C. Alternatively, compounds of Formula (1) where A is CR and R is defined above, may be synthesized through intermediates (22) and (23) .

Compounds of Formula (4) or (10) may be treated with compounds of Formula (21), where R1 is defined above and Re is alkyl (1 - 6 carbons), in the presence or absence of base in an inert solvent at temperatures ranging from 0°C to 250°C to give compounds of Formula (1), where A is CR and R is defined above. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide) , alkali metal carbonates, alkali metal bis (trialkylsilyl ) amides (preferably sodium bis (trimethylsilyl) amide) , trialkyl amines (prefereably di-isopropylethyl amine) or aromatic amines (preferably pyridine) . Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol) , lower alkanenitriles (1 to 6 carbons, preferably acetonitrile) , dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1, -dioxane) , N, N-dialkylformamides (preferably dimethylformamide ) , N, N-dialkylacetamides (preferably dimethylacetamide ) , cyclic amides (preferably N-methylpyrrolidin-2-one ) , dialkylsulfoxides (preferably dimethylsulfoxide ) or aromatic hydrocarbons (preferably benzene or toluene) . Preferred reaction temperatures range from 0°C to 100°C. Compounds of Formula (22) may be treated with a halogenating agent or sulfonylating agent in the presence or absence of a base in the presence or absence of an inert solvent at reaction temperatures ranging from -80°C to 250°C to give products of Formula (23) (where X is halogen, alkanesulfonyloxy , arylsulfonyloxy or haloalkane-sulfonyloxy) . Halogenating agents include, but are not limited to, SOC12 POCI3, PCI3, PCI5, POBrs, PBr3 or PBr5. Sulfonylat ing agents include, but are not limited to, alkanesulfonyl halides or anhydrides (such as methanesulfonyl chloride or methanesulfonic acid anhydride), arylsulfonyl halides or anhydrides (such as p-toluenesulfonyl chloride or anhydride) or haloalkylsulfonyl halides or anhydrides (preferably trifluoromethanesulfonic anhydride) . Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride) , alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide) , alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide) , alkali metal bis (trialkylsilyl) amides (preferably sodium bis (trimethylsilyl) amide) , trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofura or 1 ,4-dioxane), Ν,Ν-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of I to 10 carbons and 1 to 10 halogens (preferably dichloromethane). Preferred reaction temperatures range from -20°C to 100°C.

Compounds of Formula (23) may be reacted with compounds of Formula R3H (where R3 is defined as above except R3 is not SH, COR7, CO2R7, aryl or heteroaryl) in the presence or absence of a base in the presence or absence of an inert solvent at reaction temperatures ranging from -80°C to 250°C to generate compounds of Formula (I). Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal bicarbonates, alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (I to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1, 4-dioxane) , N, N-dialkyiformamides (preferably dimethylformamide) , N, N-dialkylacetamides (preferably dimethylacetamide) , cyclic amides (preferably N-methylpyrrolidin-2-one) , dialkylsulfoxides (preferably dimethylsulfoxide) , aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane) . Preferred reaction temperatures range from 0°C to 140°C.

Some compounds of Formula (1) may also be prepared using the methods shown in Scheme 15. 127871/2 SCHEME IS ( 27)Y = O, S (1) Z = CR2 A compound of Formula (24) (Rc is a lower alkyl group and Ar is defined as above) may be reacted with hydrazine in. the presence or absence of an inert solvent to afford an intennediate of Formula (25), where Ar is defined as above. The conditions employed are similar to those used for the preparation of intennediate of Formula (4) from compound of Fonnula (3) in Scheme 4. Compounds of Fonnula (25), where A is N, may be reacted with reagents of the fonnula R1C(=NH)ORe, where R1 is 127871/3 defined above and Re is a lower alkyl group) in the presence or absence of an acid in an inert solvent, followed by reaction with a compound of formula Y=C(Rd)2 (where Y is O or S and Rd is halogen (preferably chlorine), alkoxy (1 to 4 carbons) or alkylthio (1 to 4 carbons)) in the presence or absence of a base in an inert solvent to give compounds of Formula (27) (where A is N and Y is O, S). The conditions for these transformations are the same as those employed for the conversions of compounds of Formula (4) to compounds of Formula (7) in Scheme 4.

Alternatively, compounds of Formula (25), where A is CR, may be reacted with compounds of the formula. R1(C=0)CHR(C=Y)ORc (where R1 and R are defined as above and Rc is a lower alkyl group) to give a compound of Formula (27) (where A is CR) using conditions similar to those employed for the conversion of compounds of Formula (21) to compounds of Formula (22) in Scheme 14. Intermediates of Formula (27) (where Y is O) may be treated with halogenating agents or sulfonylating agents in the presence or absence of a base in an inert solvent, followed by reaction with R3H or R2H in the presence or absence of a base in an inert solvent to give compounds of Formula (1) (where Z is CR2).

It will be recognized by those skilled in the art that various combinations of halogenating agents, sulfonylating agents, R3H or R2H may be used in different orders of reaction sequences in Scheme 15 to afford compounds of Formula (1). For example, in some cases, it may be desirable to react compounds with stoichiometric amounts of halogenating agents or sulfonylating agents, react with R2H (or R3H), then repeat the reaction with halogenating agents or sulfonylating agents and react with R3H (or R2H) to give compounds of Formula (1). The reaction conditions and reagents used for these conversions are similar to the ones employed for the conversion of intermediate compounds of Formulae (22) to (23) to (1) in Scheme 14 (for A is CR) or the conversion of intermediate compounds of Formulae (7) to (8) to (1) in Scheme 1 (where A is N) .

Alternatively, compounds of Formula (27) (where Y is S) may be converted to compounds of Formula (1) in Scheme 15. Intermediate compounds of Formula (27) may be- alkylated with a compound RfX (where Rf is lower alkyl and X is halogen, alkanesulfonyloxy or haloalkanesulfonyloxy) in an inert solvent, (then optionally oxidized with an oxidizing agent in an inert solvent) and then reacted with R3H in the presence or absence of a base in an inert solvent to give a compound of Formula (1) . The conditions and reagents employed are similar to those used in the conversion of intermediate compounds of Formulae (7) to (12) (or to (13)) to compounds of Formula (1) in Scheme 2.

Compounds of Formula (1) may be prepared from compounds of Formula (24), using an alternate route as depicted in Scheme 15. Compounds of Formula (24) may be converted to compounds of Formula (27) via reaction with compounds of formula H2NH (C=NH) H2 in the presence or absence of an acid in an inert solvent, followed by reaction with compounds R1C(ORc)3 (where Rc is lower alkyl and R1 is defined as above) , using the conditions employed for the conversion of compounds of Formulae (3) to (17) to (7) in Scheme 10.

Some compounds of Formula (2) may be prepared by the methods illustrated in Scheme 16.

SCHEME 16 Compounds of Formula (27b) may be treated with various alkylating agents R14X (where R14 is defined above and X is halogen, alkanesulfonyloxy or haloalkanesulfonyloxy) in the presence or absence of a base in an inert solvent to afford structures of Formula (28) . Compounds of Formula (28) (Y is 0) may then be converted to compounds of Formula (2) by treatment with halogenating agents or sulfonylating agents in the presence or absence of a base in an inert solvent, followed by reaction with R3H in the presence or absence of a base in an inert solvent to give compounds of Formula (2) . The reaction conditions used for these conversions are similar to the P ones employed for the conversion of intermediate compounds (22) to (23) to (1) in Scheme 14 (for A is CR) or the conversion of intermediate compounds of Formulae (7) to (8) to (1) in Scheme 1 (where A is N) .

Alternatively, compounds of Formula (28) (Y is S) may be alkylated with a compound RfX (where Rf is lower alkyl and X is halogen, alkanesulfonyloxy or haloalkanesulfonyloxy) in an inert solvent, (then op-ionally oxidized with an oxidizing agent in an inert solvent) and then reacted with R3H in the presence or absence of a base in an inert solvent to give a compound of Formula (1) . The conditions and reagents employed are similar to those used in the conversion of intermediate compounds of Formulae (7) to (12) (or to (13)) to compounds of Formula (1) in Scheme 2.

Compounds of Formula (1), where Z is COH, may be converted to compounds of Formula (2) as illustrated in Scheme 16. Treatment with various alkylating agents R14X (where R14 is defined above and X is halogen, alkanesulfonyloxy or haloalkanesulfonyloxy) in the presence or absence of a base in an inert solvent to afford structures (2) . It will be recognized by one skilled in the art that the methods used in Scheme 16 may also be used to prepare compounds of Formula (1) where Z is COR7.

For Scheme 16, the terms "base" and " inert solvent" may have the meanings given below. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide) , alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide) , alkali metal bis (trialkylsilyl) amides (preferably sodium bis (trimethylsilyl) amide) , trialkyl amines (preferably N, -di-isopropyl-N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine) . Inert solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile) , dialkyl ethers (preferably diethyl ether) , cyclic ethers (preferably tetrahydrofuran or 1, 4-dioxane) , N, -dialkylformamides (preferably dimethylformarnide) , N, N-dialkylacetamides (preferably dimethylacetamide) , cyclic amides (preferably N- methylpyrrolidin-2-one) , dialkylsulfoxides (preferably dir.iethylsulfoxide) , aromatic hydrocarbons (preferably benzene or toluene)' or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane) .

Preferred reaction temperatures range from -20°C to 100°C.

EXAMPLES Analytical data were recorded for the compounds described below using the following general procedures . Proton NMR spectra were recorded on an IBM-Bruker FT-NMR (300 MHz) ; chemical shifts were recorded in ppm (δ) from an internal tetramethysilane standard in deuterochloroform or deuterodimethylsulfoxide as specified below. Mass spectra (MS) or high resolution mass spectra (HRMS) were recorded on a Finnegan MAT 8230 spectrometer (using chemi-ionization (CI) with NH3 as the carrier gas or gas chromatography (GC) as specified below) or a Hewlett Packard 5988A model spectrometer. Melting points were recorded on a Buchi Model 510 melting point apparatus and are uncorrected. Boiling points are uncorrected. All pH determinations during workup were made with indicator paper.

Reagents were purchased from commercial sources and, where necessary, purified prior to use according to the general procedures outlined by D. Perrin and W.L.F. Armarego, Purification of Laboratory Chemicals, 3rd ed., (New York: Pergamon Press, 1988). Chromatography was 127871/3 performed on silica gel using the solvent systems indicated below. For mixed solvent systems, the volume ratios are given. Otherwise, parts and percentages are by weight.

The following examples are provided to describe the invention in further detail. These examples, which set forth the best mode presently contemplated for carrying out the invention, are intended to illustrate and not to limit the invention.

EXAMPLE 1 2,7-dimethyl-8-(2,4-dimethylphenyl)- pyrazolo-[l,5-a]-[l,3,5]-triazin-4(3H)-one (Formula 7, where Y is O, Ri is CH3, Z is C-CH3, Ar is 2,4-dimethylphenyl) A. 1 -Cyano- 1 -(2,4-dimethylphenyl)propan-2-one Sodium pellets (9.8g, 0.43 mol) were added portionwise to a solution of 2,4-dimethylphenylacetonitrile (48 g, 0.33 mol) in ethyl acetate (150 mL) at ambient temperature. The reaction mixture was heated to reflux temperature and stirred for 16 hours. The resulting suspension was cooled to room temperature and filtered. The collected precipitate was washed with copious amounts of ether and then' air-dried. The solid was dissolved in water and a IN HC1 solution was added until the pH = 5-6. The mixture was extracted with ethyl acetate (3 X 200 mL); the combined organic layers were dried over MgS04 and filtered. Solvent was removed in vacuo to afford a white solid (45.7g, 74% yield): NMR (CDC13,300 MHz): CI-MS: 188 (M + H).

B . 5- Amino-4-(2,4-dimethylphenyl)-3 -methylpyrazol e 127871/2 A mixture of l-cyano-l-(2,4-dimethylphenyl)propan-2-one (43.8g, 0.23 mol), hydrazine-hydrate (22 mL, 0.46 mol), glacial acetic acid (45 mL, 0.78 mol) and toluene (500 mL) were stirred at reflux temperature for 18 hours in an apparatus fitted with a Dean-Stark trap. The reaction mixture was cooled to ambient temperature and solvent was removed in vacuo. The residue was dissolved in 6N HCl and the resulting solution was extracted with ether three times. A concentrated ammonium hydroxide solution was added to the aqueous layer until pH = 11. The resulting semi-solution was extracted three times with ethyl acetate. The combined organic layers were dried over MgS0 and filtered. Solvent was removed in vacuo to give a pale brown viscous oil (34.6g, 75% yield): NMR (CDC13, 300 MHz): 57.10 (s, 1H), 57.05 (d, 2H, J=l), 52.37 (s, 3H), 52.10 (s, 3H); CI-MS: 202 (M + H).

C. 5-Acetamidino-4-(2,4-dimethylphenyl)-3-methylpyrazole) acetic acid salt Ethyl acetamidate hydrochloride (60g, 0.48 mol) was added quickly to a rapidly stirred mixture of potassium carbonate (69.5g. 0.50 mol), dichloromethane (120 mL) and water (350 mL). The layers were separated and the aqueous layer was extracted with dichloromethane (2 X 120 mL). The combined organic layers were dried over MgS04 and filtered. Solvent was removed by simple distillation and the pot residue, a clear pale yellow liquid, (35.0 g) was used without further purification.

Glacial acetic acid (9.7 mL, 0.17 mol) was added to a stirred mixture of 5-amino-4-(2,4-dimethylphenyl)-3-methylpyrazole (34g, 0.17 mol), ethyl acetamidate (22g. 0.25 mol) and acetonitrile (500 mL). The resulting reaction mixture was stirred at room temperature for 3 days; at the end of which time, it was concentrated in vacuo to about one-third of its original volume. The resulting suspension was filtered and the collected 127871/2 solid was washed with copious amounts of ether. The white solid was dried in vacuo (31.4g, 61 % yield): NMR (DMSO-d6, 300 MHz): 67.00 (s, 1H), 6.90 (dd, 2H, 5=7, 1), 52.28 (s, 3H), 52.08 (s, 3H), 52.00 (s, 3H), 51.90 (s, 3H), 51 .81 (s, 3H); CI-MS: 243 (M + H).

D. 2,7-dimethyl-8-(2,4-dimethylphenyl) -pyrazolo-[l ,5-a]-[l ,3,5]-triazin-4(3H)-one Sodium pellets (23g, 1 mol) were added portionwise to ethanol (500 mL) with vigorous stirring. After all the sodium reacted, 5-acetamidmo-4-(2,4-dimethylphenyl)-3-methylpyrazole, acetic acid salt (31.2g, 0.1 mol) and diethyl carbonate ( 97 mL, 0.8 mol) were added. The resulting reaction mixture was heated to reflux temperature and stirred for 18 hours. The mix was cooled to room temperature and solvent was removed in vacuo. The residue was dissolved in water and a IN HC1 solution was added slowly until pH = 5-6. The aqueous layer was extracted with ethyl acetate three times; the combined organic layers were dried over MgS04 and filtered. Solvent was removed in vacuo to give a pale tan solid (26g, 98% yield): NMR (CDC13, 300 MHz): 57.15(s, 1H), 57.09 (s, 2H), 52.45 (s, 3H), 52.39 (s, 3H), 52.30 (s, 3H); CI-MS: 5269 (M + H).

EXAMPLE 2 Preparation of 5-methyl-3-(2,4,6-trimethylphenyl)'[l,2,3]-triazolo- [1 ,5-a]- [ 1 ,3 , 5]-tri azin-7(6H)-one (Formula 7, where Y is O, Ri is CH3, Z is N, Ar is 2,4,6-trimethylphenyl) A. 1 -Phenylmethyl-4-(2,4,6-trimethylphenyl)-5-aminotriazole A mixture of 2,4,6-trimethylbenzyl cyanide (l .Og, 6.3 mmol), benzyl azide (0.92g, 6.9 mmol) and potassium 127871/2 t-butoxide (0.78g, 6.9 mmol) in tetrahydrofuran (lOmL) was stirred at ambient temperature for 2.5 days. The resulting suspension was diluted with water and extracted three times with ethyl acetate. The combined organic layers were dried over MgSC>4 and filtered. Solvent was removed in vacuo to give a brown oil. Trituration with ether and filtration afforded a yellow solid (1.12g, 61% yield): NMR (CDC13,300 MHz): 57.60-57.30 (m, 5H), 57.30-57.20 (m, 2H), 55.50 (s, 2H), 53.18 (br s, 2H), 52.30 (s, 3H), 52.10 (s, 6H); CI-MS: 293 (M + H).

B. 4-(2,4,6-Trimemylphenyl)-5-ammotriazole Sodium (500 mg, 22 mmol) was added with stirring to a mixture of liquid ammonia (30 mL) and l-phenylrnethyl-4-(2,4,6-trimethylphenyl)-5-aniinotriazole (l . lg, 3.8 mmol). The reaction mixture was stirred until a dark green color persisted. An ammonium chloride solution (mL) was added and the mixture was stirred while warming to ambient temperature over 16 hours. The residue was treated with a 1M HC1 solution and filtered. The aqueous layer was basified with a concentrated ammonium hydroxide solution (pH = 9) and then extracted with ethyl acetate three times. The combined organic layers were dried over MgSC>4 and filtered. Solvent was removed in vacuo to give a yellow solid (520 mg), which was homogeneous by thin layer chromatography (ethyl acetate): NMR (CDC13,300 MHz): 56.97 (s, 2H),' 53.68-53.50 (br.s, 2H), 52.32 (s, 3H), 52.10 (s, 6H); CI-MS: 203 (M + H).

C. 4-(2,4,6-Tiimethylphenyl)-5-acetamidinotriazole. acetic acid salt A mixture of 4-(2,4,6-trimethylphenyl)-5-aminotriazole (400 mg, 1.98 mmol), ethyl acetamidate (261 mg, 3 mmol) and glacial acetic acid (0.1 mL, 1.98 mmol) in aceionitrile (6 mL) was stirred at ambient 127871/2 temperature for 4 hours. The resulting suspension was filtered and the collected solid was washed with copious amounts of ether. Diying in vacuo afforded a white solid (490 mg, 82% yield): NMR (DMSO-d6, 300 MHz):57.90-57.70 (br s, 0.5H), 57.50-57.20 (br. s, 0.5H), 56.90 (s, 2H), 56.90 (s, 2H), 53.50-53.10 (br s, 3H), 62.30-52.20 (br s, 3H), 52.05 (d, 1H, J = 7), 51.96 (s, 6H), 51.87 (s, 6H); CI-MS: 244 (M + H).

D. 5-memyl-3-(2,4,6-trimethylphenyl)[l,5-a]- [l ,2,3]-triazolo-[l,3,5]-triazin-7(4H)-one Sodium (368 mg, 16.2 mmol) was added with stirring to ethanol (10 mL) at room temperature. After the sodium had reacted, 4-(2,4,6-trimethylphenyl)-5-acetamidino-triazole, acetic acid salt (490 mg, 1.6 mmol) and diethyl carbonate (1.6 mL, 13 mmol) were added. The reaction mixture was stirred at reflux temperature for 5 hours, then cooled to room temperature. The reaction mixture was diluted with water; a IN HC1 solution was added until pH = 5-6 and three extractions with ethyl acetate were performed. The combined organic layers were dried over MgS04 and filtered. Solvent was removed in vacuo to give a yellow residue. Trituration with ether and filtration afforded a yellow solid (300 mg, 69% yield): NMR (CDC13,300 MHz): 56.98 (s, 2H), 52.55 (s, 3H), 52.35 (s, 3H), 52.10 (s, 6H); CI-MS: 270 (M + H).

EXAMPLE 3 Preparation of 4-(di(carbomethoxy)methyl)- 2,7-dimethyl-8-(2,4-dimethylpheny])-pyrazolo-[l,5-a]- 1,3,5-triazine (Formula 1 , where R3 is CH(CHC02CH3)2) Ri is CH3, Z is C-CH3, Ar. is 2,4- dimethylphenyl) 127871/3 A. 4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)-pyrazolo-[l,5-a]-l ,3,5-triazine A mixture of 2,7-dimethyl-8-(2,4-dimethylphenyl) -pyrazolo [1,5-a] -l,3,5-triazin-4-one (Example 1, 1.38g, 4.5 mmol), Ν,Ν-dimethylaniline (1 mL, 8 mmol) and phosphorus oxychloride (10 mL) was stirred at reflux temperature for 48 hours. The excess phosphorus oxychloride was removed in vacuo. The residue was poured onto ice-water, stirred briefly and extracted quickly with ethyl acetate three times. The combined organic layers were washed with ice water, then dried oyer MgS04 and filtered. Solvent was removed in vacuo to give a brown oil. Flash column chromatography (ethyl acetate:hexanes::l:4) gave one fraction (Rf- 0.5) Solvent was removed in vacuo to afford a yellow oil (1.0 g, 68% yield): NMR (CDC13, 300 MHz): 57.55 (d, 1H, J - 1), 57.38 (dd, 1H, J - 7,1 ), 57.30 (d, 1H, J - 7), 52.68 (s, 3H), 52.45 (s, 3H); CI-MS:327(M + H).

B. 4-(bis(carb0methoxy)methyl)-2,7-dimethyl-8-(2,4-dimethylphenyl)-p)Tazolo-[l,5-a]-l,3,5-triazine Sodium hydride (60% in oil, 80 mg, 2 mmol) was washed with hexanes twice, decanted after each washing and taken up in anhydrous tetrahydrofuran (THF, 1 mL). A solution of diethyl malonate (0.32g, 2 mmol) in THF (2 mL) was added dropwise over 5 min, during which time vigorous gas evolution ensued. A solution "of 4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl) pyrazolo [1,5-a]- 1,3,5-triazine (0.5g, 1.75 mmol) in THF (2 mL) was added and the reaction mixture was then stirred under a nitrogen atmosphere for 48 hours. The resulting suspension was poured onto water and extracted three times with ethyl acetate. The combined organic layers were washed once with brine, dried over MgS04 and filtered. Solvent was removed in vacuo to give a brown 127871/3 oil. Column chromatography (ethyl acetate:hexanes:: l :9) afforded, after removal of solvent in vacuo, a pale yellow solid (Rf = 0.2, 250 mg, 35% yield): mp 50-52°C; NMR (CDCl'j, 300 MHz): 512.35 (br.s, 1H), 67.15-57.00 (m, 3H), 54.40 (q, 2H, J = 7), 54.30 (q, 21 Γ, J = 7), 52.4, 52.35, 52.3, 52.2, 52.1 (5s, 12H), 51.4 (t, 3H, J = 7), 51.35-51.25 (m, 3H); CI-HRMS: Calcd: 411.2032, Found: 411.2023.

EXAMPLE 6 Preparation of 4-(l,3-dimethoxy-2-propylamino)- 2,7-dimethyl-8-(2,4-dichlorophenyl) --pyrazolo-[l,5-a]-l,3,5-triazine (Formula 1, where R3 is NHCH(CH2OCH3)2, Ri is CH3, Z is C-CH3, A is 2 , 4-dichlorophenyl) A. 4-chloro-2,7-dimeth)'l-8-(2,4-dichlorophenyl)-pyrazolo-[l ,5-a]-l,3,5- triazine A mixture of 2,7-dimethyl-8-(2,4 dimethylphenyl) -p>Tazolo-[l ,5 -a]-l ,3,5-triazin-4-one (Example 1 , 1.38g, 4.5 mmol), Ν,Ν-dimethyl aniline (1 mL, 8 mmol) and phosphorus oxychloride (10 mL) was stin'ed at reflux temperature for 48 hours. The excess phosphorus oxychloride was removed in vacuo. The residue was poured onto ice-water, stirred briefly and exti'acted quickly with ethyl acetate three times. The combined organic layers were washed with ice water, then dried over MgS04 and filtered. Solvent as removed in vacuo to give a brown oil. Flash column chromatography (ethyl acetate: hex anes:: 1:4) gave one fraction (Rf = 0.5) Solvent was removed in vacuo to afford a yellow oil (l.Og, 68% yield): NMR (CDC13,300 MHz): 67.55 (d, 1H, J = 1), 57.38 (dd, 1 H, J - 7,1 ), 57.30 (d, 1H, J = 7), 52.68 (s, 3H), 52.45 (s, 3H); CI-MS: 327 (M + H). 127871/2 B. 4-(],3-dimemoxy-2-propylamino)-2)7-dirnethyl-8-(2,4-dichlorophenyl)-[l,5-a]-pyrazolo-1 ,3 , 5 -triazine A mixture of 4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[l,5-a]- pyrazolo-1 ,3,5-triazine (Part A, 570 mg, 1.74 mmol), l,3-dimethoxypropyl-2-aminopropane (25mg, 2.08 mmol) and ethanol (10 mL) was stirred at ambient temperature for 18 hours. The reaction mixture was poured onto water (25 mL) and extracted three times with ethyl acetate. The combined organic layers were dried over MgS04 and filtered. Solvent was removed in vacuo. Column chromatography (CH2Cl2:CH3OH::50:l) afforded one fraction. Removal of solvent in vacuo gave a solid (250 mg, 35% yield): mp 1 18-120°C; NMR (CDC13, 300 MHz): 67.50 (s, 1H), 57.28 (dd, 2H, J = 8,1), 56.75 (d, IH, J - 8), 54.70-54.58 (m, IH), 53.70-53.55 (m, 4H), 53.43 (s, 6H), 52.50 (s, 3H), 52.35 (s, 3H); CI-HRMS: Calcd: 409.1072, Found: 409.1085; Analysis Calcd. for C18H21 CI2N5O2: C, 52.69, H, 5.17, N, 17.07, CI, 17.28; Found: C, 52.82, H, 5.06, N, 16.77, CI, 17.50.

Using the above procedures and modifications known to one skilled in the art of organic synthesis, the following additional examples of Tables 1-4 may be prepared.

The examples delineated in TABLE 1 may be prepared by the methods outlined in Examples 1, 2, 3 or 6. Commonly used abbreviations are: Ph is phenyl, Pr is propyl, Me is methyl, Et is ethyl, Bu is butyl, Ex is Example. Δ mp (AC) 6a C-Me NHCH (CH20Me) 2 2, 4-Cl2-Ph 118-120 7b C-Me NHCHP r2 2, -Cl2-Ph 114-116 C-Me NEtBu 2, -Cl2-Ph oil C-Me NPr (CH2-C-C3H5) 2, 4-Cl2-Ph oil 10e C-Me (CH2CH20Me) 2 2, 4-Cl2-Ph oil 11* C-Me NH-3-heptyl 2, -Cl2-Ph 90-92 129 C-Me NHCH (Et)'CH20Me · 2, -Cl2-Ph 179-181 13h C-Me NE 2 2, -Cl2-Ph 133-134 14 C-Me NHCH (CH20Et) 2 2, -Cl2-Ph oil 153 C-Me NH-3-pentyl 2, 4-Cl2-Ph 139-140 16" C-Me NMePh 2, 4-Cl2-Ph 60-62 17l C-Me Pr2 2, -Cl2~Ph oil liem C-Me NH-3-hexyl 2, -Cl2-Ph 130-132 19 C-Me mo pholino 2, -Cl2-Ph 20 C-Me (CH2P ) CH2CH20Me 2, 4-Cl2-Ph 21 C-Me NHCH (CH2Ph) CH20Me 2, 4-Cl2-Ph 22 C-Me NH-4-te rahydropyranyl 2, 4-Cl2-Ph 23 C-Me NH-cyclopentyl 2, -Cl2-Ph 24 C-Me 1,2,3, 4-tetrahydro- 2, 4-Cl2~Ph isoquinolinyl 25 C-Me CH2- (1, 2, 3, 4-tetrahydro- 2, 4-Cl2~Ph isoquinolinyl ) 26n C-Me OEt 2, -Cl2-Ph 141-143 27 C-Me OCH (Et) CH20Me 2, 4-Cl2"Ph 28 C-Me OCH2Ph 2, -Cl2-Ph 29 . C-Me O-3-pencyl 2, 4-Cl2-Ph 30 C-Me SEt 2, 4-Cl2-Ph 31 C-Me S(0)Et 2, 4-Cl2-Ph 32 C-Me S02E 2, -Cl2-Ph 33 C-Me CH (C02Et) 2 2, 4-Cl2-Ph 34 C-Me C (Et) (C02Et) 2 2, 4-Cl2-Ph 35 C-Me CH (Et) CH20H 2, 4-Cl2-Ph 36 C-Me CH (Et) CH20Me 2, 4-Cl2-Ph 37 C-Me CONMe2 2, -Cl2-Ph 38 C-Me COCH3 2, 4-Cl2-Ph 39 C-Me CH (OH) CH3 2, 4-Cl2-Ph 40 G^Me C (OH) Ph-3-pyridyl 2, 4-Cl2-P 41 C-Me Ph 2, 4-Cl2-Ph 42 C-Me 2-CF3-Ph 2, 4-Cl2-Ph 43 C-Me 2-Ph-Ph 2, 4-Cl2~Ph 44 C-Me 3-pentyl 2, 4-Cl2-Ph 45 C-Me cyclobutyl 2, 4-Cl2-Ph 46 C-Me 3-pyridyl 2, -Cl2-Ph 47 C-Me CH (Et) CH2CO Me2 2, -Cl2-Ph 48 C-Me CH(Et)CH2CH2 Me2 2,4-Cl2-Ph 49° C-Me NHCH (CH20Me) 2 2,4, 6-Me3-P 125-127 50 C-Me NHCHPr2 2,4, 6-Me3-Ph 51 C-Me NEtBu 2, 4, 6-Me3-Ph 52 C-Me NPr (CH2-C-C3H5) 2, , 6-Me3-Ph 53ae C-Me (CH2CH20Me) 2 2, 4, 6-Me3-Ph 123-124 54 C-Me NH-3-heptyl 2,4, 6-Me3-Ph 55ac C-Me NHCH (Et)CH20Me 2, 4, 6-Me3-Ph 145-146 56ah C-Me NEt2 2,4, 6-Me3-Ph 88-90 57ai C-Me NHCH (CH20Et) 2 2, 4, 6-Me3-P 132-134 58ad C-Me NH-3-pentyl 2,4, 6-Me3-Ph 134-135 59 C-Me NMePh 2,4, 6-Me3-Ph 60 C-Me Pr2 2,4, 6-Me3-Ph 61 C-Me NH-3- exyl 2, , 6-Me3-Ph 62 C-Me morpholino 2,4, 6-Me3-Ph 63 C-Me (CH2Ph)CH2CH20Me 2,4, 6-Me3-Ph 64 C-Me NHCH (CH2Ph) CH20Me 2,4, 6-Me3~Ph 65 C-Me NH-4-tetrahydropyranyl 2,4, 6-Me3-Ph 66 C-Me NH-cyclopentyl 2,4, 6-Me3~Ph 67 C-Me 1, 2, 3 , 4-cetrahydro- 2, 4, 6-Me3-Ph isoquinolinyl 68 C-Me CH2- (1, 2, 3 , 4-tetrahydro- 2, 4, 6-Me3-Ph isoquinolinyl ) 69 C-Me OEt 2,4, 6-Me3-Ph 70 C-Me OCH (Et)CH20Me 2,4, 6-Me3-Ph 71 C-Me OCH2Ph 2,4, 6-Me3-Ph 72 C-Me O- 3-pentyl 2 , 4, 6-Me3÷Ph 7 3 C-Me SEt 2,4, 6-Me3-Ph 74 C-Me S (0) Et 2,4, 6-Me3-Ph 75 C-Me 502Et 2,4, 6-Me3-Ph 7 6 C-Me CH (C02Et) 2 2,4, 6-Me3-Ph 77 C-Me C(Et) (C02Et)2 2,4, 6-Me3-Ph 78 C-Me CH (EUCH2OH 2,4, 6-Me3-Ph 7 9 C-Me CH (Et)GH20Me 2,4, 6-Me3-Ph 8 0 C-Me CONMe2 2,4, 6-Me3~Ph 81 C-Me COCH3 2,4, 6-Me3~Ph 82 C-Me CH (OH) CH3 2,4, 6-Me3-Ph 83 C-Me C (OH) Ph- 3-pyridyl 2,4, 6-Me3-Ph 84 C-Me Ph 2,4, 6-Me3-Ph 85 C-Me 2-CF3-Ph 2,4, 6-Me3~Ph 86 C-Me 2-Ph-Ph 2,4, 6-Me3-Ph 87 C-Me 3-pencyl 2,4, 6-Me3-Ph 88 C-Me cyclobutyl 2,4, 6-Me3-Ph 89 C-Me 3-pyridyl 2, , 6-Me3-P 90 C-Me CH(Et)CH2CONMe2 2,4, 6-Me3~Ph 91 C-Me CH(£t)CH2CH2NMe2 2, 4, 6-Me3-Ph 92P C-Me NHCH (CH20Me) 2 2, 4-Me2-Ph 44-45 933 C-Me N(CH2CH20Me) 2 2, 4-Me2"Ph oil 94 r C-Me NHCH(Et)CH20Me 2, 4-Me2-Ph 102-104 95s C-Me NH- 3-pentyl 2, 4-Me2" h 102-104 96* C-Me NEt2 2, 4-Me2~Ph oil 97u C-Me N (CH2CN) 2 2, 4-Me2~Ph 148-150 98v C-Me NHCH (Me) CH20Me 2, -Me2-Ph 102-104 99w C-Me OCH (Et) CH20Me 2, -Me2-Ph Oil 100x C-Me NPr-c-C3Hs 2, -Me2-Ph oil 101* C-Me NHCH(Me)CH2NMe2 2, -Me2~Ph 47-48 102z C-Me N(c-C3H5)CH2CH2C 2, -Me2-Ph 117-118 103aa C-Me N(Pr)CH2CH2CN 2, 4- e2"P oil 104ab C-Me (Bu) CH2CH2CN 2, 4-Me2~Ph oil 105 C-Me NHCHPr2 2, -Me2-Ph 105· C-Me NEtBu 2, -Me2~Ph 107 C-Me NPr (CH2-C-C3H5) 2, 4- e2-Ph 108 C-Me NH-3-heptyl 2, -Me2~Ph 109 C-Me NEt2 2, 4-Me2"Ph 110 C-Me NHCH (CH20Et) 2 2, 4-Me2-Ph 111 C-Me NH-3-pentyl 2, 4-Me2-Ph 112 C-Me NMePh 2, -Me2~Ph 113 C-Me NPr2 2, 4-Me2-Ph 114 C-Me NH-3-hexyl 2, 4-Me2~P 115 C-Me morpholino 2, 4-Me2"Ph 116 C-Me N (CH2Ph) CH2CH20Me 2, -Me2~Ph 117 C-Me NHCH (CH2Ph) CH20Me 2, -Me2"Ph 118 C-Me NH-4-tet rahydropyranyl 2,4-Me2-Ph 119 C-Me NH-cyclopentyl 2, -Me2"Ph 120 C-Me 1,2, 3, 4-tetrahydro- 2, 4-Me2-Ph isoquinolinyl 121 C-Me CH2- (1,2, 3, 4-tetrahydro- 2, 4-Me2~Ph isoquinolinyl) 122 C-Me OEt 2, 4-Me2"Ph 123 C-Me OCH(Et)CH20Me 2, 4-Me2"Ph 124 C-Me OCH2Ph 2, 4-Me2"Ph 125 C-Me O-3-pentyl 2, 4- e2*Ph 126 C-Me SEt 2, 4-Me2~Ph 127 C-Me S (O) Et 2, 4- e2~ h 128 C-Me S02Et 2, 4-Me2~Ph 3 C-Me CH (C02Et) 2 2, -Me2~Ph 50-52 129 C-Me C(Et) (C02Et)2 2, 4-Me2~Ph 130 C-Me CH (Et) CH2OH 2, -Me2~Ph 131 C-Me CH(Et)CH20Me 2, 4-Me.2"Ph 132 C-Me CH (Et) CH20Et 2, 4-Me2-Ph 133 C-Me CONMe2 2, - e2~Ph 134 C-Me COCH3 2, 4-Me2-Ph 135 C-Me CH (OH)CH3 2, 4-Me2-P 136 C-Me C (OH) Ph-3-pyridyl 2, 4-Me2-Ph 137 C-Me Ph 2, 4-Me2-Ph 13S- C-Me 2-CF3-Ph 2, -Me2-Ph 139 C-Me 2-Ph-Ph 2, 4-Me2-Ph 140 C-Me 3-pentyl 2, -Me2-Ph 141 C-Me cyclobutyl 2,4-Me2-Ph 142 C-Me 3-pyridyl 2, -Me2~Ph 143 C-Me CH (Et)CH2CONMe2 2, 4-Me2-Ph 144 C-Me CH (Et) CH2CH2NMe2 2 , 4-Me2-P 145bc C-Me NHCH (CH20Me) 2 2-Me-4-MeO-Ph 45-46 1 6bd C-Me N (CH2CH20Me) 2 2-Me-4-MeO-Ph oil 147be C-Me NHCH (Et)CH20Me 2-Me-4-MeO-Ph 86-88 148bf C-Me N (Pr) CH2CH2CN 2-Me-4-MeO-Ph oil 149 C-Me OCH (Et) CH20Me 2-Me-4-MeO-Ph 150af C-Me NHCH (CH20Me) 2 2-Br-4-MeO-Ph 88-90 151al C-Me N (CH2CH20Me) 2 2-Br-4-MeO-Ph oil 152a9 C-Me NHCH (Et)CH20Me 2-Br-4-MeO-Ph 95-97 153 C-Me (Pr)CH2CH2C 2-Br-4-MeO-Ph 154 C-Me OCH (Et) CH20Me 2-Br-4-MeO-Ph 155 C-Me NHCH (CH20Me) 2 2-Me-4-NMe2~Ph 156 C-Me N(CH2CH20 e)2 2-Me-4-NMe2~Ph oil 157 C-Me NHCH (Et) CH20 e 2-Me-4-NMe2-Ph 158 C-Me N(Pr)CH2CH2CN 2-Me-4-NMe2-P 159 C-Me OCH (Et) CH20Me 2-Me-4-NMe2~Ph 160 C-Me NHCH (CH20Me) 2 2-Br-4-NMe2~Ph 161 C-Me N(CH2CH20 e) 2 2-Br-4-NMe2~Ph 162 C-Me NHCH (Et)CH20Me 2-Br-4-NMe2~Ph 163 C-Me (Pr)CH2CH2C 2-Br-4-NMe2~Ph 164 C-Me OCH(Et)CH20Me 2-Br-4-NMe2"Ph 165 C-Me NHCH (CH20Me) 2 2-Br-4-i-Pr-Ph 166 C-Me N (CH2CH20Me) 2 2-Br-4-i-Pr-Ph 167 C-Me NHCH(Et)CH20Me 2-Br-4-i-Pr-Ph 168 C-Me N (Pr) CH2CH2C 2-Br-4-i-Pr-Ph 169 C-Me OCH (Et)CH20Me 2-Br-4-i-Pr-Ph 170 C-Me NHCH (CH20Me) 2 2-Br-4-Me-Ph 171 C-Me N (CH2CH20Me) 2 2-Br-4-Me-Ph 172 C-Me NHCH (Et)CH20Me 2-Br-4-Me-P 173 C-Me (Pr) CH2CH2CN 2-Br-4-Me-Ph 17* C-Me OCH (Et)CH20Me 2-Br-4-Me-Ph 175ar C-Me NHCH (CH20Me) 2 2-Me-4-Br-Ph 108-109 176 C-Me (CH2CH20Me) 2 2-Me-4-Br-Ph 177 C-Me NHCH (Et)CH20Me 2-Me-4-Br-Ph 17Θ C-Me (Pr ) CH2CH2C 2-Me-4-Br-Ph 179 C-Me OCH (Et) CH20Me 2-Me-4-Br-Ph 180 C-Me NHCH (CH20Me) 2 2-C1-4, 6-Me2-Ph 181 C-Me N (CH2CH20Me) 2 2-C1- , 6-Me2-Ph 182 C-Me NHCH (CH20Me) 2 4-Br-2, 6- (Me) 2-Ph 183 C-Me N (CH2CH 0Me) 2 4-Br-2, 6- (Me) 2~Ph 184 C-Me NHCH (CH20Me) 2 4-i-Pr-2-SMe-Ph 185 C-Me (CH2CH20Me) 2 4-i-Pr-2-SMe-P 186 C-Me NHCH (CH20Me) 2 2-Br-4-CF3-Ph 187 C-Me N (CH2CH20Me) 2 2-Br-4-CF3-Ph 188 C-Me NHCH (CH20Me) 2 2-Br-4 , 6- (MeO) 2~ h 189 C-Me N (CH2CH20Me) 2 2-Br-4, 6- (MeO) 2~ h 190 C-Me NHCH (CH20Me) 2 2-C1-4, 6- (MeO) 2- h 191 C-Me N (CH2CH20Me) 2 2-C1-4, 6- (MeO) 2-Ph 192 C-Me NHCH (CH20Me) 2 2, 6- (Me) 2-4-SMe-P 193 C-Me N (CH2CH20Me) 2 2, 6- (Me) 2-4-SMe-Ph 194 C-Me NHCH (CH20Me) 2 4- (COMe) -2-Br-Ph 195 C-Me (CH2CH20Me) 2 4- (COMe) -2-Br-Ph 196 C-Me NHCH (CH20Me) 2 2, 4, 6-Me3-pyrid-3-yl 197 C-Me N (CH2CH20Me) 2 2, 4, 6-Me3-pyrid-3-yl 198 C-Me NHCH (CH20Me) 2 2,4-(Br)2-Ph 199 C-Me (CH2CH20Me) 2 2,4-(Br)2~Ph 200 C-Me NHCH (CH20Me) 2 4-i-Pr-2-SMe-Ph 201 C-Me N (CH2CH20Me) 2 4 -i-Pr-2-SMe-Ph 127871/2 202 C-Me NHCH (CH20Me> 2 4-i-Pr-2-S02Me-Ph 203 C-Me · (CH2CH20Me)2 4-i-Pr-2-S02Me-Ph 204 C-Me NHCH (CH20Me) 2 2, 6- (Me) 2-4-SMe-Ph 205 C-Me N (CH2CH20Me) 2 2,6- (Me) 2-4-SMe-Ph 206 C-Me NHCH(CH20Me)2 2, 6- (Me) 2-4-S02Me-Ph 207 C-Me N (CH2CH20Me) 2 2, 6- (Me) 2-4-S02Me-Ph 208 C-Me NHCH (CH20Me)2 2-I-4-i-Pr-Ph 209 C-Me (CH2CH20Me)2 2-I-4-i-Pr-Ph .21 C- C-Me NHCH (CH20Me)2 2-Br-4- (Me) 2-6-MeO-Ph 211 C-Me (CH2CH20Me)2 2-Br-4- (Me) -6-MeO-Ph 212 C-Me NHCH (CH20Me) 2 2, - [SMe] 2-Ph 213 C-Me (CH2CH20Me)2 2, - [SMe] 2-Ph 214 C-Me NHCH (CH20Me) 2 2, - [S02 e] 2-Ph 215 C-Me (CH2CH20Me) 2 2, - [S02Me] 2-Ph 216 C-Me NHCH (CH20Me) 2 4-i-Pr-2-SMe-Ph 217 C-Me N (CH2CH20Me)'2 4-i-Pr-2-SMe-Ph 218 C-Me NHCH (CH20Me) 2 4-i-?r-2-S02Me-Ph 219 C-Me (CH2CH20Me) 2 4-i-Pr-2-S02Me-Ph 220 C-Me NHCH (CH20Me)2 2-N (Me) 2-4-Me-?h 22.1 C-Me N (CH2CH20Me) 2 2-N (Me) 2-4-Me-Ph 222 C-Me NHCH (CH20 e) 2 2-MeS- , 6- (Me) 2~P 223 C-Me (CH2CH20Me) 2 2-MeS-4 , 6r (Me) 2-Ph 224 C-Me NHCH (CH20Me) 2 2- (CH3CO) -4, 6- (Me) 2-Ph 225 C-Me N (CH2CH20Me) 2 2- (CH3CO) -4, 6- (Me) 2-P 227 H NHCH (CH20Me) 2 2 , - e2~Ph :229 CF3 N 1 C-Me (CH2CH20Me) 2 2-Cl-4-MeOPh oil 356bm C-Me NHCH (Et) CH20Me 2-Cl-4-MeOPh 108-110 357bn C-Me N (c-Pr) CH2CH2C 2-Cl-4-MeOPh 127-129 358bo C-Me NEt2 2-Cl-4-MeOPh oil 359bP C-Me NH-3-pentyl 2-Cl-4-MeOPh 77-79 360 C-Me NHCH (Et)CH2CH20Me 2-Cl-4-MeOPh 361 C-Me NHCH (Me) CH2CH20 e 2-Cl-4-MeOPh 362 C-Me NHCH(Et)CH2CH20Me 2-Br-4-MeOPh 363 C-Me NHCH (Me)CH2CH20Me 2-Br-4-MeOPh 364 C-Me NHCH (Et) CH2CH20Me 2-Me-4-MeOPh 365 C-Me NHCH (Me) CH2CH20Me 2-Me-4-MeOPh 366 C-Me NHCH (CH20Me) 2 2 -Cl-4, 5- (MeO) 2Ph 367 C-Me N (CH2CH20Me) 2 2 -Cl-4 , 5- (MeO) 2Ph 368 C-Me NHCH (EC) CH20Me 2 -Cl-4, 5- (MeO) 2 h 369 C-Me (c-Pr) CH2CH2CN 2 -Cl-4, 5- (MeO) 2 h 370 C-Me NEt2 2 -Cl-4, 5- (MeO) 2Ph 371 C-Me NH-3-pentyl 2 -Cl-4, 5- (MeO) 2Ph 372 C-Me NHCH (Et) CH2CH20 e 2· -Cl-4, 5- (MeO) 2Ph 373 C-Me NHCH (Me)CH2CH20Me 2--Cl-4, 5- (MeO) 2Ph 374bc? C-Me NHCH (CH20Me) 2 2· -Br-4 , 5- (MeO) 2Ph 137-138 375 C-Me N(CH2CH20 e)2 2--Br-4, 5- (MeO) 2p h 376br C-Me NHCH (Et) CH20Me 2--Br-4, 5-(MeO)2Ph 147-148 377 C-Me N (C-PDCH2CH2CN 2-■Br-4, 5- (MeO) 2Ph 378bs C-Me NEt2 2--Br-4, 5- (MeO) 2Ph 52-58 379 C-Me NH- 3-pentyl 2-Br-4, 5 - (MeO) 2Ph 380 C-Me NHCH(Et)CH2CH20Me 2-Br-4, 5 - (MeO) 2Ph 381 C-Me NHCH (Me) CH2CH20Me 2-Br- , 5 - (MeO) 2Ph 382 C-Me NHCH (CH20Me) 2 2-C1-4, 6 - (MeO) 2Ph 383 C-Me (CH2CH20Me) 2 2-C1-4, 6 - (MeO) 2Ph 384 C-Me NHCH (Et)CH20Me 2-C1-4, 6 - (MeO) 2Ph 385 C-Me N (c-Pr) CH2CH2CN 2-C1-4, 6- (MeO) 2Ph 386 C-Me NEt2 2-C1-4, 6 - (MeO) 2Ph 38V C-Me NH- 3-pentyl 2-C1-4, 6 - (MeO) 2?h 388 C-Me NHCH (Et) CH2CH20Me 2-C1-4, 6 - (MeO) 2Ph 389 C-Me NHCH (Me) CH2CH20Me 2-C1-4, 6 - (MeO) 2Ph 390 C-Me NHCH (CH20Me) 2 2-Me- , 6 - (MeO) 2Ph 391 C-Me (CH2CH20Me) 2 2-Me-4, 6 - (MeO) 2P 392 C-Me NHCH (Et)CH20Me 2-Me-4, 6 - (MeO) 2P 393 C-Me N (c-Pr) CH2CH2CN 2-Me-4, 6 - (MeO) 2Ph 395 C-Me NEt2 2-Me- , 6 - (MeO) 2 h 396 C-Me NH- 3-pentyl 2-Me-4, 6 - (MeO) 2 h 397 C-Me NHCH(Et)CH2CH20Me 2-Me- , 6 - (MeO) 2Ph 398 C-Me NHCH(Me)CH2CH20Me 2-Me- , 6- (MeO) 2Ph 399 C-Me N (c-Pr) CH2CH2C 2-Br- , 6 - (MeO) 2Ph 400 C-Me NEt2 2-Br-4, 6 - (MeO) 2Ph 401 C-Me NH- 3-pencyl 2-Br-4, 6 - (MeO) 2Ph 402 C-Me NHCH (Et)CH2CH20Me 2-Br-4, 6 - (MeO) 2Ph 403 C-Me NHCH (Me) CH2CH20 e 2-Br-4, 6 - (MeO) 2Ph 404 C-Me NHCH (Et)CH2CH20Me 2-Me-4-MeOPh 405 C-Me NHCH (Me) CH2CH20Me 2-Me-4-MeOPh 406 C-Me NHCH (CH20Me) 2 2-Me0-4-MePh 407 C-Me N (CH2CH20Me) 2 2-MeO-4-MePh 408 C-Me NHCH (Et) CH20Me 2-Me0-4-MePh 409 C-Me N(c-Pr)CH2CH2CN 2-MeO-4-MePh 410 C-Me NEt2 2-MeO-4-MePh 411 C-Me NH- 3-pentyl 2-Me0-4-MePh 412 C-Me NHCH(Et)CH2CH20Me 2-Me0-4-MePh 413 C-Me NHCH (Me)CH2CH20Me 2-MeO-4-MePh 414 C-Me NHCH(CH20Me)2 2-MeO-4-MePh 415 C-Me N(CH2CH20Me) 2 2-MeO-4-MePh 127871/4 416 C-Me NHCH(Et)CH2OMe 2-MeO-4-MePh 417 C-Me N(c-Pr)CH2CH2CN 2-MeO-4-MePh 418 C-Me NEt2 2-MeO-4-MePh 419 C-Me NH-3-pentyl 2-MeO-4-MePh 420 C-Me NHCH(Et)CH2CH2OMe 2-MeO-4-MePh 421 C-Me NHCH(Me)CH2CH2OMe 2-MeO-4-MePh 423bt C-Me NHCH(CH2OMe)2 2-MeO-4-ClPh 424 C-Me N(CH2CH2OMe)2 2-MeO-4-ClPh 425 C-Me NHCH(Et)CH2OMe 2-MeO-4-ClPh 426 C-Me N(c-Pr)CH2CH2CN 2-MeO-4-ClPh 427 C-Me NEt2 2-MeO-4-ClPh 428 C-Me NH-3-pentyl 2-MeO-4-ClPh 429 C-Me NHCH(Et)CH2CH2OMe 2-MeO-4-ClPh 430 C-Me NHCH(Me)CH2CH2OMe 2-MeO-4-ClPh NOTES FOR TABLE 1: a) Analysis Calcd: C, 52.69, H, 5.17, N, 17.07, CI, 17.28; Found: C 52.82, H, 5.06, N, 16.77, CI, 17.50. b) CI-HRMS: Calcd: 406.1565, Found: 405.1573 (M + H); Analysis Calcd: C: 59.1 1 ; H: 6.20; N: 17.23; CI: 17.45; Found: C: 59.93; H: 6.34; N: 16.50; CI: 16.95; NMR (CDCI3, 300 MHz): 60.95 (t, J= 8, 4H), 51.30- 51.40 (m, 4H), 51.50- 51.75 (m, 4H), 52.35 (s, 3H), 52.48 (s, 3H), 54.30- 54.45 (m, 1H), 56.15 (d, J = 8, 1H), 57.30 (s, 2H), 57.50 (s 1H). c) CI-HRMS: Calcd: 392.1409, Found: 392.1388 (M + H); NMR (CDCI3, 300 MHz): 51.00 (t, J =8, 3H), 51.35 (t, J = 8, 3H), 51.41 (q, J = 8, 2H), 51.65- 51.85 (m, 2H), 52.30 (s, 3H), 52.40 (s, 3H), 53.85- 54.20 (m, 4H), 57.30 (s, 2H), 5 7.50 (s, 1H). d) CI-HRMS: Calcd: 404.1409, Found: 404.1408 (M + H); NMR(CDC13, 300 MHz): 50.35-50.45 (m, 2H), 50.52- 50.62 (m, 2H), 50.98 (t, J = 8, 3H), 51.70- 51.90 (m, 2H), 127871/2 62.30 (s, 3H), 62.40 (s, 3H), 63.85-64.02 (m 2H), 64.02-64.20 (m, 2H), 67.30 (s, 2H), 67.50 (s, 1H). e) CI-HRMS: Calcd: 424.1307, Found: 424.1307 (M + H): NMR (CDCI3, 300 MHz): 62.28 (s, 3H), 62.40 (s, 3H), 63.40 (s 6H), 63.75 (t, J = 8, 4H), 64.20-64.45 (m, 4H), 67.30 (s, 2H), 67.50 (s, 1H). f) CI-HRMS: Calcd: 406.1565, Found: 406.1578 (M + H); NMR (CDC13: 300 MHz): 60.90 (t, J = 8, 3H), 61.00 (t, J = 8, 3H), 61.28- 61.45 (m, 4H), 61.50-61.80 (m, 4H), 62.35 (s, 3H), 62.50 (s, 3H), 64.20-64.35 (m, IH), 66.10-66.23 (m, IH), 67.30 (s, 2H), 67.50 (s, 1H). g) CI-HRMS: Calcd: 394.1201 , Found: 394.1209 (M + H); NMR (CDCI3, 300 MHz): 61.02 (t, J = 8, 3H), 61.65-61.90 (m, 2H), 62.35 (s, 3H), 62.48 (s, 3H), 63.40 (s, 3H), 63.50-63.60 (m, 2H), 64.35-64.45 (brs, IH), 66.50-66.60 (m, IH), 67.30 (s, 2H), 67.50 (s, IH). h) CI-HRMS: Calcd: 364.1096, Found: 364.1093 (M + H); Analysis: Calcd: C: 56.05; H: 5.27; N: 19.23; CI: 19.46; Found: C: 55.96; H: 5.24; N: 18.93; CI: 19.25; NMR (CDC13, 300 MHz): 61.35 (t, J = 8, 6H), 62.30 (3, 3H), 62.40 (s, 3H), 63.95-64.15 (m, 4H), 67.30 (s, 2H), 67.50 (d, J = 1 , IH). i) CI-HRMS: Calcd: 438-.1464, Found: 438.1454 (M + H); NMR (CDCI3, 300 MHz): 61.22 (t, J = 8, 6H), 62.35 (s, 3H), 62.47 (s, 3H), 63.39 (q, J = 8, 4H), 63.65 (dd, J = 8, 1 , 2H), 63.73 (dd, J = 8,1 , 2H), 64.55- 64.65 (m, IH), 66.75 (d, J - 8, IH), 67.30 (d, J - 1 , 2H), 67.50 (s, IH). j) CI-HRMS: Calcd: 378.1252, Found: 378.1249 (M + H); Analysis: Caicd: C: 57.15; H: 5.61; N: 18.51; CI: 18.74; Found: C: 57.56; H: 5.65; N: 18.35; CI; 18.45; NMR (CDCI3, 300 MHz): 61.00 (t, J - 8, 6H), 61.55-61.70 (m, 2H), 61.70- 61.85 (m, 2H), 62.35 (s, 3H), 62.50 127871/2 (s, 3H), 54.15-54.25 (m, IH), 56.18 (d, J = 8, 1H), 57.30 (s, 2H), 57.50 (s, IH). k) CI-HRMS: Calcd: 398.0939, Found: 398.0922 (M + H); Analysis: Calcd: C: 60.31 ; H: 4.30; N: 17.58; CI: 17.80; Found: C: 60.29; H: 4.59; N: 17.09; CI: 17.57; NMR (CDC13, 300 MHz): 52.05 (s, 3H), 52.50 (s, 3H), 53.78 (s, 3H), 57.20- 57.45 (m, 7H), 57.50(d,J=l,lH). 1) CI-HRMS: Calcd: 392.1409, Found: 392.1391 (M + H); NMR (CDC13, 300 MHz): 50.98 (t, J = 8, 6H), 51.70-51.85 (m, 4H), 52.30 (s, 3H), 52.40 (s, 3H), 53.80-54.10 (m, 4H), 57.30 (s, 2H): 57.50 (d, J = 1,1 H). m) CI-HRMS: Calcd: 392.1409, Found: 392.1415 (M+ H); Analysis: Calcd: C: 58.17; H: 5.92; N: 17.85; CI: 18.07; Found: C: 58.41 ; H: 5.85:N: 18.10; CI: 17.75; NMR (CDC13, 300 MHz): 50.90-51.05 (m, 6H), 51.35-51.55 (m, 2H), 51.55- 51.85 (m, 4H), 52.35 (s, 3H), 52.48 (s, 3H), 54.20-54.35 (m, IH), 56.15 (d, J = 8,1H), 57.30 (s, 2H), 57.50 (d, J= 1, IH). n) CI-HRMS: Calcd: 337.0623, Found: 337.0689 (M + H); Analysis: Calcd: C: 53.43; H: 4.18; N: 16.62; CI: 21.03, Found: C: 53.56; H: 4.33; N: 16.56; CI: 20.75; NMR (CDCI3, 300 MHz): 51.60 (t, .1 = 83 3H), 52.40 (s, 3H), 52.55 (s, 3H), 54.80 (q, J = 8, 2H), 57.30 (d, J = 8,1H), 57.35 (dd, J = 8, 1 ,1H), 57.55 (d, J = 1 , IH) o) CI-HRMS: Calcd: 383.2321, Found: 383.2309 (M + H); NMR (CDCU, 300 MHz): 52.00 (s, 6H), 52.20 (s, 3H), 52.30 (s, 3H), 52.45 (s, 3H), 53.45 (s, 6H), 53.61 (dd, J = 8, 8, 2H), 53.70 (dd, J - 8, 8, 2H), 54.60- 54.70 (m, IH) 56.70 (d, J-8, IH), 56.94 (s,2H). p) CI-HRMS: Calcd: 370.2243, Found: 370.2246 (M + H); 127871/2 Analysis: Calcd: C: 65.02; H: 7.38; N: 18.96; Found: C: 65.22; H: 7.39; N: 18.71 ; NMR (CDC13, 300 MHz): 52.18 (s, 3H), 52.30 (s, 3H), 52.45 (s, 3H), 53.45 (s, 6H), 53.60 (dd, J = 8, 8, 2H), 53.69 (dd, J = 8, 8, 2H), 54.60-54.70 (m, IH), 56.70 (d, J = 8, 1H), 57,05 (d, J=8, IH), 57.07 (d, J = 8, 1H), 57.10 (s, 1H). q) CI-HRMS: Calcd: 384.2400, Found: 384.2393 (M + H); NMR (CDC13, 300 MHz): 52.16 (s, 3H), 52.25 (s, 3H), 52.35 (s, 3H), 52.39 (s, 3H), 53.40 (s, 6H), 53.77 (t, J=8, 4H), 54.20-54.45 (m, 4H), 57.02 (d, J=8, IH) 57.05 (s, IH), 57.10(d, J = 7, IH). r) CI-HRMS: Calcd: 354.2294, Found: 354.2271 (M + H); Analysis: Calcd: C: 67.96; H: 7.71 ; N: 19.81; Found: C: 67.56; H: 7.37; N: 19.60; NMR (CDC13, 300 MHz): 51.03 (t, J = 8, 3H), 51.65-51.88 (m, 2H), 52.17 (s, 3H), 52.30 (s, 3H), 52.35 (s, 3H), 52.45 (s, 3H), 53.40 (s, 3H), 53.50- 53.62 (m, 2H), 54.30-54.45 (m, IH), 56.51 (d, J = 8, IH), 57.04 (d J = 8, IH), 57.10 (d, J=8, IH), 57.12 (s, IH). s) CI-HRMS: Calcd: 338.2345, Found: 338.2332 (M + H); Analysis: Calcd: C: 71.18; H: 8.06; N: 20.75; Found: C: 71.43; H: 7.80; N: 20.70; NMR (CDC13, 300 MHz): 51.00 (t, J = 8, 6H), 51.55-51.70 (m, 2H), 5-1.70-51.85 (m, 2H), 62.19 (s, 3H), 62.30 (s, 3H), 62.35 (s, 3H), 52.46 (s, 3H), 54.15-54.26 (m, IH), 66.17 (d, J = 8, IH), 67.06 (d, J = 8, IH), 57.10 (d, J = 1 , IH), 67.13 (s, IH). t) CI-HRMS: Calcd: 324.2188, Found: 324.2188 (M + H); NMR (CDCI3, 300 MHz): 51.25 (t, J = 8, 6H), 52.16 (s, 3H), 52.28 (s, 3H), 52.35 (s, 3H), 62.40 (s, 3H), 63.95-54.20 (m, 4H), 57.05 (dd, J = 8, 1 , IH), 57.07 (s, IH), 67.10 (d, J = 1, IH) u) CI-HRMS: Calcd: 346.1780, Found: 346.1785 (M + H); Analysis: Calcd: C: 66.07; H: 5.54; N: 28.39; Found: C: 66.07; H: 5.60; N: 27.81 ; 127871/2 NMR (CDCI3, 300 MHz): 52.15 (s, 3H), 52.32 (s, 3H) 52.17 (s, 3H), 52.52 (s, 3H), 55.25-55.35 (m, 4H), 57.08 (s, 2H), 57.15 (s, 1H). v) CI-HRMS: Calcd: 340.2137, Found: 340.2137 (M + H); Analysis: Calcd: C: 67.23;H: 7.42; N: 20.63; Found:C: 67.11 ; H: 7.39; N: 20.26; NMR (CDC13, 300 MHz): 51.40 (d, J = 8, 3H), 52.16 (s, 3H), 52.32 (s, 3H), 52.35 (s, 3H), 52.47 (s, 3H), 53.42 (s, 3H), 53.50-53.60 (m; 2H), 54.50- 54.15 (m, 1H), 56.56 (d, J = 8, 1H), 57.00-57.15 (m,3H). w) CI-HRMS: Calcd: 355.2134,.Found: 355.2134 (M+ H); NMR (CDC13, 300 MHz): 51.05 (t, J = 8, 3H), 51.85-52.00 (m, 2H), 52.17 (s, 3H), 52.36 (s, 6H), 52.50 (s, 3H), 53.41 (s, 3H), 53.45 (dd, J = 8, 3, lH), 53.82 (dd, J - 8, 1, 1H), 55.70-55.80 (m, 1H), 57.00-57.20 (m, 3H). x) CI-HRMS: Calcd: 364.2501, Found: 364.2501 (M + H); NMR (CDCU, 300 MHz): 50.35-50.43 (m, 2H), 50.50-50.60 (m, 2H), 50.98 (t, J = 8, 3H), 51.20-51.30 (m, 1H): 51.72-51.90 (m, 2H), 52.18 (s, 3H) 52.28 (s, 3H), 52.35 (s, 3H), 52.40 (s, 3H), 53.88-54.03 (m, 2H), 54.03-54.20 (m, 2H), 57.00-57.15 (m, 3H), y) CI-HRMS: Calcd: 353.2454, Found: 353.2454 (M + H); Analysis: Calcd: C: 68.15; H: 8.02; N: 23.84; Found: C: 67.43; H: 7.81 ; N: 23.45; NMR (CDC13, 300 MHz): 51.38 (d, J = 8, 3H), 52.18 (s, 3H), 52.30- 52.40 (m, 12H), 52.47 93, 3H), 52.60-52.75 (m, 2H), 54.30-54.50 (m, 1H), 56.60-56.70 (m, 1H), 57.00-57.15 (m, 3H). z) CI-HRMS: Calcd: 361.2140, Found: 361.2128 (M+ H); NMR (CDCI3, 300 MHz): 50.75-50.83 (m, 2H), 51.00-51.10 (m, 2H), 52.17 (s, 3H), 52.30 (s, 3H), 52.36 (s, 3H), 52.47 (s, 3H), 52.85 (t, J = 8, 2H), 53.30- 53.40 (m, 1H), 54.40-54.55 (m, 2H), 57.00-57.18 (m, 3H). aa) CI-HRMS: Calcd: 363.2297, Found: 363.231 1 (M + H); 127871/3 NMR (CDC13, 300 MHz): 51.01 (t, 3H, J=8), 51.75-51.90 (m,2H), 52.15 (s,3H), 52.19 (s, 3H), 52.35 (s, 3H), 52.40 (s, 3H), 52.40 (s, 3H), 52.98 (t, 2H, J - 8), 53.97-54.15 (m, 2H), 54.15-54.30 (m, 2H), 57.03(d, IH, IH), 57.08 (d, IH, J = 8), 57.10 (s, IH). ab) CI-HRMS: Calcd: 363.2297, Found: 363.2295 (M + H); NMR (CDC13, 300 MHz): 51.01 (t, 3H, J = 8), 51,35-51.55 (m, 2H), 51.75- 51 .90 (m, 2H), 52.15 (s, 3H), 52.30 (s, 3H), 52.36 (s, 3H), 52.46 (s, 3H), 54.10-54.30 (m, 2H), 54.95-55.10 (br s, 2H), 57.05 (d, IH, J = 8), 57.10 (d, IH, J = 8), 57.15 ( s, IH). ac) CI-HRMS: Calcd: 368.2450, Found: 368.2436; Analysis: Calcd: C, 68.62, H, 7.95, K 19.06; Found: C, 68.73, H, 7.97, N, 19.09; NMR (CDCI3, 300 MHz): 51.05 (t, J = 8, 3H), 51.70-51.90 (m, 2H), 52.01 (d, J = 3, 6H), 52.20 (ss 3H), 52.30 (s, 3H), 52.46, 52.465 (s, s, 3H), 53.42, 53.48 (s, s, 3H), 53.53-53.63 (m, 2H), 54.35-54.45 (m, IH), 56.73 (d, J = 8, IH), 56.97 (s, 2H). ad) CI- HRMS: Calcd: 352.2501 , Found: 352.2500 (M + H): Analysis: Calcd: C: 71.76; H: 8.33; N: 19.92, Found: C: 71.55; H: 8.15; N: 19.28; NMR (CDCI3, 300 MHz): 51.01(t, J = 8, 6H), 51.58 -51.70 (m, 2H), 51.70- 51.85 (m, 2H), 52.02 (s, 6H), 52.19 (s, 3H), 52.45 (s, 3H), 54.12-54.28 (m, IH), 56.18 (d, J = 8,1H), 56.95 (s, 2H). ae) CI- HRMS: Calcd: 398.2556, Found: 398.2551 (M + H); Analysis: Calcd: C: 66.47; H: 7.86; N: 17.62, Found: C: 66.74; H: 7.79; N: 17.70; NMR (CDC13, 300 MHz): 52.00 (s, 6H), 52.12 (s, 3H), 52.30 (s, 3H), 52.37 (s, 3H), 53.40 (s, 6H), 53.78 (t, J = 8, 4H), 54.25-54.40 (m, 4H), 56.93 (s, 2H). af) CI-HRMS: Calcd: 450.1141, Found: 450.1133 (M +H); Analysis: Calcd: C: 50.67; H: 5.37; N: 15.55; Br: 17.74; Found: C: 52.36; H: 5.84; N: 14.90; Br: 17.44; NMR (CDCU, 300 MHz): 52.32 (s, 3H), 52.57 (s, 3H), 53.42 (s, 6H), 53.60 (q, J = 8, 2H), 53.69 (q, J = 8, 2H), 53.82 (s, 3H), 54.60-54.70 (m, 1H), 56.73 (d, J = 8, 1H), 56.93 (dd, J = 8,1H), 57.22 (d, J = 8, 1H). ag) CI-HRMS: Calcd: 434.1 192, Found: 434.1 169 (M + H); Analysis: Calcd: C: 52.54; H: 5.58; N: 16.12; Br: 18.40; Found: C: 52.57; H: 5.60; N: 15.98; Br: 18.22; NMR (CDC13, 300 MHz): 51.00-51.07 (m, 3H), 51 .65-51.85 (m, 2H), 52.35 (s, 3H), 52.46, 52.47 (s, s, 3H), 53.40, 53.45 (s, s, 3H), 53.83 (s, 3H), 54.35-54.45 (m, 1H), 56.55 (d, J - 8, 1H), 56.92 (dd, J - 8, 1 , 1H), 57.20-57.30 (m, 2H). ah) CI-HRMS: Calcd: 337.2266, Found: 337.2251 (M + H); Analysis: Calcd: C: 70.18; H: 8.06; N: 20.75; Found: C: 70.69; H: 7.66; N: 20.34; NMR (CDC13, 300 MHz): 51.35 (t, J = 8, 6H), 52.01 (s, 6H), 52.15 (s, 3H), 52.30 (s, 3H), 52.38 (s, 3H), 54.07 (q, J = 8, 4H), 56.93 (s, 2H). ai) CI-HRMS: Calcd: 412.2713, Found: 412.2687 (M + H); Analysis: Calcd: C: 67.13; H: 8.08; N: 17.02; Found : C: 67.22; H: 7.85; N: 17.13; NMR (CDCI3, 300 MHz): 51.24 (t, J = 8, 6H), 52.00 (s, 6H), 52.20 (s, 3H), 52.30 (s, 3H), 52.43 (s, 3H), 53.60 (q, J = 8, 4H), 53.66 (dd, J = 8, 3, 2H), 53.75 (dd, J = 8, 3, 2H), 54.55-54.65 (m, 1H), 56.75 (d, J - 8,1H), 56.95 (s, 2H). aj) CI-HRMS: Calcd: 398.2556, Found: 398.2545 (M + H); Analysis: Calcd: C: 66.47; H: 7.86; N: 17.62; Found: C: 66.87; H: 7.62; N: 17.75; NMR (CDCI3, 300 MHz): 51.95-52.10 (m, 8H), 52.20 (s, 3H), 52.32 (s, 3H), 52.44 (s, 3H), 53.38 (s, 3H), 53.42 (s, 3H), 53.50-53.70 (m, 4H), 54.58- 54.70 (m, 1H), 56.87 (d, J - 8, 1H), 56.95(s, 2H). ak) CI-HRMS: Calcd: 338.1981, Found: 338.1971 (M + H); Analysis: Calcd: C: 67.63; H: 6.87; N: 20.06; Found: C: 67.67; H: 6.82; N: 20.31 ; NMR (CDC13, 300 MHz): 52.15 (s, 3H), 52.29 (s, 3H), 52.35 (s, 3H), 52.43 (s, 3H), 53.90 (t, J = 8, 4H), 54.35-54.45 (m, 4H), 57.00-57.15 (m, 3H). al) CI-HRMS: Calcd: 464,1297, Found: 464.1297 (M + H); NMR (CDCh, 300 MHz): 52.28 (s, 3H), 52.40 (s, 3H), 53.40 (s, 6H), 53.75 (t, J = 8, 4H), 53.83 (s, 3H), 54.20-54.50 (m, 4H), 56.93 (dd, J = 8, 1 , 1H), 57.20 (s, 1H), 57.24 (d, J = 1, 1H). am) CI-HRMS: Calcd: 418.1242, Found: 418.1223 (M + H); NMR (CDCI3, 300 MHz): 51.00 (t, d, J = 8,1 , 6H), 51.55-51.75 (m, 4H), 52.34 (s, 3H), 52.49 (s, 3H), 52.84 (s, 3H), 54.15-54.27 (m, 1H), 56.19 (d9 J = 8, 1H), 56.93 (dd, J = 8, 1 , 1H), 57.21-57.30 (m, 2H). an) CI-HRMS: Calcd: 404.1086, Found: 404.1079(M + H); NMR (CDCI3, 300 MHz): 51.35 (t, J = 8, 6H), 52.28 (s, 3H), 52.40 (s, 3H), 53.83 (s, 3H), 53.90-54.08 (m, 2H), 54.08-54.20 (m, 2H), 56.92 (dd, J = 8, 1 , 1H), 57.20-57.25 (m, 2H). ao) CI-HRMS: Calcd: 308.1875, Found: 308.1872 (M + H); NMR (CDCh, 300 MHz): 50.75-50.80 (m, 2H), 50.93-51.00 (m, 2H), 52.16 (s, 3H), 52.28 (s, 3H), 52.35 (s, 3H), 52.53 (s, 3H), 53.00-53.10 (m, 1H), 56.50- 56.55 (m, 1H); 57.00-57.15 (m, 3H). ap) CI-HRMS: Calcd: 397.1988, Found: 397.1984 (M +H); NMR (CDCI3, 300 MHz): 52.43 (s, 3H), 52.50 (s, 3H), 53.43 (s, 3H), 53.61 (dd5 J = 8, 8, 2H), 53.69 (dd, J = 8, 8, 2H), 63.88 (s, 3H), 54.58-54.70 (m, 1H), 66.75 (d, J = 8, 1H), 57.20 (dd, J = 8,1 , 1H), 57.25 (d, J = 1 , 1H), 57.40 (s, 1H). aq) CI-HRMS: Calcd: 375.2297, Found: 375.2286 (M + H); Analysis: Calcd: C: 70.56; H: 7.01 ; N: 22.44; Found: C: 70.49; H: 6.99: N: 22.45; NMR (CDC13, 300 MHz): 50.79-50.85 (m, 2H), 51.00-51.05 (m, 1H), 52.00 (s, 6H), 52.19 (s, 3H), 52.32 (s, 3H), δ2.44 (s, 3Η), 62.84 (t, J = 8, 2H), 53.30-53.40 (m, 1 H), 54.50 (t, J - 8, 2H), 56.95 (s, 2H). ar) CI-HRMS: Calcd: 434.1192, Found: 434.1 189 (M + H); Analysis: Calcd: C: 52.54; H: 5.58; N: 16.12; Br: 18.40; Found: C: 52.75; H: 5.59; N: 16.09; Br: 18.67; NMR (CDC13, 300 MHz): 52.19 (s, 3H), 52.30 (s, 3H), 52.47 (s, 3H), 53.43 (s, 6H), 53.60 (dd, J = 8, 8, 2H), 53.70 (dd, J = 8,8, 2H), 54.58-54,70 (m, 1H), 56.71 (d, J - 8, 1H), 57.08 (d, J = 8, 1H), 57.37 (dd, J = 8, 1, 1H), 57.45 (d, J = 1 , 1H). as) CI-HRMS: Calcd: 448.1348, Found: 448.1332 (M + H); Analysis: Calcd: C: 53.58; H: 5.85; N: 16.62; Br: 17.82; Found: C: 53.68; H: 5.74; N: 15.52; Br: 13.03; NMR (CDC13, 300 MHz): 51.95-52.10 (m,2H), 52.20 (s, 3H), 52.30 (s, 3H), 52.47 (s, 3H) 53.38 (s, 3H), 53.41 (s, 3H), 53.50-53.67 (m, 4H), 54.55-54.70 (m, 1H), 56.89 (d, J -8, 1H), 57.05 (d, J = 8, 1H), 57.35 (dd, J = 8, 1 , 1H), 57.47 (d, J = 1, 1H). at) CI-HRMS: Calcd: 400.2349, Found: 400.2348 (M + H); Analysis: Calcd: C: C: 63.14; H: 7.32; N: 17.53; Found: C;63.40;H: 7.08; N: 17.14; NMR (CDCI3, 300 MHz): 52.16 (s, 3H), 52.20 (s, 3H), 52.30 (s, 3H), 52.46 (s, 3H), 53.42 (s, 6H), 53.60 (q, J = 8, 2H), 53.70 (q, J = 8, 2H), 53.85 (s, 3H), 54.59-54.70 (m, 1H), 56.70 (d, J = 8, 1H), 56.76 (s, 1H), 56.96 (s, 1H). au) CI-HRMS: Calcd: 414.2505, Found: 414.2493 (M + H); NMR (CDCI3, 300 MHz): 52.15 (s, 3H), 52.19 (s, 3H), 52.25 (s, 3H), 52.40 (s, 3H), 53.40 (s, 6H), 53.76 (t, J - 8, 4H), 53.84 (s, 3H)S 54.20-54.45 (m, 4H), 56.77 (s, 1H), 56.93 (s, 1H). av) CI-HRMS: Calcd: 368.2450, Found: 368.2447 (M + H); NMR (CDCI3, 300 MHz): 51.00 (t, J = 8, 6H); 51.55-51.85 (m, 4H), 52.19 (s, 3H), 52.20 (s, 3H), 52.30 (s, 127871/2 3H), 62.47 (s, 3H), 63.88 (s, 3H), 64.10-64.30 (m, 1H), 66.15 (d, J = 8, 1H), 66.78 (s, 1H), 66.98 (s, 1H). aw) CI-HRMS: Calcd: 353.2216, Found: 353.2197 (M + H); NMR (CDC13, 300 MHz): 61.35 (t, J = 8, 6H), 62.17 (s, 3H), 62.19 (s, 3H), 62.28 (s, 3H), 62.40 (s, 3H), 63.85 (s, 3H), 63.90-64.20 (m, 4H), 66.78 (s, 1H), 66.95 (s, 1H). ax) CI-HRMS: Calcd: 390.1697, Found: 390.1688 (M + H); Analysis: Calcd: C: 58.53; H: 6.20; N: 17.96; CI: 9.09; Found: C: 58.95; H: 6.28; N: 17.73; CI: 9.15; NMR (CDC13, 300 MHz): 62.35 (s, 3H), 62.37 (s, 3H), 62.48 (s, 3H), 63.42 (s, 6H), 63.60 (dd, J = 8, 8, 2H) 63.68 (dd, J = 8, 8, 2H), 64.59-64.72 (m, 1H), 66.72 (d, J = 8, 1H), 67.12 (d, J = 8, 1H), 67.23 (d, J = 8, 1H), 67.32 (s, IH). ay) CI-HRMS: Calcd: 374.1748, Found: 374.1735 (M + H); Analysis: Calcd: C: 61.04; H: 6.47; N: 18.73; CI: 9.48; Found: C: 61.47; H: 6.54; N: 18.23; CI: 9.61; NMR (CDC13, 300 MHz): 61.01 (t, J = 8, 3H), 61.62- 61.88 (m, 4H), 62.35 (s, 3H), 62.37 (s, 3H), 62.48 (d, J = 1 , 3H), 63.40, 63.45 (s, s, 3H), 63.50-63.64 (m, 2H), 64.38-64.47 (m, IH), 66.53 (d, J = 8, IH), 67.12 (d, J - 8, IH), 67.07 (d, J = 8, 1H), 67.12 (s, IH). az) CI-HRMS: Calcd: 404.1853, Found: 404.1839 (M + H); NMR (CDCb, 300 MHz): 62.29 (s, 3H), 62.38 (s, 3H), 62.40 (s, 3H), 63.40 (s, 6H), 63.76 (t, J = 8, 4H), 64.20-64.45 (m, 4H), 67.1 1 (d, J = 8, I H), 67.22 (d, J = 8, IH): 67.31 (s, IH). ba) CI-HRMS: Calcd: 404.1853, Found: 404.1859 (M + H); Analysis: C: 59.47; H: 6.50; N: 17.34; CI: 8.79; Found: C: 59.73; H: 6.46; N: 17.10; CI: 8.73; NMR (CDC13, 300 MHz): 61.95-62.08 (m, 2H), 62.35 (s, 3H), 62.38 (s, 3H), 62.46 (s, 3H), 63.38 (s, 3H), 63.41 (s, 3H), 63.50-63.65 (m, 4H), 64.56-64.70 (m, IH), 66.85 (d, J = 8, IH), 67.12 (d, J = 8, IH), 67.45 (d, J = 8,1H), 67.32 (s, IH). 127871/2 bb) Cl-HRMS: Calcd: 391.2246, Found: 391.2258 (M + H); Analysis: C: 67.67; H: 6.71 ; N: 21.52; Found: C: 67.93; H: 6.70; N: 21.48; NMR (CDCI 3, 300 MHz): 50.76-50.84 (m, 2H), 50.84-50.91 (m, 2H), 51.00- 51.08 (m, 2H), 52.15 (s, 3H), 52.20 (s, 3H), 52.29 (s, 3H), 52.45 (s, 3H), 52.85 (t, J = 8, 2H), 53.28-53.30 (m, IH), 53.85 (s, 3H), 56.78 (s, IH), 56.95 (s, IH). be) CI-HRMS: Calcd: 386.2192, Found: 386.2181 (M + H); Analysis: C: 62.32; H: 7.06; N: 18.17; Found: C: 62.48; H: 6.83; N: 18.15; NMR (CDCh, 300 MHz): 57.1 (d, IH, J = 8), 56.9 (d, IH, J = 1), 56.8 (dd, IH, J = 8,1), 56.7 (br.d, IH, J = 8), 54.7-54.6 (m, IH), 53.85 (s, 3H), 53.70-53.55 (m, 4H), 53.45 (s, 6H), 52.5 (s, 3H), 52.3 (s, 3H), 52.15 (s, 3H). bd) CI-HRMS: Calcd: 400.2349, Found: 400.2336 (M + FI); NMR (CDCI3, 300 MHz): 57.1 (d, IH, J - 7), 56.85 (d, IH, J - 1), 56.75 (dd, IH, J = 7,1), 54.45-54.25 (br.s, 4H), 53.75 (t, 4H, J = 7), 53.4 (s, 6H), 52.4 (s, 3H), 52.25 (s, 3H), 52.15 (s, 3H) be) CI-HRMS: Calcd: 370.2243, Found: 370.2247 (M + H); Analysis: C: 65.02; H: 7.38; N: 18.96; Found: C: 65.28; H: 7.27; N: 18.71 ; NMR (CDCU, 300 MHz): 57.1 (d, IH, J - 8), 56.85 (d, I H, J = 1), 56.8 (dd, IH, J = 8,1), 56.5 (br. d, IH, J = 1), 54.5-54.3 (m, IH), 53.85 (s, 3H), 53.65- 53.5 (m, 2H), 53.4 (s, 2H), 52.5 (s, 3H), 52.3 (s, 3H), 52.2 (s, 3H), 51.9-51.7 (m, 2H), 51.05 (t, 3H, J = 7). bf) CI-HRMS: Calcd: 379.2246, Found: 379.2248 (M + H); NMR (CDCI3, 300 MHz): 57.1 (d, IH, J = 8), 56.85 (d, IH, J = 1), 56.8 (dd, IH, J - 8,1), 54.3-54.0 (m, 4H), 53.85 (s, 3H), 53.0 (t, 2H, J = 7), 52.45 (s, 3H), 52.3 (s, 3H), 52.2 (s, 3H), 51.9-51.8 (m, 2H), 51 .0 (t, 3H, J = 7). bg) CI-HRMS: Calcd: 340.2137, Found: 340.2122 (M + H); 25 127871/2 NMR (CDCU, 300 MHz): 57.1 (d, 1H, J = 8), 56.85 (d, 1H, J = 1), 56.75 (dd, 1H, J = 8,1), 54.2-54.0 (br.m, 4H), 53.85 (s, 3H), 52.4 (s, 3H), 52.3 (s, 3H), 52.2 (s, 3H), 51.35 (t, 6H, J = 7). bh) CI-HRMS: Calcd: 313.1665, Found: 313.6664 (M+ H). bi) CI-HRMS: Calcd: 400.2349, Found: 400.2346 (M + H); NMR (CDCI3, 300 MHz): 57.1 (d, 1H, J = 7), 56.9-56.75 (m, 3H), 54.7-54.55 (m; 1H), 53.8 (s, 3H), 53.7-53.5 (m, 4H), 53.45 (s, 3H), 53.35 (s, 3H), 52.5 (s, 3H), 52.3 (s, 3H), 52.2 (s, 3H), 52.1-51.95 (m, 2H). bj) CI-HRMS: Calcd: 377.2090, Found: 377.2092 (M + H); Analysis: C: 67.00; H: 6.44; N: 22.32; Found: C: 67.35; H: 6.44; N: 22.23; NMR (CDCI3, 300 MHz): 57.1 (d, 1H, J = 8), 56.9 (d, 1H, J - 1), 56.8.(dd, 1H, J = 8,1), 54.55-54.4 (m, 2H), 53.85 (s, 3H), 53.4-53.3 (m, 1H), 52.85 (t, 2H, J = 7), 52.5 (s, 3H), 52.3 (s, 3H), 52.2 (s, 3H), 51.1-51.0 (m, 2H), 50.85-50.75 (m, 2H). bk) CI-HRMS: Calcd: 413.2427, Found: 413.2416 (M + H); NMR (CDCI3, 300Hz): 57.1 (d, 1H, J = 8), 56.85 (d, 1H, J = 1), 56.75 (dd, 1H, J =8,1 ), 54.6 (m, 1H), 53.85 (s, 3H), 53.75-53.6 (m, 4H), 53.6 (q, 4H, J = 7), 52.5 (s, 3H), 52.3 (s, 3HJ, 52.2 (s, 3H), 51.25 (t, 6H, J = 7). bl) CI-HRMS: Calcd: 420.1802, Found: 420.1825(M + H); bra) CI-HRMS: Calcd: 390.1697, Found: 390.1707(M + H); bn) CI-HRMS: Calcd: 397.1465, Found: 397.1462(M + H); bo) CI-HRMS: Calcd: 360.1513, Found: 360.15 i4(M+ H); bp) CI-HRMS: Calcd: 374.1748, Found: 374.1737(M + H); bq) CI-HRMS: Calcd: 479.1155, Found: 479.1 154(M + H); br) CI-HRMS: Calcd: 463.1219, Found: 463.121 1 (M +H); Analysis Calcd: C: 51.96, H: 5.23, N, 15.15, Br: 17.28; Found: C: 52.29, H: 5.62, N: 14.79, Br: 17.47 bs) CI-HRMS: Calcd: 433.1113, Found: 433.11 14(M, 79Br); bt) NH3-CI MS: Calcd: 406, Found: 406 (M + H)+; 127871/3 NMR (CDCI3, 300 MHz) .: 67.28 (d, J=10Hz, 1H), 57.03 (d, J=8Hz, 1H), 56.96 (s, 1 H), 56.7 (d, J=9, 1H), 54.63 (m, 1H), 53.79 (s, 3H), 53.6 (m, 4H), 53.42 (s, 6H), 52.47 (s, 3H), 52.32 (s, 3H).

EXAMPLE 431 Preparation of 2,4,7-dimethyl-8-(4-methoxy-2-methylphenyl)-pyrazolo- [l ,5-a]-l,3,5-triazine (Formula 1, where R3 is CH3, Ri is CH3, Z is C-CH3, Ar is 2-methyl-4-methoxylphenyl) 5-Acetamidino-4-(4-methoxy-2-methylphenyl)-3-methylpyrazole, acetic acid salt (602 mg, 2 mmol) was mixed with a saturated NaHC03 solution (10 mL). The aqueous mixture was extracted with EtOAc three times. The combined organic layers were dried over MgS04, filtered and concentrated in vacuo. The residue was taken up in toluene (10 mL) and trimethyl orthoacetate ( 0.36 g, 3 mmol) was added to the suspension. The reaction mixture was heated to reflux temperature under a nitrogen atmosphere and stirred for 16 hours. After being cooled to ambient temperature, the reaction mixture was concentrated in vacuo to give an oily solid. Column chromatography (CHCl3:MeOH::9: 1) afforded, after removal of solvent in vacuo, a yellow viscous oil (Rf = 0.6, 210 mg, 37% yield): NMR (CDCI3, 300 MHz): 57.15 (d, 1H, J = 8), 56.9 (d, 1 H, J = 1 ), 56.85 (dd, 1 H, J = 8, 1), 53.85 (s, 3H), 52.95 (s, 3H), 52.65 (s, 3H), 52.4 (s, 3H), 52.15 (s, 3H); CI-HRMS: Calcd: 283.1559, Found: 283.1554 (M + H). 127871/2 EXAMPLE 432 7-hydroxy-5-memyl-3-(2-chloro-4-memylphenyl)pyrazolo[l,5-a]pyrimidine (Formula 1 where A is CH, Rl is Me, R3 is OH, Z is C-Me, Ar is 2-chloro-4- methylphenyl) 5-Amino-4-(2-chloro-4-methylphenyl)-3-methylpyrazole (1.86 g, 8.4 mmol) was dissolved in glacial acetic acid (30 mL) with stirring. Ethyl acetoacetate (1.18 mL, 9.2 mmol) was then added dropwise to the resulting solution. The reaction mixture was then heated to reflux temperature and stirred for 16 hours, then cooled to room temperature. Ether (100 mL) was added and the resulting precipitate was collected by filtration.

Drying in vacuo afforded a white solid (1.0 g, 42% yield): NMR (CDC13, 300Hz): δ 8.70 (br.s IH), 7.29 (s, IH), 7.21-7.09 (m, 2H), 5.62 (s, IH) , 2.35 (s, 6H) , 2.29 (s, 3H) ; CI-MS: 288 (M+H) .

EXAMPLE 433 7-chloro-5-methyl-3-(2-chloro- 4-methylphenyl)pyrazolo[l,5-a]pyrimidine (Formula 1 where A is CH, Rl is Me, R3 is CI, Z is C-Me, Ar is 2-chloro-4- methylphenyl) A mixture of 7-hydroxy-5-methyl-3-(2-chloro-4-methylphenyl)-pyrazolo[l,5-a]pyrimidine (1.0 g, 3.5 mmol), phosphorus oxychloride (2.7 g, 1.64 mL, 17.4 30 mmol), N,N-diethylaniline (0.63 g, 0.7 mL, 4.2 mmol) and toluene (20 mL) was stirred at reflux temperature for 3 hours, then it was cooled to ambient temperature. The volatiles were removed in vacuo. Flash chromatography (EtOAc:hexane:: 1 :2) on the residue gave 7-chloro-5-methyl-3-(2-chloro-4-methylphenyl)-pyrazolo[l ,5-ajpyrimidine (900 mg, 84% yield) as a yellow oil: NMR 127871/2 (CDC13, 300Hz): δ 7.35 (s, 1H), 7.28-7.26 (m, 1H), 71.6 (d, 1H, J = 7), 6.80 (s, 1H), 2.55 (s, 3H), 2.45 (s, 3H), 2.40 (s, 3H); CI-MS: 306 (M+H).

EXAMPLE 434 7-(pentyl-3-amino)-5-methyl-3-(2-chloro-4-methylphenyl)pyrazolo[l, 5-a]pyrimidine (Formula 1 where A is CH, Rl is Me, R3 is pentyl-3-amino, Z is C-Me, Ar is 2-chloro-4- methylphenyl) A solution of 3-pentylamine (394mg, 6.5 mmol) and 7-chloro-5-methyl-3-(2-chloro-4-methylphenyl)pyrazolo[l,5-a]pyrimidine (200 mg, 0.65 mmol) in dimethylsulfoxide (DMSO, 10 mL) was stirred at 150°C for 2 hours; then it was cooled to ambient temperature. The reaction mixture was then poured onto water (100 mL) and mixed. Three extractions with dichloromethane, washing the combined organic layers with brine, drying over MgS04, filtration and removal of solvent in vacuo produced a yellow solid. Flash chromatography (EtOAc:hexanes::l :4) afforded a white solid (140 mg, 60% yield): mp 139-141°C; NMR (CDC13, 300Hz): δ 7.32 (s, 1H), 7.27 (d, 1H, J = 8), 7.12 (d, 1H, J = 7), 6.02 (d, 1H, J = 9), 5.78 (s, 1H), 3.50-3.39 (m, 1H), 2.45 (s, 3H), 2.36 (s, 6H), 1.82-1.60 (m, 4H), 1.01 (t, 6H, J = 8); Analysis Calc'd for C20H25C1N4: C, 67.31, H, 7.06, N, 15.70, CI: 9.93; Found: C, 67.32, H, 6.95, N, 15.50, CI, 9.93.

The examples delineated in TABLE 2 may be prepared by the methods outlined in Examples 1A, IB, 432, 433, and 434. Commonly used abbreviations are: Ph is phenyl, Pr is propyl, Me is methyl, Et is ethyl, Bu is butyl, Ex is Example, EtOAc is ethyl acetate.

TABLE 2 Ex, Z R Ar m (0O 435b C-Me N(CH2CH20Me)2 2,4-Cl2-Ph 71-73 436c C-Me N(Bu)Et 2,4-Cl2-Ph 86-87 437d C-Me NHCH(Et)CH20Me 2,4-Cl2-Ph 110-111 438e C-Me N(Pr)CH2CH2CN 2,4-Cl2-Ph 83-85 439f C-Me H-3-pentyl 2,4-Cl2-Ph 175-176 440§ C-Me NHCH(CH20Me)2 2,4-Cl2-Ph 107 441h C-Me HCH(Et)2 2,4-Me2-Ph oil 4421 C-Me NHCH(CH20Me)2 2,4-Me2-Ph 103-105 443J C-Me N(CH2CH20Me)2 2,4-Me2-Ph 87-89 444k C-Me N(c-Pr)CH2CH2CN 2,4-Me2-Ph 133(dec) 4451 C-Me Ν(Ο¾Ο¾0Μβ)2 2-Cl,4-MePh 77-78 446m C-Me NHCH(CH20Me)2 2-Cl,4-MePh 131-133 447η C-Me HCH(Et)2 2-Cl,4-MePh 139-141 448° C-Me NEt2 2,4-Me2-Ph 92-94 449P C-Me N(Pr)CH2CH2CN 2,4-Me2-Ph 143-144 450<Ι C-Me N(Bu)CH2CH2CN 2,4-Me2-Ph 115-117 451r C-Me NHCH(Et)CH2OMe 2,4-Me2-Ph oil 452s C-Me NHCH(Et)2 2-Me,4-MeOPh 104-106 453* C-Me NHCH(CH20Me)2 2-Me,4-MeOPh 115-116 454u C-Me (CH2CH20Me)2 2-Me,4-MeOPh oil 455v C-Me (S)-NHCH(CH2CH20Me)- 2-Me,4-MeOPh oil (CH20Me) 456w C-Me (S)-NHCH(CH2CH20Me)- 2,4-Me2-Ph oil 457* C-Me N (CH2CH20Me) 2 2 -Me, -ClPh oil 458V C-Me NHEt ( 2(4-Me2-Ph oil 459z C-Me NHCH (Et) 2 2-Me, 4-ClPh 94-96 460aa C-Me NHCH (CH20Me) 2 2 -Me, 4-ClPh 113-114 461ab C-Me (Ac) Et 2, 4-Me2-Ph oil 462ac C-Me (S) -NHCH (CH2CH20Me) - 2-Me, 4-ClPh oil (CH20Me) 463ad C-Me N(Pr)CH2CH2CN 2 -Me, -MeOPh 118-119 464ae C-Me NEt2 2 -Me, -MeOPh 97-99 465af C-Me (S) -NHCH (CH2CH20Me) - 2-CI, -MePh 101-103 (CH20Me) 466a? C-Me NEt2 2 -CI, 4-MePh 129-130 467ah C-Me N (c-Pr) CH2CH2CN 2 -Me, 4-MeOPh 177-178 468ai C-Me N (c-Pr) CH2CH2CN 2-Cl, 4-MePh 162-163 469a^ C-Me NHCH (Et) CH20Me 2 -Me, 4-MeOPh oil 470ak C-Me NHCH (Et)CH20Me 2-Cl, 4-MePh 111-113 471 C-Me NHCH (CH20Me) 2 2-Cl-4-MeOPh 472 C-Me N (CH2CH20Me) 2 2-Cl-4-MeOPh 473 C-Me NHCH (Et) CH20Me 2-Cl-4-MeOPh 474 C-Me N (c-Pr) CH2CH2CN 2-Cl-4-MeOPh 475 C-Me NEt2 2-Cl-4-MeOPh 476 C-Me NH-3-pentyl 2-Cl-4-MeOPh 477 C-Me NHCH (Et) CH2CH20Me 2-Cl-4-MeOPh 478 C-Me NHCH (Me)CH2CH20Me 2-Cl-4-MeOPh 479 C-Me NHCH(Et)CH2CH20Me 2-Br-4-MeOPh 480 C-Me NHCH (Me)CH2CH20Me 2-Br-4-MeOPh 481 C-Me NHCH(Et)CH2CH20Me 2-Me-4-MeOPh 482 C-Me NHCH (Me)CH2CH20Me 2-Me-4-MeOPh 483 C-Me NHCH (CH20Me) 2 2-C1-4, 5- (MeO)2Ph 484 C-Me N(CH2CH20Me)2 2-C1-4, 5- (MeO) 2Ph 485 C-Me NHCH (Et) CH20Me 2-C1-4, 5- (MeO) 2Ph 486 C-Me N (c-Pr) CH2CH2CN 2-C1-4, 5- (MeO) 2Ph 487 C-Me NEt2 2-C1-4, 5- (MeO) 2Ph 99-101 488 C-Me NH-3-pentyl 2-C1-4, 5- (MeO) 2 h 169-170 489 C-Me NHCH (Et) CH2CH20 e 2-C1-4, 5- (MeO) 2Ph 490 C-Me NHCH(Me)CH2CH2OMe 2-Cl-4,5-(MeO)2Ph 491 C-Me NHCH(CH20Me)2 2-Br-4,5-(MeO)2Ph 492 C-Me N(CH2CH20Me)2 2-Br-4,5-(MeO)2Ph 493 C-Me NHCH(Et)Cti20Me 2-Br-4,5-(MeO)2Ph 494 C-Me N(c-Pr)CH2CH2CN 2-Br-4,5-(MeO)2Ph 495 C-Me NEt2 2-Br-4,5-(MeO)2Ph 496 C-Me H-3-pentyl 2-Br-4,5-(MeO)2Ph 497 C-Me NHCH(Et)CH2CH20Me 2-Br-4,5-(MeO)2Ph 498 C-Me NHCH(Me)CH2CH20Me 2-Br-4,5-(MeO)2Ph 499 C-Me NHCH(CH20Me)2 2-Cl-4,6-(MeO)2Ph 500 C-Me (CH2CH20Me)2 2-Cl-4,6-(MeO)2Ph 501 C-Me HCH(Et)CH20Me 2-Cl-4,6-(MeO)2Ph 502 C-Me N(c-Pr)CH2CH2CN 2-Cl-4,6-(MeO)2Ph 503 C-Me NEt2 2-Cl-4,6-(MeO)2Ph 504 C-Me NH-3-pentyl 2-Cl-4,6-(MeO)2Ph 505 C-Me HCH(Et)CH2CH20Me 2-Cl-4,6-(MeO)2Ph 506 C-Me NHCH(Me)CH2CH20Me 2-Cl-4,6-(MeO)2Ph 507 C-Me NHCH(CH2OMe)2 2-Me-4,6-(MeO)2Ph 508 C-Me N(CH2CH2OMe)2 2-Me-4,6-(MeO)2Ph 509 C-Me NHCH(Et)CH2OMe 2-Me-4,6-(MeO)2Ph 510 C-Me N(c-Pr)CH2CH2CN 2-Me-4,6-(MeO)2Ph 511 C-Me NEt2 2-Me-4,6-(MeO)2Ph 512 C-Me H-3-pentyl 2-Me-4,6-(MeO)2Ph 513 C-Me NHCH(Et)CH2CH20Me 2-Me-4,6-(MeO)2Ph 514 C-Me NHCH(Me)CH2CH20Me 2-Me-4,6-(MeO)2Ph 515 C-Me N(c-Pr)CH2CH2CN 2-Br-4,6-(MeO)2Ph 516 C-Me NEt2 2-Br-4,6-(MeO)2Ph 517 C-Me NH-3-pentyl 2-Br-4,6-(MeO)2Ph 518 C-Me NHCH(Et)CH2CH20Me 2-Br-4,6-(MeO)2Ph 519 C-Me NHCH(Me)CH2CH2OMe 2-Br-4,6-(MeO)2Ph 520 C-Me NHCH(Et)CH2CH2OMe 2-Me-4-MeOPh 521 C-Me NHCH(Me)CH2CH20Me 2-Me-4-MeOPh 522 C-Me NHCH(CH20Me)2 2-MeO-4-MePh 523 C-Me N(CH2CH20Me)2 2-MeO-4-MePh 524 C-Me NHCH(Et)CH20Me 2-MeO-4-MePh 525 C-Me N(c-Pr)CH2CH2CN 2-MeO-4-MePh 526 C-Me NEt2 2-MeO-4-MePh 527 C-Me NH-3-pentyl 2-MeO-4-MePh 528 C-Me NHCH(Et)CH2CH20Me 2-MeO-4-MePh 529 C-Me NHCH(Me)CH2CH20Me 2-MeO-4-MePh 530 C-Me NHCH(CH20Me)2 2-MeO-4-MePh 531 C-Me N(CH2CH2OMe)2 2-MeO-4-MePh 532 C-Me NHCH(Et)CH20Me 2-MeO-4-MePh 533 C-Me N(c-Pr)CH2CH2CN 2-MeO-4-MePh 534 C-Me NEt2 2-MeO-4-MePh 535 C-Me NH-3-pentyl 2-MeO-4-MePh 536 C-Me NHCH(Et)CH2CH20Me 2-MeO-4-MePh 537 C-Me NHCH(Me)CH2CH20Me 2-MeO-4-MePh 538 C-Me HCH(CH20Me)2 2-MeO-4-CIPh 539 C-Me N(CH2CH20Me)2 2-MeO-4-ClPh 540 C-Me NHCH(Et)CH20Me 2-MeO-4-ClPh 541 C-Me N(c-Pr)CH2CH2CN 2-MeO-4-ClPh 542 C-Me NEt2 2-MeO-4-ClPh 543 C-Me NH-3-pentyl 2-MeO-4-ClPh 544 C-Me NHCH(Et)CH2CH20Me 2-MeO-4-ClPh 545 C-Me NHCH(Me)CH2CH20Me 2-MeO-4-ClPh NOTES FOR TABLE 2: CI-HRMS: Calcd: 423.1355; Found: 423.1337 (M + H).

Analysis: Calcd: C, 61.38, H, 6.18, N, 14.32: Found: C, 61.54, H, 6.12, N, 1.4.37.

Analysis: Calcd: C: 58.02, H, 5.65, N, 14.24; Found: C, 58.11 , H, 5.52, N, 14.26.

Analysis: Calcd: C, 59.71, H, 5.26, N, 14.85; Found: C, 59.94, H, 5.09, N, 17.23.

Analysis: Calcd: C, 60.48, H, 5.89, N, 14.85, Found: C, 60.62, H, 5.88, N, 14.82.

CI-HRMS: Calcd: 337.2388; Found: 337.2392 (M + H).

Analysis: Calcd: C, 68.45, H, 7.669, N, 15.21, Found: C, 68.35, H, 7.49 N, 14.91. j) Analysis: Calcd: C, 69.08, H, 7.915, N, 14.65, Found: C, 68.85, H, 7.83, N, 14.54. k) Analysis: Calcd: C, 73.51, H, 7.01, N, 19.48, Found: C, 71.57, H, 7.15, N, 19.12. 1) CI-HRMS: Calcd: 403.1899; Found: 403.1901 (M + H) m) Analysis: Calcd: C, 61.77, H, 6.49, N, 14.41, CI. 9.13/ Found: C, 61.90, H, 6.66, N, 13.62, CI, 9.25 n) Analysis: Calcd: C, 67.31, H, 7.06, N, 15.70, CI. 9.93; Found: C, 67.32, H, 6.95, N, 15.50, CI, 9.93 o) Analysis: Calcd: C, 74.50, H, 8.14, N, 17.38, Found: C, 74.43, H, 7.59, N, 17.16. p) Analysis: Calcd: C, 73.10, H, 7.54, N, 19.37, Found: C, 73.18, H, 7.59, N, 18.81. q) Analysis: Calcd: C, 73.57, H, 7.78, N, 18.65, Found: C, 73.55, H, 7.79, N, 18.64. r) CI-HRMS: Calcd: 353.2333; Found: 353.2341 (M + H) . s) Analysis: Calcd: C, 71.56, H, 8.02, N, 15.90, Found: C, 71.45, Η,- 7.99, N, 15.88. t) Analysis: Calcd: C, 65.60, H, 7.34, N, 14.57, Found: C, 65.42, H, 7.24, , 14.37. u) CI-HRMS: Calcd: 399.2398; Found: 399.2396 (M + H) . v) CI-HRMS: Calcd: 399.2398; Found: 399.2396 (M + H) . w> CI-HRMS: Calcd: 383.2450; Found: 383.2447 (M + H) . x) CI-HRMS: Calcd: 403.1887; Found: 403.1901 (M + H) . y) CI-HRMS: Calcd: 295.1919; Found: 295.1923 (M + H) . z) Analysis: Calcd: C, 67.31, H, 7.06, N, 15.70, Found: C, 67.12, H, 6.86, N, 15.53. aa) Analysis: Calcd: C, 61.77, H, 6.49, N, 14.41, CI, 9.13; Found: C, 62.06, H, 6.37, N, 14.25, CI, 9.12. ab) CI-HRMS: Calcd: 337.2017; Found: 337.2023 (M + H) . ac) CI-HRMS: Calcd: 403.1893; Found: 403.1901 (M + H) . ad) Analysis: Calcd: C, 70.00, H, 7.22, N, 18.55, Found: C, 70.05, H, 7.22, N, 18.36. ae) Analysis: Calcd: C, 70.98, H, 7.74, N, 16.55, Found: C, 71.15, H,7.46, N, 16.56. 127871/3 ag) Analysis: Calcd: C, 66.59, H, 6.76, N, 16.34, Found: C, 66.69, H,6.82, N, 16.20. ah) Analysis: Calcd: C, 70.38, H, 6.71, N, 18.65, Found: C, 70.35, H,6.82, N, 18.83. ai) Analysis: Calcd: C, 66.39, H, 5.85, N, 18.44, CI, 9.33; Found: C, 66.29, H, 5.51, N, 18.36, CI, 9.31. aj) CI-HRMS: Calcd: 369.2278; Found: 369.2291 (M + H). ak) Analysis: Calcd: C, 64.42, H, 6.77, N, 15.02, Found: C, 64.59, H,6.51 , N, 14.81.

The examples delineated in TABLE 3 may be prepared by the methods outlined in Examples 1, 2, 3 or 6. Commonly used abbreviations are: Ph is phenyl, Pr is propyl, Me is methyl, Et is ethyl, Bu is butyl, Ex is Example.

TABLE 3 Ex, Z Ar mp(°0 546a C-Me NHCH(Et)2 2-Me-4-Me2N-Ph 164-166 547b C-Me S-NHCH(CH2CH20Me) 2,4-Me2-Ph oil -CH20Me 548c C-Me S-NHCH(CH2CH20Me) 2-Me-4-Cl-Ph oil -CH20Me 549d C-Me N(c-Pr)CH2CH2CN 2-Me-4-Cl-Ph 115-1 16 550e C-Me NHCH(Et)CH2CN 2-Me-4-Cl-Ph 131-132 55lf C-Me N(Et)2 2,3-Me2-4-OMe-Ph oil 5528 C-Me N(CH2CH20Me)CH2CH20H 2,4-Cl2-Ph oil 553h C-Me N(CH2CH2OMe)2 2,3-Me2-4-OMe-Ph oil 554' C-Me NHCH(Et)2 2,3-Me2-4-OMePh 123-124 555) C-Me N(CH2-c-Pr)Pr 2-Me-4-Cl-Ph oil 556k C-Me N(c-Pr)CH2CH2CN 2,3-Me2-4-OMePh 158-160 557 C-Me N(c-Pr)Et 2-Cl-4-OMePh 558 C-Me N(c-Pr)Me 2-Cl-4-OMePh 559 C-Me N(c-Pr)Pr 2-Cl-4-OMePh 560 C-Me N(c-Pr)Bu 2-Cl-4-OMePh 5611 C-Me N(Et)2 2-Cl-4-CN-Ph 115-117 562 C-Me N(c-Pr)2 2-Cl-4-OMe-Ph 127-129 563m C-Me NHCH(CH20H)2 2,4-Cl2-Ph 128-129 564 C-Me N(c-Pr)Et 2-Br-4,5-(MeO)2Ph 565 C-Me N(c-Pr)Me 2-Br-4,5-(MeO)2Ph 566 C-Me NH-c-Pr 2-Me-4-MeOPh 126-128 567 C-Me HCH(Et)CH20H 2-Me-4-MeOPh 60-62 568 C-Me Me2 2-Br-4,5-(MeO)2Ph 569 C-Me NHCH(Et)2 2-Me-4-MeOPh 103-105 570 C-Me N(c-Pr)Et 2-Me-4-MeOPh 173-174 571 C-Me H-2-pentyl 2,4-Cl2-Ph 118-120 572 C-Me NHCH(Et)C¾CN 2,4-Cl2-Ph 141-142 573 C-Me NHCH(Pr)C¾OMe 2,4-Cl2-Ph 87-88 574 C-Me NHCH(CH2-iPr)CH2OMe 2,4-Cl2-Ph amorphous 575 C-Me NH-2-butyl 2,4-Me2-Ph oil 576 C-Me NH-2-pentyl 2,4-Me2-Ph oil 577 C-Me NH-2-hexyl 2,4-Me2-Ph oil 578 C-Me NHCH(i-Pr)Me 2,4-Me2-Ph oil 579 C-Me NHCH(Me)CH2-iPr 2,4-Me2-Ph oil 580 C-Me NHCH(Me)-c-C6Hl l 2,4-Me2-Ph oil 581 C-Me NH-2-indanyl 2,4-Me2-Ph oil 582 C-Me NH-l-indanyl 2,4-Me2-Ph oil 583 C-Me NHCH(Me)Ph 2,4-Me2-Ph oil 584 C-Me NHCH(Me)CH2-(4-ClPh) 2,4-Me2-Ph oil 585 C-Me HCH(Me)CH2COCH3 2,4-Me2-Ph oil 586 C-Me NHCH(Ph)C¾Ph 2,4-Me2-Ph oil 587 C-Me NHCH(Me)(CH2)3NEt2 2,4-Me2-Ph oil 588 C-Me NH-(2-Ph-c-C3H4) 2,4-Me2-Ph oil 589 C-Me NHCH(Et)CH2CN 2,4-Me2-Ph 119-120 590 C-Me NH-3-hexyl 2,4-Me2-Ph oil 591n C-Me NEt2 2-MeO-4-ClPh oil 592° C-Me NHCH(Et)2 2-MeO-4-ClPh oil 593P C-Me NHCH(Et)CH20Me 2-MeO-4-ClPh oil 594 C-Me NMe2 2-MeO-4-ClPh oil 5959 C-Me NHCH(Et)2 2-OMe-4-MePh oil 596r C-Me NEt2 2-OMe-4-MePh oil 597s C-c-Pr NHCH(CH20Me)2 2,4-Cl2-Ph oil 598 C-Me N(c-Pr)Et 2,4-Me2-Ph 599 C-Me N(c-Pr)Et 2,4-Cl2-Ph 600 C-Me N(c-Pr)Et 2,4,6-Me3-Ph 601 C-Me N(c-Pr)Et 2-Me-4-Cl-Ph 602 C-Me N(c-Pr)Et 2-Cl-4-Me-Ph 603 C-Me HCH(c-Pr)2 2,4-Cl2-Ph 604 C-Me NHCH(c-Pr)2 2,4-Me2-Ph 605 C-Me HCH(c-Pr)2 2-Me-4-Cl-Ph 606 C-Me NHCH(c-Pr)2 2-Cl-4-Me-Ph 607 C-Me HCH(c-Pr)2 2-Me-4-OMe-Ph 608 C-Me NHCH(c-Pr)2 2-Cl-4-OMe-Ph 609 C-Me NHCH(CH20Me)2 2-Cl-5-F-OMePh 610 C-Me NEt2 2-Cl-5-F-OMePh 611 C-Me N(c-Pr)CH2CH2CN 2-Cl-5-F-OMePh 612 C-Me NHCH(Et)2 2-Cl-5-F-OMePh 613 C-Me N(CH2CH20Me)2 2-Cl-5-F-OMePh 614 C-Me NEt2 2,6-Me2-pyrid-3-yl 615 C-Me N(c-Pr)CH2CH2CN 2,6-Me2-pyrid-3-yl 616 C-Me NHCH(Et)2 2,6-Me2-pyrid-3-yl 617 C-Me N(CH2CH20Me)2 2,6-Me2-pyrid-3-yl 618 C-OH NHCH(CH20Me)2 2,4-Me2-Ph 619 C-OH NEt2 2,4-Me2-Ph 620 C-OH N(c-Pr)CH2CH2CN 2,4-Me2-Ph 621 C-OH NHCH (Et) 2 2, -Me2-Ph 623 C-OH N(CH2CH20Me)2 2, 4-Me2-Ph 624 C-NEt2 NHCH (CH20Me) 2 2, 4-Me2-Ph 625 C-NEt2 Et2 2, -Me2-P 626 C-NEt2 N(c-Pr)CH2CH2CN 2, - e2~P 627 C-NEt2 NHCH(Et) 2 2, 4- e2-Ph 626 C-NEt2 (CH2CH20Me) 2 2, 4-Me2~Ph 629 C-Me NHCH (Et) 2 2-Me-4-CN-P 63 J C-Me N (CH2CH20Me) 2 2-Me-4-CN-P Notes for Table 3: a) CI-HRMS : Calcd :367 .2610, Found : 367 .2607 (M + H) ; b) CI-HRMS : Calcd :384 .2400, Found : 384 .2393 (M + H) ; c) CI-HRMS : Calcd • 404 .1853, Found : 404 .1844 (M + H) ; d) CI-HRMS : Calcd •381 .1594 , Found : 381 .1596 (M + H) ; Analysis : Calcd: C : 63.07, H, 5 .57, N, 22.07, CI, 9.32; Found: C : 63.40, H, 5.55, N, 21 .96, CI: 9.15 e) CI-HRMS : Calcd 369 1594, Found : 369 1576 (M + H) ; f) CI-HRMS : Calcd: 354 2216, Found : 354 2211 (M + H) ; g) CI-HRMS : Calcd: 410 1072, Found : 410 1075 (M + H) ; h) CI-HRMS : Calcd: 414. 2427, Found : 414 2427 (M + H) ; i) CI-HRMS : Calcd: 368. 2372, Found : 368. 2372 (M + H) ; j) CI-HRMS : Calcd: 384. 1955, Found : 384. 1947 (M + H) ; k) CI-HRMS : Calcd: 391. 2168, Found: 391. 2160 (M + H) ; 1) CI-HRMS : Calcd: 335. 1984, Found : 335. 1961 (M + H) ; m) CI-HRMS : Calcd: 382. 0759, Found : 382. 0765 (M + H) ; n) NH3-CI MS: Calcd: 360, Found: 360 (M + H) + o) NH3-CI MS: Calcd: 374, Found: 374 (M + H) + ; NMR (CDCI3, 300 MHz) :δ 7.29 (d, J=8.4Hz, 1H) , 7.04 (dd, J=1.8,8Hz, 1H) , 6.96 (d, J=1.8Hz, 1H) , 6.15 (d, J-10, 1H) , 4.19 (m, 1H) , 3.81 (s, 3H) , 2.47 (s, 3H) , 2.32 (s, 3H) , 1.65 (m, 4H) , 0.99 (t, J=7.32Hz, 6H) p) NH3-CI MS: Calcd: 390, Found: 390 (M + H)+; NMR (CDCI3, 300 MHz) :□□ 7.28 (d, J=8Hz, 1H), 7.03 (d, J=8Hz, 1H), 6.96 (s: 1H), 6.52 (d, J=9Hz, 1H), 4.36 (m, 1H), 3.8 (s, 3H), 3.55 (m, 2H), 3.39 (s, 3H), 2.47 (s, 3H), 2.32 (s, 3H), 1.76 (m, 2H), 1.01 (t, J=7.32Hz, 3H).

CI-HRMS: Calcd: 354.2294, Found: 354.2279 (M + H)+ CI-HRMS: Calcd: 340.2137, Found: 340.2138 (M + H)+ CI-HRMS: Calcd: 436.1307, Found: 436.1296 (M + H)+ The examples delineated in TABLE 4 may be prepared by the methods outlined in Examples 1 A, IB, 432, 433, 434. Commonly used abbreviations are: Ph is phenyl, Pr is propyl, Me is methyl, Et is ethyl, Bu is butyl, Ex is Example, EtOAc is ethyl acetate.

TABLE 4 Ex, Z K Ar mp(°g 631 C-Me NHCH(Et)2 2-Br-4,5-(MeO)2Ph 160-161 632 C-Me NHCH(Et)2 2-Br-4-MeOPh 1 10-11 1 633 C-Me N(CH2CH20Me)2 2-Br-4-MeOPh 74-76 634 C-Me NHCH(CH20Me)2 2-Br-4-MeOPh 128-130 635 C-Me N(Et) 2 2-Me-4-ClPh 636 C- e N (c-Pr) Et 2, -Cl2Ph 637 C-Me . N(c-Pr)Et 2, 4-Me2Ph 638 C-Me N(c-Pr) Et 2, 4, 6-Me3Ph 639 C-Me N(c-Pr) Et 2-Me-4-Me0Ph 640 C-Me N(c-Pr)Et 2-Cl-4-Me0Ph 641 C-Me N{c-Pr)Et 2-Cl-4-MePh 642 C-Me N(c-Pr) Et 2-Me-4-ClPh 643" C-Me NHCH (c-Pr) 2 2, -Cl2~Ph 644 C-Me NHCH (c-Pr) 2 2, -Me2-Ph 645 C-Me NHCH (c-Pr) 2 2-Me-4-Cl-Ph 646 C-Me NHCH (c-Pr) 2 2-Cl-4-Me-Ph 647 C-Me NHCH (c-Pr) 2 2-Me-4-0Me-Ph 648 C-Me NHCH (c-Pr) 2 2-Cl-4-OMe-Ph 649 C-Me NHCH (CH20Me) 2 2-Cl-5-F-0MePh 650 C-Me NEt2 2-Cl-5-F-0MePh 651 C-Me N(c-Pr)CH2CH2CN 2-C1-5-F-OMePh 652 C-Me NHCH (-Et ) 2 2-Cl-5-F-OMePh 653 C-Me (CH2CH 0Me) 2 2-Cl-5-F-0MePh 654 C-Me NEt2 2, 6-Me2-pyrid-3-yl 655 C-Me (c-Pr) CH2CH2C 2, 6-Me2-pyrid-3-yl 656 C-Me NHCH (Et) 2 2, 6-Me2~pyri.d-3-yl 657 C-Me N(CH2CH20Me)2 2, 6-Μβ2 -pyrid-3-yl 658 C-OH NHCH (CH2OMe) 2 2, -Me2-Ph 659 C-OH NEt2 2, -Me2~P 660 C-OH N (c-Pr) CH2CH2CN 2, -Me2~Ph 661 C-OH NHCH (Et) 2 2, 4-Me2~P 662 C-OH N(CH2CH20Me)2 2, 4-Me2-Ph 663 C-NEt2 NHCH (CH20Me) 2 2, 4-Me2-Ph 664 C-NEt2 NEt2 2, -Me2-Ph 665 C-NEt2 N(c-Pr) CH2CH2CN 2, -Me2-Ph 666 C-NEt2 NHCH(Et) 2 2, 4-Me2-Ph 667 C-NEt2 (CH2CH20Me) 2 2, -Me2-Ph 668 C-Me NHCH (Et) 2 2-Me-4-CN-Ph 669 C-Me (CH2CH20Me) 2 2-Me-4-CN-Ph The examples in Tables 5 or 6 may be prepared by the methods illustrated in Examples 1A, IB, 2, 3, 6, 431, 432, 433, 434 or by appropriate combinations thereof. Commonly used abbreviations are: Ph is phenyl, Pr is propyl, Me is methyl, Et is ethyl, Bu is butyl, Ex is Example.

Table 5 Ex, Rl4 s Ar 670 Me HCH(CH2OMe)2 2,4-Cl2-Ph 671 Me HCHPr2 2,4-Cl2-Ph 672 Me NEtBu 2,4-Cl2-Ph 673 Me NPr(CH2-c-C3H5) 2,4-Cl2-Ph 674 Me N(CH2CH20Me)2 2,4-Cl2-Ph 675 Me NH-3-hepty! 2,4-Cl2-Ph 676 Me NHCH(Et)CH20Me 2,4-Cl2-Ph 677 Me NEt2 2,4-Cl2-Ph 678 Me NHCH(CH20Et)2 2,4-Cl2-Ph 679 Me NH-3-pentyl 2,4-(¾-Ph 680 Me NMePh 2,4-Cl2-Ph 681 Me Pr2 2,4-Cl2-Ph 682 Me NH-3-hexyl 2,4-Cl2-Ph 683 Me morpholino 2,4-Cl2-Ph 684 Me N(CH2Ph)CH2CH20 e 2, -Cl2-Ph 685 Me NHCH (CH2Ph)CH20 e 2, 4-Cl2~Ph 686 Me NH-4-tetra ydropyranyl 2, 4-Cl2-Ph 687 Me NH-cyclopentyl 2, 4-Cl2-Ph 688 Me OEt 2,4-Cl2-Ph 689 Me OCH(Et)CH20Me 2, 4-Cl2~Ph 690 Me OCH2Ph 2, 4-Cl2~Ph 691 Me O-3-pentyl 2,4-Cl2-P 692 Me SEt 2, 4-Cl2-Ph 693 Me S (0) Et 2, 4-Cl2-Ph 694 Me S02E 2, -Cl2-Ph 695 Me Ph 2, 4-Cl2-Ph 696 Me 2-CF3-Ph 2, -Cl2-Ph 697 Me 2-Ph-Ph 2, -Cl2-Ph 698 Me 3-pentyl 2, -Cl2-Ph 699 Me cyclobutyl 2, -Cl2-Ph 700 Me 3-pyridyl 2 , 4-Cl2~Ph 701 Me CH (Et) Ctf2CON e2 ' 2, -Cl2-Ph 702 Me CH (Et) CH2CH2NMe2 2, 4-Cl2-Ph 703 Me NHCH (CH20Me) 2 2,4, 6-Me3-Ph 704 Me NHCHPr2 2,4, 6-Me3-Ph 705 Me NEtBu 2, 4, 6-Me3-Ph 706 Me NPr (CH2-C-C3H5) 2,4, 6-Me3-Ph 707 Me (CH2CH20Me) 2 2,4, 6-Me3-Ph 708 Me NH-3-heptyl 2,4, 6-Me3-Ph 709 Me NHCH (Et) CH20Me 2, , 6-Me3-Ph 710 Me NEt2 2, 4, 6-Me3-Ph 711 Me NHCH (CH20Et) 2 2, 4, 6-Me3-Ph 712 Me NH-3-pentyl 2, 4, 6-Me3-Ph 713 Me NMePh 2, , 6-Me3-Ph 714 Me NPr2 2, 4, 6-Me3-Ph 715 Me NH-3-hexyl 2,4, 6-Me3-Ph 716 Me morpholino 2, 4, 6-Me3-Ph 717 Me (CH2Ph)CH2CH20Me 2, 4, 6-Me3-Ph 718 Me NHCH(CH2Ph)CH20Me 2,4, 6-Me3-Ph 719 Me NH-4-tetrahydropyranyl 2, 4, 6-Me3-P 720 Me NH-cyclopentyl 2,4, 6-Me3-Ph 721 Me OEt 2,4, 6-Me3-Ph 722 Me OCH(Et)CH20Me 2, , 6-Me3-Ph 723 Me OCH2Ph 2,4, 6-Me3-P 724 Me O-3-pentyl 2,4, 6-Me3-P 725 Me SEt 2,4, 6-Me3-Ph 726 Me S (OEt 2,4, 6-Me3-Ph 727 Me S02Et 2, , 6-Me3-Ph 728 Me CH (C02Et) 2 2, , 6-Me3-Ph 729 Me C (Et) (C02Et) 2 2,4, 6-Me3-Ph 730 Me CH (Et) CH2OH 2,4, 6-Me3-Ph 731 Me CH (Et) CH20Me 2,4, 6-Me3-Ph 732 Me CONMe2 2,4, 6-Me3-Ph 733 Me COCH3 2,4, 6-Me3-Ph 734 Me CH (OH) CH3 2,4, 6-Me3-Ph 735 Me C (OH) P -3-pyridyl 2,4, 6-Me3-Ph 736 Me Ph 2,4, 6-Me3-Ph 737 Me 2-Ph*-Ph , 4, 6-Me3-P 738 Me 3-pentyl , 4, 6-Me3~Ph 739 Me cyclobutyl , 4 , 6-Me3-Ph 740 Me 3-pyridyl ,4, 6-Me3-Ph 741 Me CH (Et) CH2CONMe2 , 4 , 6-Me3~P 742 Me CH (Et)CH2CH2 Me2 , 4, 6-Me3-Ph 743 Me NHCH (CH20Me) 2 2, 4-Me2-Ph 744 Me N(CH2CH20 e) 2 2, -Me2~ h 745 Me NHCH(Et)CH20Me 2, 4-Me2" 746 Me NH-3-pentyl 2, 4-Me2~Ph 747 Me NE 2 2, 4- e2~P 748 Me N(CH2CN) 2 2, 4-Me2"P 749 Me NHCH (Me)CH20Me 2, 4-Me2-Ph 750 Me OCH(Et)CH20Me 2, 4-Me2~Ph 751 Me NPr-c-C3H5 2, 4-Me2~Ph 752 Me NHCH(Me)CH2NMe2 2, 4-Me2-Ph 753 Me (c-C3H5)CH2CH2C 2, 4- e2-Ph 754 Me N(Pr)CH2CH2CN 2, 4-Me2-Ph 755 Me N(Bu)CH2CH2CN 2, 4-Me2-Ph 756 Me NHCHPr2 2, -Me2-P 757 Me NEtBu 2, -Me2-P 758 Me NPr (CH2-C-C3H5) 2, -Me2-Ph 759 Me NH-3-heptyl 2, -Me2-Ph 760 Me NEt2 2, 4-Me2~Ph 761 Me NHCH (CH20Et) 2 2, -Me2-Ph 762 Me NH-3-pentyl 2, 4-Me2~Ph 763 Me NMePh 2, - e2~Ph 764 Me ΡΓ2 2, 4-Me2-Ph 765 Me NH-3-hexyl 2, 4- e2~Ph 766 Me morpholino 2, - e2"Ph 767 Me N (CH2 h) CH2CH20Me 2, -Me2~Ph 768 Me NHCH (CH2P ) CH20Me 2, -Me2"Ph 769 Me NH- -tet rahydropyranyl 2, -Me2~Ph 770 Me NH-cyclopentyl 2, - e2-P 771 Me NHCH (CH20Me) 2 2-Me-4-MeO-Ph 772 Me N (CH2CH20Me) 2 2-Me-4-MeO-Ph 773 Me NHCH (Et) CH20 e 2-Me-4-MeO-Ph 774 Me (Pr) CH2CH2C 2-Me-4-MeO-Ph 775 Me OCH (Et) CH20 e 2-Me-4-MeO-Ph 776 Me NHCH (CH20Me) 2 2-Br-4-MeO-Ph 777 Me N (CH2CH20 e) 2 2-Br-4-MeO-Ph 778 Me NHCH (Et) CH20Me 2-Br-4-MeO-Ph 779 Me N(Pr)CH2CH2CN 2-Br-4-MeO-Ph 780 Me OCH (Et) CH20Me 2-Br-4-MeO-Ph 781 Me NHCH (CH20Me) 2 2-Me-4-NMe2~Ph 782 Me (CH2CH20Me) 2 2-Me-4-NMe2-Ph 783 Me NHCH (Et) CH20Me 2-Me-4-NMe2~P 784 Me N(Pr)CH2CH2CN 2-Me-4-NMe2~Ph 785 Me OCH(Et)CH20Me 2-Me-4-NMe2-Ph 786 Me NHCH (CH20Me) 2 2-Br-4-NMe2~Ph 787 Me N (CH2CH20Me) 2 2-Br-4-NMe2-P 788 Me NHCH(Et)CH20Me 2-Br-4-NMe2"Ph 789 Me N(Pr)CH2CH2CN 2-Br-4-NMe2~Ph 790 Me OCH(Et)CH20Me 2-Br-4-NMe2~Ph 791 Me NHCH (CH20Me) 2 2-Br-4-i-Pr-Ph 792 Me (CH2CH20 e) 2 2-Br-4-i-Pr-Ph 793 Me NHCH (Et) CH20Me 2-Br-4-i-Pr-Ph 794 Me (Pr)CH2CH2C 2-Br-4-i-Pr-Ph 795 Me OCH (Et)CH20Me 2-Br-4-i-Pr-Ph 796 Me NHCH (CH20Me) 2 2-Br-4-Me-Ph 797 Me (CH2CH20Me) 2 2-Br-4-Me-Ph 798 Me NHCH (Et) CH20Me 2-Br-4-Me-Ph 799 Me N(Pr)CH2CH2CN 2-Br-4-Me-Ph 80J Me OCH (Et)CH20Me 2-Br-4 -Me-P 801 Me NHCH (CH20Me) 2 2-Me-4-Br-Ph 802 Me N(CH2CH20Me) 2 2-Me-4-Br-P 803 Me NHCH (Et) CH20Me 2-Me-4-Br-Ph 804 Me N (Pr) CH2CH2C 2-Me-4-Br-P 805 Me OCH (Et) CH20Me 2-Me-4-Br-Ph 806 Me NHCH (CH20Me) 2 2-C1-4, 6-Me2-Ph 807 Me N (CH2CH20 e) 2 2-C1- , 6-Me2-Ph 808 Me NHCH (CH20Me) 2 4-Br-2, 6 - (Me) 2-Ph 809 Me N (CH2CH20Me) 2 4-Br-2, 6 - (Me) 2-Ph 810 Me NHCH (CH20Me) 2 4-i-Pr-2-SMe-Ph 811 Me (CH2CH20Me) 2 4-i-Pr-2-SMe-Ph 812 Me NHCH (CH20Me) 2 2-Br-4-CF3-Ph 813 Me (CH2CH20Me) 2 2-Br-4-CF3-Ph 814 Me NHCH (CH20Me) 2 2-Br-4, 6 - (MeO) 2~Ph 815 Me N(CH2CH20Me) 2 2-Br-4, 6 - (MeO) 2-Ph 816 Me NHCH (CH20Me) 2 2-C1-4, 6 - (MeO) 2-Ph 817 Me N (CH2CH20Me) 2 2-C1-4, 6 - (MeO) 2~P 818 Me NHCH (CH20Me) 2 2, 6 - (Me) 2-4-SMe-Ph 819 Me N(CH2CH20Me)2 2, 6 - (Me) 2-4-SMe-Ph 820 Me NHCH(CH20Me)2 4- (COMe) -2-Br-Ph 821 Me (CH2CH20Me) 2 4- (COMe) -2-Br-Ph 822 Me NHCH (CH20Me) 2 2,4, 6-Me3~pyrid-3-yl 823 Me (CH2CH20Me) 2 2,4, 6-Me3~pyrid-3-yl 824 Me NHCH (CH20Me) 2 2, 4-(Br)2~Ph 825 Me (CH2CH20Me) 2 2,4-(Br>2-Ph 826 Me NHCH (CH20Me) 2 4-i-Pr-2-SMe-Ph 827 Me N (CH2CH20Me) 2 4-i-Pr-2-SMe-Ph 828 Me NHCH (CH20Me) 2 4-i-Pr-2-S02Me-Ph 829 Me (CH2CH20Me)2 4-i-Pr-2-S02Me-Ph 830 Me NHCH (CH20Me) 2 2, 6- (Me) 2-4-SMe-Ph 831 Me N(CH2CH20Me)2 2,6- (Me) 2-4-SMe-Ph 832 Me NHCH (CH20Me) 2 2, 6- (Me) 2-4-S02Me-Ph 833 Me (CH2CH20Me)2 2, 6- (Me) 2-4-S02Me-Ph 834 Me NHCH (CH20Me) 2 2-I-4-i-Pr-P 835 Me (CH2CH20Me) 2 2-I-4-i-Pr-P 835- Me NHCH (CH20Me) 2 2-Br-4-N (Me) 2-6-MeO-Ph 837 Me (CH2CH20Me)2 2-Br-4- (Me) 2-6-MeO-Ph 838 Me NE 2 2-Br-4-MeO-Ph 839 Me NH-3-pentyl 2-Br-4-MeO-Ph 840 Me NHCH (CH20Me) 2 2-CN-4-Me-Ph 841 Me N (c-C3H5)CH2CH2C 2, , 6-Me3~Ph 842 Me NHCH (CH2CH20 e) CH20Me 2-Me-4-Br-Ph 843 Me NHCH (CH20Me) 2 2, 5-Me2-4-MeO-Ph 844 Me N (CH2CH20 e) 2 2, 5-Me2-4-MeO-Ph 845 Me NH-3-pentyl 2, 5-Me2-4-MeO-Ph 846 Me E 2 2, 5-Me2-4-MeO-Ph 847 Me NHCH (CH20Me) 2 2-Cl-4-MePh 848 Me NCH (Et) CH20 e 2-Cl-4-MePh 849 Me N (CH2CH20Me) 2 2-ci-4-MePh 850 Me (S) -NHCH (CH2CH20Me) CH20Me 2-Cl-4-MePh 851 Me N (C-C3H5) CH2CH2C 2, 5-Me2-4-MeOPh 852 Me NEt2 2-Me-4-MeOPh 853 Me OEt 2-Me-4-MeOPh 854 Me (S) -NHCH (CH2CH20Me) CH20Me 2-Me-4-MeOPh 855 Me N (C-C3H5} CH2CH2CN 2-Me-4-MeOPh 856 Me NHCH (CH2CH20E ) 2 2-Me-4-MeOPh 857 Me (c-C3H5)CH2CH2C 2, 4-Cl2-Ph 858 Me NEt2 2-Me-4-ClPh 859 Me NH-3-pentyl 2-Me-4-ClPh 860 Me (CH2CH20Me)2 2-Me-4-ClPh 861 Me NHCH (CH20Me) 2 2-Me-4-ClPh 862 Me NEt2 2-Me-4-ClPh 863 Me NEt2 2-Cl-4-MePh 864 Me NH-3-pentyl 2-Cl-4-MePh 865 Me NHCH (CH20Me) 2 2-Cl-4-MeOPh 866 Me N (CH2CH20Me) 2 2-Cl-4-MeOPh 867 Me NHCH(Et)CH20Me 2-ci-4-MeOPh 868 Me N(c-Pr)CH2CH2CN 2-ci-4-MeOPh 869 Me NEt2 2-ci-4-MeOP 870 Me NH-3-pentyl 2-Cl-4-MeOPh 871 Me NHCH(Et)CH2CH20Me 2-Cl-4-MeOPh 872 Me NHCH (Me) CH2CH20Me 2-d-4-MeOPh 873 Me NHCH (Et) CH2CH20 e 2-Br-4-MeOPh 874 Me NHCH (Me) CH2CH20Me 2-Br-4-MeOP 875 Me NHCH (Et) CH2CH20 e 2-Me-4-MeOPh 876 Me NHCH (Me) CH2CH20Me 2-Me-4-MeOPh 877 Me NHCH (CH20Me) 2 2-C1-4, 5- (MeO) 2 h 878 Me N (CH2CH20 e) 2 2-C1-4 , 5- (MeO) 2?h 879 Me NHCH (Et) CH20Me 2-C1-4, 5- (MeO) 2Ph 880 Me N (c-Pr) CH2CH2 2-C1- , 5- (MeO) 2Ph 881 Me Et2 2-C1-4, 5- (MeO) 2Ph 882 Me NH-3-pentyl 2-C1-4, 5- (MeO) 2Ph 883 Me NHCH (Et) CH2CH20Me 2-C1-4, 5- (MeO) 2?h 884 Me NHCH (Me) CH2CH20Me 2-C1-4, 5- (MeO) 2Ph 885 Me NHCH (CH20Me) 2 2-Br-4, 5- (MeO) 2Ph 886 Me (CH2CH20 e) 2 2-Br-4, 5- (MeO) 2?h 887 Me NHCH (Et) CH20Me 2-Br-4, 5- (MeO) 2Ph 888 Me N(c-Pr)CH2CH2CN 2-Br-4, 5- (MeO) 2 h 889 Me NEt2 2-Br-4, 5- (MeO) 2 h 890 Me NH-3-pentyl 2-Br-4, 5- (MeO) 891 Me NHCH (CH20Me) 2 2-C1-4, 6- (MeO) 2Ph 892 Me N (CH2CH20Me) 2 2-C1-4, 6- (MeO) 2Ph 893 Me NEt2 2-C1-4, 6- (MeO) 2Ph 894 Me NH-3-pentyl 2-C1-4, 6- (MeO) 2Ph 895 Me NHCH (CH20Me) 2 2-Me-4, 6- (MeO) 2Ph 896 Me N(CH2CH20Me) 2 2-Me-4, 6- (MeO) 2Ph 897 Me NHCH (Et) CH20Me 2-Me-4, 6-(MeO)2Ph 898 Me Et2 2-Me-4, 6- (MeO) 2Ph 899 Me NH-3-pentyl 2-Me-4, 6- (MeO) 2 h 900 Me NHCH(Et)CH2CH20Me 2-Me-4-MeOPh 901 Me NHCH(Me)CH2CH20Me 2-Me-4-MeOPh 902 Me NHCH(CH20Me)2 2-MeO-4-MePh 903 Me N(CH2CH20Me)2 2-MeO-4-MePh 904 Me NHCH(Et)CH20Me 2-MeO-4-MePh 905 Me N(c-Pr)CH2CH2CN 2-MeO-4-MePh 906 Me NEt2 2-MeO-4-MePh 907 Me NH-3-pentyl 2-MeCM-MePh 908 Me HCH(Et)CH2CH20Me 2-MeO-4-MePh 909 Me NHCH(Me)CH2CH20Me 2-MeO-4-MePh 910 Me NHCH(CH20Me)2 2-MeO-4-MePh 911 Me N(CH2CH20Me)2 2-MeO-4-MePh 912 Me HCH(Et)CH20Me 2-MeO-4-MePh 913 Me N(c-Pr)CH2CH2CN 2-MeO-4-MePh 914 Me NEt2 2-MeO-4-MePh 915 Me NH-3-pentyl 2-MeO-4-MePh 916 Me NHCH(CH2OMe)2 2-MeO-4-ClPh 917 Me N(CH2CH20Me)2 2-MeO-4-CIPh 918 Me HCH(Et)CH20Me 2-MeO-4-ClPh 919 Me NEt2 2-MeO-4-ClPh 920 Me NH-3-pentyl 2-MeO-4-ClPh Table 6 &14 R Ax 921 Me NHCH(CH20Me)2 2,4-Cl2-Ph 922 Me NHCHPr2 2,4-<¾-Ph 923 Me NEtBu 2,4-Cl2-Ph 924 Me NPr(CH2-c-C3H5) 2,4-Cl2-Ph 925 Me N(CH2CH20Me)2 2,4-Cl2-Ph 926 Me NH-3-heptyl 2,4-Cl2-Ph 927 Me NHCH(Et)CH20Me 2,4-Cl2-Ph 928 Me NEt2 2,4-Cl2-Ph 929 Me NHCH(CH20Et)2 2,4-Cl2-Ph 930 Me H-3-pentyl 2,4-Cl2-Ph 931 Me MePh 2,4-Cl2-Ph 932 Me NPr2 2,4-Cl2-Ph 933 Me NH-3-hexyl 2,4-Cl2-Ph 934 Me morpholtno 2,4-C!2-Ph 935 Me N(CH2Ph)CH2CH2OMe 2,4-Cl2-Ph 936 Me NHCH(CH2Ph)CH20Me 2,4-Cl2-Ph 937 Me H-4-tetrahydropyranyl 2,4-Cl2-Ph 938 Me NH-cyclopentyl 2,4-Cl2-Ph 939 Me OEt 2,4-Cl2-Ph 940 Me OCH(Et)CH20Me 2,4-Cl2-Ph 941 Me 0CH2Ph 2,4-Cl2-Ph 942 Me O-3-pentyl 2,4-Cl2-Ph 943 Me SEt 2,4-(¾-Ph 944 Me S (0) Et 2, 4-Cl2-Ph 945 Me S02Et 2, 4-Cl2"Ph 946 Me Ph 2, 4-Cl2"Ph 947 Me 2-CF3-Ph 2, 4-Cl2~Ph 948 Me 2-Ph-Ph 2, 4-Cl2~Ph 949 Me 3-pentyl 2, 4-Cl2~Ph 950 Me cyclobutyl 2, -Cl2-Ph 951 Me 3-pyridyl 2, -Cl2-P 952 Me CH (Et)CH2CONMe2 · 2, 4-Cl2-Ph 953 Me CH(Et)CH2CH2 e2 2, 4-Cl2-Ph 954 Me NHCH (CH20Me) 2 2,4, 6-Me3-Ph 955 Me NHCHPr2 2,4, 6-Me3-Ph 956 Me NEtBu 2, , 6-Me3-Ph 957 Me NPr (CH2-C-C3H5) 2,4, 6-Me3-P 958 Me N (CH2CH20Me) 2 2,4, 6-Me3-Ph 959 Me NH-3-heptyl 2,4, 6-Me3~Ph 960 Me NHCH(Et)CH20Me 2,4, 6-Me3-Ph 961 Me NBt2 2, 4 , 6-Me3-Ph 962 Me NHCH (CH2OE 2 2,4, 6-Me3-Ph 963 Me NH-3-pentyl 2, , 6-Me3-Ph 964 Me NMePh 2,4, 6-Me3-Ph 965 Me NPr2 2,4, 6-Me3-Ph 966 Me NH-3-hexyl 2,4, 6-Me3-Ph 967 Me morpholino 2,4, 6-Me3-Ph 968 Me (CH2Ph) CH2CH20Me 2, 4 , 6-Me3-Ph 969 Me NHCH (CH2P )CH20Me 2, 4, 6-Me3-P 970 Me NH-4-tetrahydropyranyl 2,4, 6-Me3-Ph 971 Me NH-cyclopentyl 2,4, 6-Me3-Ph 972 Me OEt 2, 4 , 6-Me3~Ph 973 Me OCH(Et)CH20Me 2, 4 , 6-Me3~Ph 974 Me OCH2Ph 2, 4 , 6-Me3-Ph 975 Me O-3-pentyl 2, 4 , 6-Me3~Ph 976 Me SEt 2, 4 , 6-Me3-Ph 977 Me S(0)Et 2, 4 , 6-Me3-Ph 978 Me S02Et 2, 4 , 6-Me3-Ph 979 Me CH (C02Et) 2 2, 4 , 6-Me3-Ph 9Θ0 Me C (Et) (C02Et) 2 2,4, 6-Me3~Ph 981 Me CH (Et) CH2OH 2,4, 6-Me3-Ph 982 Me CH (Et) CH20Me 2,4, 6-Me3~Ph 983 Me CONMe2 2, , 6-Me3-Ph 984 Me COCH3 2,4, 6-Me3-Ph 985 Me CH (OH)CH3 2,4, 6-Me3-Ph 986 Me C (OH) Ph-3-pyridyl 2,4, 6-Me3-Ph 987 Me Ph 2,4, 6-Me3-Ph 96t) Me 2-Ph-Ph 2,4, 6-Me3-Ph 989 Me 3-pentyl 2,4, 6-Me3-Ph 990 Me cyclobutyl 2, 4, 6-Me3-Ph 991 Me 3-pyridyl 2,4, 6-Me3~Ph 992 Me CH (Et) CH2CO Me2 2,4, 6-Me3-Ph 993 Me CH (Et) CH2CH2NMe2 2,4, 6-Me3-Ph 994 Me NHCH (CH20Me) 2 2, 4- e2~Ph 995 Me N(CH2CH20Me) 2 2, 4-Me2~Ph 996 Me NHCH(£t)CH20Me 2, 4-Me2-Ph 997 Me NH-3-pentyl 2, - e2-Ph 998 Me NEt2 2, 4-Me2-Ph 999 Me N (CH2CN) 2 2, 4-Me2- 1000 Me NHCH (Me)CH20Me 2, 4-Me2-Ph 1001 Me OCH (Et)CH20Me 2, 4-Me2~P 1002 Me NPr-c-C3H5 2, 4-Me2-Ph 1003 Me NHCH (Me) CH2NMe2 2, 4-Me2~Ph 1004 Me N (C-C3H5) CH2CH2C 2, -Me2~Ph 1005 Me N(Pr)CH2CH2CN 2, 4-Me2~Ph 1006 Me N(Bu)CH2CH2CN 2, -Me2~Ph 1007 Me NHCHPr2 2, 4- e2~Ph 1008 Me NEtBu 2, 4-Me2~Ph 1009 Me NPr (CH2-C-C3H5) 2, 4-Me2-Ph 1010 Me NH-3-heptyl 2, 4-Me2-Ph 1011 Me NEt2 2, 4-Me2~Ph 1012 Me NHCH (CH20Et) 2 2, -Me2~Ph 1013 Me NH-3-pentyl 2, 4-Me2~Ph 1014 Me NMePh 2, 4-Me2~Ph 1015 Me Pr2 2, 4-Me2-P 1016 Me NH-3-hexyl 2, 4-Me2~Ph 1017 Me morpholino 2, -Me2-Ph 1018 Me N(CH2Ph)CH2CH20 e 2, -Me2~Ph 1019 Me NHCH (CH2Ph) CH20 e 2, -Me2-Ph 1020 Me NH-4 -tetrahydropyranyl 2, -Me2-Ph 1021 Me NH-cyclopentyl 2, -Me2-Ph 1022 Me NHCH (CH20Me) 2 2-Me-4 -MeO-Ph 1 023 Me (CH2CH20 e) 2 2-Me-4-MeO-Ph 1024 Me NHCH (Et) CH20Me 2-Me-4-MeO-Ph 1025 Me N(P )CH2CH2C 2-Me-4-MeO-Ph 1026 Me OCH(Et)CH20Me 2-Me-4-MeO-Ph 1027 Me NHCH (CH20Me) 2 2-Br-4-MeO-Ph 1028 Me N (CH2CH20Me) 2 2-Br-4-MeO-Ph 1029 Me NHCH (EC) CH20 e 2-Br-4-MeO-Ph 1030 Me (Pr) CH2CH2C 2_Br-4-MeO-Ph 1031 Me OCH (Et) CH20Me 2-Br-4-MeO-Ph 1032 Me NHCH (CH20Me>2 2-Me-4-NMe2-Ph 1033 Me N(CH2CH20Me) 2 2-Me-4-NMe2~Ph 1034 Me NHCH ( Et ) CH2<0Me 2-Me-4-NMe2-Ph 1035 Me N (Pr) CH2CH2CN 2-Me-4-NMe2~Ph 1036 Me OCH (Et) CH20Me 2-Me-4-NMe2~Ph 1037 Me NHCH (CH20Me) 2 2-Br-4-NMe2-Ph 1038 Me N (CH2CH20Me) 2 2-Br-4-NMe2-Ph 1039 Me NHCH (Et)CH20Me 2-Br-4-NMe2-Ph 1040 Me N (Pr) CH2CH2C 2-Br-4-NMe2~Ph 1041 Me OCH(Et)CH20Me 2-Br-4-NMe2~Ph 1042 Me NHCH (CH20Me) 2 2-Br-4-i-Pr-Ph 1043 Me N (CH2CH20 e) 2 2-3r-4-i-Pr-Ph 1044 Me NHCH (Et) CH20 e 2-Br-4-i-Pr-Ph 1045 Me N(Pr)CH2CH2CN 2-Br-4-i-Pr-Ph 1046 Me 0CH(Et)CH2OMe 2-Br-4-i-Pr-Ph 1047 Me NHCH(CH20Me) 2 2-Br-4-Me-Ph 1048 Me N (CH2CH20Me) 2 2-Br-4-Me-Ph 1049 Me NHCH(Et)CH20Me 2-Br-4-Me-Ph 1050 Me N(Pr)CH2CH2CN 2-Br-4-Me-Ph 1051 Me OCH (Et)CH20Me 2-Br-4-Me-Ph 1052 Me NHCH (CH20Me) 2 2-Me-4-Br-Ph 1053 Me (CH2CH20Me) 2 2-Me-4-Br-Ph 1054 Me NHCH (Et) CH20Me 2-Me-4-Br-Ph 1055 Me N(Pr)CH2CH2CN 2-Me-4-Br-Ph 1056 Me OCH (Et)CH20Me 2-Me-4-Br-P 1057 Me NHCH (CH20Me) 2 2-C1-4, 6-Me2-Ph 1058 Me N(CH2CH20 e)2 2-C1-4, 6-Me2"Ph 1059 Me NHCH (CH20Me) 2 4-Br-2, 6- (Me) 2-Ph 1000 Me N (CH2CH20Me) 2 4-Br-2, 6- (Me) 2" 1061 Me NHCH(CH20Me)2 4-i-Pr-2-SMe-Ph 1062 Me N (CH2CH20 e) 2 4-i-Pr-2-SMe-Ph 1063 Me NHCH (CH20Me) 2 2-Br-4-CF3-Ph 1064 Me N (CH2CH20Me) 2 2-Br-4-CF3-Ph 1065 Me NHCH (CH20Me) 2 2-Br-4, 6-(MeO)2"P 1066 Me N (CH2CH20Me) 2 2-Br-4, 6- (MeO) 2~Ph 1067 Me NHCH(CH20Me)2 2-C1-4, 6- (MeO) 2-Ph 1068 Me N (CH2CH20Me) 2 2-C1- , 6- (MeO) 2-Ph 1069 Me NHCH (CHgOMe) 2 2, 6- (Me) 2-4-SMe-Ph 1070 Me (CH2CH20Me) 2 2, 6- (Me) 2-4-SMe-Ph 1071 Me NHCH (CH20Me) 2 4- (COMe) -2-3r-Ph 1072 Me (CH2CH20Me) 2 4- (COMe) -2-Br-Ph 1073 Me NHCH(CH20Me) 2 2,4» 6-Me3-pyrid-3-yl 1074 Me N (CH2CH20Me) 2 2, 4, 6-Me3~pyrid-3-yl 1075 Me NHCH(CH20Me)2 2, 4- (Br) 2- h 1076 Me N (CH2CH20Me) 2 2, 4- (Br) 2-P 1077 Me NHCH (CH20Me) 2 4-i-Pr-2-SMe-Ph 1078 Me N(CH2CH20Me>2 4-i-Pr-2-SMe-Ph 1079 Me NHCH(CH20Me)2 4-i-Pr-2-S02Me-Ph 1080 Me N (CH2CH20Me) 2 4-i-Pr-2-S02Me-Ph 1081 Me NHCH (CH20Me) 2 2, 6- (Me) 2-4-SMe-Ph 1082 Me N (CH2CH20Me) 2 2 , 6- (Me) 2-4-SMe-Ph 1083 Me NHCH (CH20Me) 2 2, 6- (Me) 2-4-S02Me-Ph 1084 Me N(CH2CH20Me>2 2, 6- (Me) 2-4-S02Me-Ph 1085 Me NHCH (CH20Me) 2 2-I-4-i-Pr-Ph 1086 Me (CH2CH20Me) 2 2-I-4-i-Pr-Ph 1087 Me NHCH(CH20Me)2 2-Br-4-N (Me) 2-6-MeO-Ph 1088 Me N (CH2CH20Me) 2 2-Br-4- (Me) 2-6-MeO-Ph 1089 Me Et2 2-Br-4-MeO-Ph 1090 Me NH-3-pentyl 2-Br-4-MeO-Ph 1091 Me NHCH (CH20Me) 2 2-CN-4-Me-Ph 1092 Me N(c-C3H5)CH2CH2C 2,4, 6-Me3-Ph 1093 Me NHCH (CH2CH20Me) CH20Me 2-Me-4-Br-Ph 1094 Me NHCH (CH20Me) 2 2 , 5-Me2-4-MeO-Ph 1095 Me N (CH2CH20Me) 2 2, 5-Me2-4-MeO-Ph 1096 Me NH-3-pentyl 2, 5-Me2~4-MeO-Ph 1097 Me NE 2 2, 5-Me2-4-MeO-Ph 1098 Me NHCH (CH20Me) 2 2-Cl-4-MeP 1099 Me NCH (Et) CH20Me 2-Cl-4-MePh 1100 Me N ( H2CH20Me) 2 2-Cl-4-MePh 1101 Me (S) -NHCH(CH2CH20Me)CH20Me 2-Cl-4-MePh 1102 Me N (C-C3H5) CH2CH2CN 2, 5-Me2-4-MeOPh 1103 Me NEt2 2-Me-4-MeOPh 1104 Me OEt 2-Me-4-MeOPh 1105 Me I S ) -NHCH (CH2CH20Me) CH20 e 2-Me-4-MeOPh 1106 Me N (C-C3H5) CH2CH2C 2-Me-4-MeOPh 1107 Me NHCH (CH2CH20Et) 2 2-Me-4-MeOPh 1108 Me (C-C3H5) CH2CH2C 2, -Cl2~Ph 1109 Me NEt2 2-Me-4-ClPh 1110 Me NH-3-pentyl 2-Me-4-ClPh 1111 Me (CH2CH20Me) 2 2-Me-4-ClPh 1112 Me NHCH (CH20Me) 2 2-Me-4-ClPh 1113 Me NEt2 2-Me-4-ClPh 1114 Me NEt2 2_ci-4-MePh 1115 Me NH-3-pentyl 2-Cl-4-MePh 1116 Me NHCH (CH20Me) 2 2-Cl-4-MeOPh 1117 Me (CH2CH20Me)2 2-Cl-4-MeOPh 1118 Me NHCH(Et)CH20Me 2-Cl-4-MeOPh 1119 Me N(c-Pr)CH2CH2CN 2-Cl-4-MeOPh 1120 Me NEt2 2-Cl-4-MeOPh 1121 Me NH-3-pentyl 2-Cl-4-MeOPh 1123 Me NHCH (Et) CH2CH20 e 2-Cl-4-MeOPh 1124 Me NHCH (Me) CH2CH20Me 2-Cl-4-MeOP 1125 Me NHCH(Et)CH2CH20Me 2-Br-4-MeOPh 1126 Me NHCH(Me)CH2CH20 e 2-Br-4-MeOPh 1127 Me NHCH(Et)CH2CH20Me 2-Me-4-MeOPh 1 128 Me HCH(Me)CH2CH20Me 2-Me-4-MeOPh 1 29 Me NHCH(CH20Me)2 2-Cl-4,5-(MeO)2Ph 1130 Me N(CH2CH2OMe)2 2-Cl-4,5-(MeO)2Ph 1131 Me NHCH(Et)CH20Me 2-Cl-4,5-(MeO)2Ph 1132 Me N(c-Pr)CH2CH2CN 2-Cl-4,5-(MeO)2Ph 1133 Me NEt2 2-Cl-4,5-(MeO)2Ph 1134 Me NH-3-pentyl 2-Cl-4,5-(MeO)2Ph 1 135 Me NHCH(Et)CH2CH20Me 2-Cl-4,5-(MeO)2Ph 136 Me NHCH(Me)CH2CH20Me 2-CI-4,5-(MeO)2Ph 1137 Me HCH(CH20Me)2 2-Br-4,5-(MeO)2Ph 1138 Me N(CH2CH20Me)2 2-Br-4,5-(MeO)2Ph 1139 Me NHCH(Et)CH20Me 2-Br-4,5-(MeO)2P 1140 Me N(c-Pr)CH2CH2CN 2-Br-4,5-(MeO)2Ph 1141 Me NEt2 2-Br-4,5-(MeO)2Ph 1142 Me NH-3-pentyl 2-Br-4,5-(MeO)2Ph 1143 Me NHCH(CH20Me)2 2-Cl-4,6-(MeO)2Ph 1144 Me N(CH2CH2OMe)2 2-Cl-4,6-(MeO)2Ph 1145 Me " Et2 2-Cl-4,6-(MeO)2Ph 1146 Me NH-3-pentyl 2-Cl-4,6-(MeO)2Ph 1147 Me NHCH(CH20Me)2 2-Me-4,6-(MeO)2P 1148 Me N(CH2CH2OMe)2 2-Me-4,6-(MeO)2Ph 1149 Me NHCH(Et)CH20Me 2-Me-4,6-(MeO)2Ph 1150 Me Et2 2-Me-4,6-(MeO)2Ph 1151 Me NH-3-pentyl 2-Me-4,6-(MeO)2Ph 1152 Me HCH(Et)C¾CH20Me 2-Me-4-MeOPh 1153 Me NHCH(Me)CH2CH2OMe 2-Me-4-MeOPh 1154 Me NHCH(CH20Me)2 2-MeO-4-MePh 1155 Me (CH2CH20Me)2 2-MeO-4-MePh 1156 Me NHCH(Et)CH20Me 2-MeO-4-MePh 1157 Me N(c-Pr)CH2CH2CN 2-MeO-4-MePh 1158 Me NEt2 2-MeO-4-MePh 1159 Me NH-3-pentyl 2-MeO-4-MePh 1160 Me NHCH(Et)CH2CH20Me 2- eO-4- ePh 1 161 Me NHCH(Me)CH2CH20Me 2-MeO-4-MePh 1162 Me NHCH(CH20Me)2 2-MeO-4-MePh 1 163 Me N(CH2CH20Me)2 2-MeO-4-MePh 1 164 Me NHCH(Et)CH20Me 2-MeO-4-MePh 1 165 Me N(c-Pr)CH2CH2CN 2-MeO-4-MePh 1 166 Me NEt2 2-MeO-4-MePh 1 167 Me NH-3-pentyl 2-MeO-4-MePh 1 168 Me NHCH(CH20Me)2 2-MeO-4-ClPh 1 169 Me N(CH2CH20Me)2 2-MeO-4-C1Ph 1 170 Me NHCH(Et)CH20Me 2-MeO-4-ClPh 1171 Me NEt2 2-MeO-4-CIPh 1172 Me NH-3-pentyl 2-MeO-4-ClPh Utility CRF-R1 Receptor Binding Assay for the Evaluation of Biological Activity The following is a description of the isolation of cell membranes containing cloned human CRF-R1 receptors for use in the standard binding assay as well as a description of the assay itself.

Messenger RNA was isolated from human hippocampus. The mRNA was reverse transcribed using oligo (dt) 12-18 and the coding region was amplified by PCR from start to stop codons The resulting PCR fragment was cloned into the EcoRV site of pGEMV, from whence the insert was reclaimed using Xhol + Xbal and cloned into the Xhol + Xbal sites of vector pm3ar ( which contains a CMV promoter, the SV40 't' splice and early poly A signals, an Epstein-Barr viral origin of replication, and a hygromycin selectable marker) . The resulting expression vector, called phchCRF was transfected in 293EBNA cells and cells retaining the episome were selected in the presence of 400 μΜ hygromycin. Cells surviving 4 weeks of selection in hygromycin were pooled, adapted to growth in suspension and used to generate membranes for the binding assay described below. Individual aliquots containing approximately 1 x 10^ of the suspended cells were then centrifuged to form a pellet and frozen.

For the binding assay a frozen pellet described above containing 293EBNA cells transfected with hCRFRl receptors is homogenized in 10 ml of ice cold tissue buffer ( 50 m HEPES buffer pH 7.0, containing 10 mM MgCl2, 2 mM EGTA, 1 g/l aprotinin, 1 g/ml leupeptin and 1 g/ml pepstatin) . The homogenate is centrifuged at 40,000 x g for 12 min and the resulting pellet rehomogenized in 10 ml of tissue buffer. After another centrifugat ion at 40, 000' x g for 12 min, the pellet is resuspended to a protein concentration of 360 g/ml to be used in the assay.

Binding assays are performed in 96 well plates; each well having a 300 μΐ capacity. To each well is added 50 μΐ of test drug dilutions (final concentration of drugs range from 10-10 - 10-5 M) , 100 μΐ of 125χ_ ovine-CRF (^Sl-o-CRF) (final concentration 150 pM) and 150 μΐ of the cell homogenate described above. Plates are then allowed to incubate at room temperature for 2 hours before filtering the incubate over GF/F filters (presoaked with 0.3% polyethyleneimine ) using an appropriate cell harvester. Filters are rinsed 2 times with ice cold assay buffer before removing individual filters and assessing them for radioactivity on a gamma counter .

Curves of the inhibition of 125I-o-CRF binding to cell membranes at various dilutions of test drug are analyzed by the iterative curve fitting program LIGAND [P.J. Munson and D. Rodbard, Anal. Bioc em. 107:220 (1980) , which provides Ki values for inhibition which are then used to assess biological activity.

A compound is considered to be active if it has a K value of less than about 10000 nM for the inhibition of CRF .

Inhibition oj CRF-St imulated Adenylate Πν ^Ρ Activity Inhibition of CRF-st imulated. adenylate cyclase activity can be performed as described by G.

Battaglia et al . Synapse 1:572 (1987) . Briefly, assays are carried out at 37° C for 10 min in 200 ml of buffer containing 100 mM Tris-HCl (pH 7.4 at 37° C), 10 mM MgCl2/ 0. mM EGTA, 0.1% BSA, 1 mM isobutylmethylxanthine (IBMX), 250 units/ml phosphocreatine kinase, 5 mM creatine phosphate, 100 mM guanosine 5 '-triphosphate, 100 nM oCRF, antagonist peptides (concentration range 10"^ to 10~^m) and 0.8 mg original wet weight tissue (approximately 40-60 mg protein) . Reactions are initiated by the addition of 1 mM TP/ 2p]ATP (approximately 2-4 mCi/tube) and terminated by the addition of 100 ml of 50 mM Tris-HCL, 45 mM ATP and 2% sodium dodecyl sulfate. In order to monitor the recovery of cAMP, 1 μΐ of [½]cAMP (approximately 40, 000 dpm) is added to each tube prior to separation. The separation of [32p]CAMP from [32p]A,TP is performed by sequential elution over Dowex and alumina columns .

Tn vivo Biological Assay The in vivo activity of the compounds of the present invention can be assessed using any one of the biological assays available and accepted within the art. Illustrative of these tests include the Acoustic Startle Assay, the Stair Climbing Test, and the Chronic Administration Assay. These and other models useful for the testing of compounds of the present invention have been outlined in C.W. Berridge and A.J. Dunn Brain Research Reviews 15:71 (1990).

Compounds may be tested in any species of rodent or small mammal.

Compounds of this invention have utility in the treatment of imbalances associated with abnormal levels of corticotropin releasing factor in patients suffering from depression, affective disorders, and/or anxiety.

Compounds of this invention can be administered to treat these abnormalities by means that produce contact of the active agent with the agent's site of action in the body of a mammal. The compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals either as individual therapeutic agent or in combination of therapeutic agents. They can be administered alone, but will generally be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

The dosage administered will vary depending on the use and known factors such as pharmacodynamic character of the particular agent, and its mode and route of administration; the recipient's age, weight, and health; nature and extent of symptoms; kind of concurrent treatment; frequency of treatment; and desired effect. For use in the treatment of said diseases or conditions, the compounds of this invention can be orally administered daily at a dosage of the active ingredient of 0.002 to 200 mg kg of body weight. Ordinarily, a dose of 0.01 to 10 mg kg in divided doses one to four times a day, or in sustained release formulation will be effective in obtaining the desired pharmacological effect.

Dosage forms (compositions) suitable for administration contain from about I mg to about 100 mg of active ingredient per unit. In these pharmaceutical compositions, the active ingredient will ordinarily be present in an amount of about 0.5 to 95% by weight based on the total weight of the composition.

The active ingredient can be administered orally is solid dosage forms, such as capsules, tablets and powders; or in liquid forms such as elixirs, syrups, and or suspensions. The compounds of this invention can also be administered parenterally in sterile liquid dose formulations.

Gelatin capsules can be used to contain the active ingredient and a suitable carrier such as but not limited to lactose, starch, magnesium stearate, stearic acid, or cellulose derivatives. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of time. Compressed tablets can be sugar-coated or film-coated to mask any unpleasant taste, or used to protect the active ingredients from the atmosphere, or to allow selective disintegration of the tablet in the gastrointestinal tract.

Liquid dose forms for oral administration can contain coloring or flavoring agents to increase patient acceptance.

In general, water, pharmaceutically acceptable oils, saline, aqueous dextrose (glucose), and related sugar solutions and glycols, such as propylene glycol or polyethylene glycol, are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, butter substances.

Antioxidizing agents, such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or in combination, are suitable stabilizing agents. Also used are citric acid and its salts, and EDTA. In addition, parenteral solutions can contain preservatives such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol .

Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences", A. Osol, a standard reference in the field.

Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows: Capsules A large number of units capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 mg of powdered active ingredient, 150 mg lactose, 50 mg cellulose, and 6 mg magnesium stearate .

Soft Gelatin Capsules A mixture of active ingredient in a digestible oil such as soybean, cottonseed oil, or olive oil is prepared and injected by means of a positive displacement was pumped into gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules were washed and dried.

Tablets A large number of tablets are prepared by conventional procedures so that the dosage unit was 100 mg active ingredient, 0.2 mg of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of macrocrystalline cellulose, 11 mg of starch, and 98.8 mg lactose. Appropriate coatings may be applied to increase palatability or delayed adsorption.

The compounds of this invention may also be used as reagents or standards in the biochemical study of neurological function, dysfunction, and disease.

Although the present invention has been described and exemplified in terms of certain preferred embodiments, other embodiments will be apparent to those skilled in the art . The invention is, therefore, not limited to the particular embodiments described and exemplified, but is capable of modification or variation without departing from the spirit of the invention, the full scope of which is delineated by the appended claims . 127871/12

Claims (1)

1. CLAIMS 1. A compound of Formulae (1) or (2): Ar Ar (1) (2) and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof, wherein: A is N; Z is N or CR2; Ar is selected from phenyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, benzothienyl, benzofuranyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, indanyl, 2H-[l]-benzopyranyl, 3,4-dihydro-2H-[l]-benzopyranyl, tetralinyl, each Ar optionally substituted with 1 to 5 R^ groups; R 1 is selected from H, C I -C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halo, CN, C 1 - C4 haloalkyl, C1-C12 hydroxyalkyl, C2-C12 alkoxyalkyl, C2-C10 cyanoalkyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, NR9R10, C1-C4 alkylene-NR9R10, NR9COR!0, OR! 1, SH or S(0)nRl2; R2 is selected from H, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, Ci -C4 hydroxyalkyl, halo, CN, -NR6R7, NR9COR1 °, - NR6S(0)nR7, S(0)NNR6R75 C1-C4 haloalkyl, -OR7, SH or -S(0)nR12; R^ is selected from: 127871/12 (a) -CpCio alkyl, C2-Ci0 alkenyl, C2-Ci0 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C4-C12 cycloalkylalkyl or C6-Ci0 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from CrC6 alkyl, C3-C6 cycloalkyl, halo, C, -C4 haloalkyl, cyano, COR15 , SH, S(0)NR13, COR15, C02R15, OC(0)R13, NR8COR15, N(CORL 5)2, NR8CONR,6R15, NR8C02R13, NR16R15, CONR16R15, aryl, heteroaryl and heterocyclyl, or (b) -H, OR7, SH, S(0)NR13, COR7, C02R7, OC(0)R13, NR8COR7, N(COR7)2, NR8CONR6R7, NR8C02R13, NR6AR7A, N(OR7)R6, CONR6R7, aryl, heteroaryl and heterocyclyl; R4 is independently selected at each occurrence from: CpCio alkyl, C2-Ci0 alkenyl, C2-Ci0 alkynyl, C3-C6 cycloalkyl, C4-Q2 cycloalkylalkyl, N02, halo, CN, C C4 haloalkyl, NR6R7, NR8COR7, NR8C02R7, COR7, OR7, ΟΟΝ¾7, CO(NOR9)R7, C02R7, or S(0)NR7, where each such Cj-Cio alkyl, C2-Ci0 alkenyl, C2-C)0 alkynyl, C3-C6 cycloalkyl and C4-C12 cycloalkylalkyl are optionally substituted with 1 to 3 substituents independently selected at each occurrence from d-C4 alkyl, N02, halo, CN, NR6R7, NR8COR7, NR8C02R7, COR7, OR7, CONR6R7, C02R7 CO(NOR9)R7, or S(0)NR7; R6 and R7, R6A and R7A are independently selected at each occurrence from: (a) -C|-Cio alkyl, C3-Ci0 alkenyl, C3-C]0 alkynyl, CrCi0 haloalkyl with 1-10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4-C)2 cycloalkylalkyl, C5-C10 cycloalkenyl, or C6-C14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from CrC6 alkyl, C3-C6 cycloalkyl, halo, Q-C4 haloalkyl, cyano, OR15, SH, S(0)NR'3, COR15, C02R15, OC(0)R13, NR COR15, N(COR15)2) NR8CONR16R15, NR8C02R13, NR' 6R' 5, CONR16R15, aryl, heteroaryl or heterocyclyl, or (b) -H, -aryl, aryl(CrC4 alkyl), heteroaryl, heteroaryl(CrC4 alkyl), heterocyclyl or heterocyclyl (C,- C4 alkyl); alternatively, NR6R7 and NR6AR7A are independently piperidino, pyrrolidino, piperazino, N-methylpiperazino, morpholino or thiomorpholino, each optionally substituted with 1-3 C1-C4 alkyl groups; R8 is independently selected at each occurrence from H or Ci-C4 alkyl; R9 and R10 are independently selected at each occurrence from H, C C4 alkyl, or C3-C¾ cycloalkyl; R ' ' is selected from H, Ci-C4 alkyl, CrC4 haloalkyl, or C3-C6 cycloalkyl; DM-6864 127871/8 R12 is C1-C4 alkyl or C1-C4 haloalkyl; Rl3 is selected from C1-C4 alkyl, C1-C4 haloalkyl, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyl, aryl, aryl(C i-C4 alkyl)-, heteroaryl or heteroaryl(Ci-C4 alkyl)-; R1 is selected from (a) C 1 -C 10 alkyl, C3 -C 10 alkenyl, C3 -C 10 alkynyl, C3 -C 8 cycloalkyl, or C4-C 12 cycloalkylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR1 5, SH, S(0)nR15, COR15, CO2R15, OC(0)R15, NR8COR15, N(COR15)2, NR CONR16R1 5, NR8C02R15, NR16R1 5, CONR16R15, and (b) C 1 -C6 alkylthio, C 1 -C6 alkylsulfinyl and C\-C^ alkylsulfonyl; R15 and R16 are independently selected at each occurrence from H, C 1-C6 alkyl, C3-C10 cycloalkyl, C4-C16 cycloalkylalkyl, except that for S(0)nR15, R1 5 cannot be H; aryl is phenyl or naphthyl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, halo, Q-C4 haloalkyl, cyano, OR15, SH, S(0)nR15, COR15, CO2R15, OC(0)R15, NR8COR1 5, N(COR15)2, NR8CONR16R15, NR8C02R1 5, NR16R15, and CONR16R1 5; heteroaryl is pyridyl, pyrimidinyl, triazinyl, furanyl, pyranyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, isoxazolyl, pyrazolyl, 2,3-dihydrobenzothienyl or 2,3-dihydrobenzofuranyl, each being optionally substituted with 1 to 5 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, halo, C 1-C4 haloalkyl, cyano, OR15, SH, S(0)nR15, -COR15, CO2R15, OC(0)R15, NR8COR15, N(COR15)2, NR8CONR16R15, NR8C02R15, NR16R15, and C0NR16R1 5; heterocyclyl is saturated or partially saturated heteroaryl, optionally substituted with 1 to 5 substituents independently selected at each occurrence from C 1-C6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR1 5, SH, S(0)nR1 5, COR1 5, CO2R1 5, OC(0)R15, NR8COR15, N(COR15)2, NR8CONR16R1 5, NR8C02R1 5, NR1 5R1 6, and CONR1 6R1 5; and n is independently at each occurrence 0, 1 or 2, 33053 triazine claims 18-Apr-2005.doc -171- 127871/1 1 with.the provisos that: (a) when R1 is -(CrC2 alkyl ene)-0-(C C2 alkyl) or (CrC2 alkylene)-OH, then at least one of the following conditions (i), (ii) and (iii) is true: (i) the compound is a compound of formula (2); (ii) Ar is selected from optionally substituted naphthyl, optionally substituted triazinyl, optionally substituted furanyl, optionally substituted thienyl, optionally substituted benzothienyl optionally substituted benzofuranyl, optionally substituted 2,3-dihydrobenzofuranyl, optionally substituted 2,3-dihydrobenzothienyl, optionally substituted indanyl, optionally substituted 2H- [l]-benzopyranyl, optionally substituted 3,4-dihydro-2H-[l]-benzopyranyl, and optionally substituted tetralinyl; (iii) R3 is selected from H, SH, S(0)nR13 wherein n > 1 , C02R7, OC(0)R13, NR8COR7, N(COR7)2, NR8CONR6R7, NR8C02R13, N(OR7)R6, CONR6R7, aryl other than optionally substituted phenyl, heteroaryl other than (a) optionally substituted pyrazinyl, (b) optionally substituted pyrimidyl or (c) optionally substituted pyridazinyl, or heterocyclyl; (b) when R3 is C5-Cs cycloalkenyl or C6-Ci0 cylcoalkenylalkyl, then at least one of the following conditions (i), (ii) and (iii) is true: (i) the compound is a compound of formula (2); (ii) Ax is selected from optionally substituted naphthyl, optionally substituted triazinyl, optionally substituted furanryl, optionally substituted thienyl, optionally substituted benzothienyl, optionally substituted benzofuranyl, optionally substituted 2,3-dihydrobenzofuranyl, optionally substituted 2,3-dihydrobenzothienyl, optionally substituted indanyl, optionally substituted 2H- [l ]-benzopyranyl; optionally substituted 3,4-dihydro-2H-[l] -benzopyranyl, and optionally substituted tetralinyl; (iii) R1 is selected from C2-C4 alkenyl, C2-C4 alkynyl, CN, CrC haloalkyl, C3-Ci2 hydroxyalkyl, C4- Ci2 alkoxyalkyl other than -(Ci-C2 alkylene)-0-(Ci-C2 alkyl), C2-C]0 cyanoalkyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, NR9R16, C,-C4 alkylene-NR9R10, NR9COR16, OR1 1, SH or S(0)nR12; and (c) when Z is CR2, R1 is H; R2 is H, and Ar is unsubstituted pyridyl or unsubstituted pyrirnidinyl, then R3 is not -NH2, -NR8COR7 wherein R7 is C C5 alkyl, NR8CONR6R7 wherein R6 is H or CrC5 alkyl, or -NR6aR7a wherein R6a and R7a are each independently selected from H and C]-C5 alkyl; in the preparation of a medicament for treating a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in a mammal, substantially as described in the specification. 127871/9 2. Use according to claim 1 of a compound of Formulae (I) or (II) iii the ■ preparation of a medicament wherein said disorder the treatment of which can be effected or facilitated by antagonizing CRF is selected from the group consisting of i affective disorder, anxiety, depression, headache, irritable bowel syndrome, post- . traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, head and spinal cord traumas epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, and hypoglycemia, substantially as described in the specification. 3. Use according to claim 1 or claim 2 of a compound of Formulae (I) or (II) in the preparation of a medicament wherein, in the compound of Formulae (1) or (2), Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, each optionally substituted with 1 to 4 R4 substituents, substantially as described in the specification. 4. Use according to claim 3 of a compound of Formulae (I) or (II) in the preparation of a medicament wherein, in the compound of Formulae (1) or (2), Ar is 2,4-dichlorophenyl, 2,4-dimethylphenyl or 2,4,6-trimethylphenyl, R1 and R2 are CH3, and R3 is NR6aR7a, substantially as described in the specification. 5. A compound of Formulae (1) or (2): ( 1 ) (2 ) and stereoisomer^ forms thereof, or mixtures of stereoisomer^ forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein: A is N; 127871/9 Z is N or CR2; Ar is selected from phenyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, benzothienyl, benzofuranyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, indanyl, 2H-[l]-benzopyranyl, 3,4-dihydro~2H-[l]-benzopyranyl, tetralinyl, each Ar optionally substituted with 1 to 5 R^ groups; >■■- ■ is selected from H, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halo, CN, Cj- C4 haloalkyl, C1-C12 hydroxyalkyl, C2-C12 alk xy?Jkyl, C2-C10 cyanoalkyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyi, NR9R10, C1-C4 alkylene-NR9 1 0, ^COR!O, OR1 1 , SH or S(0)NR12; R is selected from H, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyi, C1-C4 hydroxyalkyl, halo, CN, -NR6R7, NR9COR1 0, ~NR6S(0)NR7, S(0)NNR6RV, C1-C4 haloalkyl, -OR7 SH or -S(0)NR12; R3 is selected from: -Ci-Cio alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C4- C12 cycloalkylalkyi or Cg-Cio cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, halo, Q-C4 haloalkyl, cyano, OR1 5, S H, S(0)NR1 3, COR1 5.. CO2R1 5, OC(0)R13, NR8COR1 5, N(COR15)2, NR8CONR1 6R 1 5, NR8C02R1 3, NR16R1 5, CONR1 6R1 5, aryl, heteroaiyl and heterocyclyl, or -H. OR7, SH, SCO^R13, COR7, CO2R7, OC(0)RL3, NR8COR7, N(C0R7)2, NR8CONR6R7, NR8C02R13, NR6AR7A, N(OR7)R6, CONR6R7, aryl, heteroaryl and heterocyclyf R4 is independently selected at each occurrence from: Ci-Cio alkyl, C2-C10 alkenyl, C?-C] 0 alkynyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyi, NO2, halo, CN, C\- C4 haloalkyl, NR6R7, NR8COR7, NR8C02R7, COR7, OR7, CONR6R7, CO(NOR9)R7, CO2R7, or S(0)NR7, where each such Ci-Qo alkyl, C2-C10 alkenyl, . 2-C10 alkynyl, C3-C6 cycloalkyl and C4-C12 cycloalkylalkyi are optionally substituted with 1 to 3 substituents independently selected at each occurrence from C 1 -C4 alkyl, NO2, halo, CN, NR6R7 NR8COR7, NR8C02R7, COR7 OR7, CONR6R7 CO2R7, CO(NOR9)R7, or S(0)NR7; R6 and R7, R6a and R7A are independently selected at each occurrence from: -Ci -Ci o alkyl, C3-C10 alkenyl, C3-C10 alkynyl, Ci-Cio haloalkyl with 1 - 10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyi, C5-C10 cycloalkenyl, or C6-C14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C] -C(i alkyl, C3.C6 cycloalkyl, halo, C] -C4 haloaikyl, cyano, OR 1 *\ SH, StO),,!*1*, COR15, CO2R15, OC(0)Rtf NR&COR13, N(COR»¾, R^CONR3 ^ l NRSCQZR1^ N ^R1 , COKR16R15, aryl,heteroerylorheierocyclyl, (b) -H, -ary'l, ary)(C ] -C4 alley)), beteroary], . ete,roaryl(C 1 -C4 alky)), heterocycly) or he.terocyclyl(Ci-C4 aUyl). alternatively, R6 7 and N 6¾ 7a arc independently piperidino, pyrrolidino, piperaaino, N-methylpiperazino, morpholino or duotnorphoUiie, each optionally substituted with 1-3 C] -C alky) groups; ^ R5 is independently selected at each occurrence from H or C J -C4 alkyl; R^ and ft) 0 are independently selected at each occurrence from H, C1-C4 alkj'l, or C3-C6 cycloalkyl; R11 is selected from H, Cj -C4 alkyl, C] -C4 haloaikyl, -or C3-C6 cycloalkyl; R12 isC]-C a-lkyl orCi^ halo&lKy); 13 is selected from C j -C4 alkyl, C 1 -C4 haloalkyj , C2O8 alkcx-yalkyl, C3 -C<$ cycloalkyl, C4-C12 cycloalkylalk l, .aryl, vyl(Ci«G4 alky})-, beteroaryJ of heteroaryl(Ct-C4 aU>yI>-; R14 is selected from C]-C]D alkyl, C3-C]0 alkenyl, C3-C10 alkynyl, Cj-Cg cycloalkyl, or G4-C 2 cycloalkylalkyl, each optionally substituted wiii. I to -3 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, halo, C1.C4 lialoelkyl, cyano, O *5, SH, S(0)nRl5, COR15, CO2R15, OC(0)R15, NR8CO l 5, N(COR>5)2, NR8CONR^R15, J 8CO2 15, NR16R15, CO Rl6R55, and C3-C6 alkylthk, CirCg allcylsulfinyl and Cj'Ci alkylsulfonyl; v R15 and R16 are independently selected at each occurrence from H, C]-C6 alkyl, C CiQ cycloalkyl, C4-C16 cycloalkylalkyl, exceptthat for S(0)nR15, R15 cannot, be H; aty) is phenyl or naplrtbyl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from C]-Ce alkyl, C3-C6 cydoallcyl, halo, C]-C haloalky}. cyano, OR15, SH, S(0),]R15, COR^, COnR15, OC(0)Rl5,NR8CO l5, N(CO »5)n, NR^O ^R15, Nf^CCbR1 S, NRl ^R15, and CONR36R l-s; 127871/8 heteroaryl pyridyl, pyrimidmy), triatloyl, furanyl, pyranyj, quinoiiny., isoouinolinyJ, liiienyl. imidazolyJ, thiazoly], indolyl, pyrroiyl. oxazoly!, benzofuranyl, berjzotbieny'l, bcnzotliiazolyl, isoxazolyl, pyrazoJyl, 2,3-dibydrobenzotlijeiTyJ or 2,3-dihydrober.zofurarjyl,' each being optionally substituted with 1 to 5 substituents independently selected at eacb occuirence from C] -Cfi alky), Ca-Cfi cycloalkyl, halo, C] -CA bdoalkyl, cyaoo. OR> 5, SH, S(O)0R^, -COR15, CO2R1 5, OC(0)R» NR8CGR15, N(COR1 5h, ITO'CONR^*, N ficOoR^, N ^IS, and CON l frRl5; "i heterocydyl is saturated or partially saturated heteroaryl, optionally substituted with 1 to 5 substituents independently selected at each occurrence from C] -C6 alky., C3-C6 cycloalkyl, halo, C}-C baloelkyl, cyano, .OR" SH, S(0)„R1J, COR'*, CO'jK", ^^ OC(0)Rl5, NRiCOR,i, N(COR,5)2f NfRiCONRl6Rli, WfCCWK NR'W*. and CO R^R15; n is independently at each occurrence 0, 1 or 2, with the provisos that: (1 ) when Z is CR2, R2 is H, R3 is -OR7 or -OCOR13, and R7 is ¾ then RJ is not ¾ OH or SH; (2) when Z is CR2, ! is CH3 or C2¾ R2 is H, apd&3 is OH, E, CH5, C2H5, CeHs, 0-C3H7, ϊ-Οϋη, SH, SCH3, MHC4H9, or (C2¾)j, then Ar is not pheoy) or m-CH3-pheuyl; (3) when Z is CR2, R1 is H. R3 is riband Ar is unsubstitutcd pyridyl or unsubstituted pyrimidinylr then R3 ¾ BOR. -NR'COR7 wherein R7 i* CrC5 alkyl. NR*CO R*R7 wherein R6 is H or CJ-CJ alkyl, or -NR^R1* wherein " and R7> are each independently selected from H and Cj-Cj alkyl; y (4) when Z is CR* and R* is -NR6S02R7 or .S03'N 6 7, then R3 is not OH or SH; (5) when Z is CR* R1 is H, SH, SCH,, methyl or ethyl, R2 is H, and R3 is H, OH, CH3, C2H3> C6H5, n-C3H7, $ O3H7, SH, SOH3, fiCn-C^), or N(C2Hs)a, then Ar is not unsubstitutcd phenyl, irt-ehlorophcHyl or ro-niethy (phenyl; (6) when R1 is -(Ci-C-.; tlien at least one of the following conditions (i), (ii) and (iii) is true; (i) the compound is a compound of fortnula (2); 127871/9 (ii) Ar is selected from optionally substituted naphthyl, triazinyl, furanyl, thienyl, benzothienyl, benzofuranyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, indanyl, 2H-[l]-benzopyranyl, 3,4-dihydro 2H-[l]-benzopyranyl, and tetralinyl; (iii) R3 is selected from H, SH, S(0)nR13 wherein n > 1 , C02R7, OC(0)R13, NR8COR7, N(COR7)2, NR8CONR6R7, NR8C02R13, N(OR7)R6, CONR6R7, aryl other than optionally substituted phenyl, heteroaryl other than (a) optionally substituted pyrazinyl, (b) optionally substituted pyrimidyl or (c) optionally substituted pyridazinyl, or heterocyclyl; (7) when R3 is C5-C8 cycloalkenyl or Cg-Qo cylcoalkenylalkyl, then at least one of the following conditions (i), (ii) and (iii) is true: (i) the compound is a compound of formula (2); (ii) Ar is selected from optionally substituted naphthyl, triazinyl, furanyl, thienyl, benzothienyl, benzofuranyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, indanyl, 2H-benzopyranyl, 3,4-dihydro- 2H-benzopyranyl, and tetralinyl; (iii) R1 is selected from C2-C4 alkenyl, C2-C4 alkynyl, CN, C C4 haloalkyl, C3-C]2 hydroxyalkyl, C4-C12 alkoxyalkyl other than -(C C2 alkylene)-0-(Ci-C2 alkyl), C2-C10 cyanoalkyl, C3-C6 cycloalkyl, C4-Ci0 cycloalkylalkyl , NR9R16, CrC4 alkyl-NR9R10, NR9COR16, OR11, SH or S(0)nR12; (8) when Z is CR2, R1 is H, R2 is CH3, and Ar is unsubstituted pyridyl or unsubstituted pyrimidinyl, then R3 is not -NHC(CH3)3. 6. A compound of claim 5 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof with the additional provisos that: (1) when R1 is H, Q-C4 alkyl, halo, CN, Q-C12 hydroxyalkyl, C2-C4 alkoxyalkyl or S02(C!-C alkyl), R3 is NR6aR7a and R6a is unsubstituted C C4 alkyl, then R7a is not phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, furanyl, benzofuranyl, benzothiazolyl, indolyl or C3-C6 cycloalkyl; and (2) when R1 is H, C C4 alkyl, halo, CN, CrCi2 hydroxyalkyl, d-C4 alkoxyalkyl or S02(Ci-C4 alkyl), R3 is NR6aR7a and R7a is unsubstituted C]-C4 alkyl, then R6a is not phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, furanyl, benzofuranyl, benzothiazolyl, indolyl or C3-C6 cycloalkyl. 7. A compound of claim 5 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, each optionally substituted with 1 to 4 R4 substituents. 127871/10 8. A compound of claim 7 and stereoisomeric forms thereof; or mixtures of stereoisomeric forms thereof and pharmaceutically acceptable salt or pro-drug forms thereof wherein Z is CR2, Ar is 2,4-dichlorophenyl, 2,4-dimethylphenyl or 2,4,6-trimethylphenyl, R1 and R2 are CH3, and R3 is NR6"R7a. 9. A pharmaceutical composition for treating a disorder the treatment of which can be effected or facilitated by antagonizing CRF including but not limited to disorders induced or facilitated by CRF, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 5 or a ' stereoisomeric form, mixture of stereoisomeric forms, pharmaceutically acceptable salt or pro-drug form thereof. 10. A pharmaceutical composition according to claim 9, wherein said compound of claim 5, or said stereoisomeric form, mixture of stereoisomeric forms, pharmaceutically acceptable salt or prodrug form thereof is a compound of claim 6 or a: stereoisomeric form, mixture of stereoisomeric forms, pharmaceutically acceptable salt or pro-drug form thereof. 1 1. A pharmaceutical composition according to claim 9, wherein said compound of claim 5, or said stereoisomeric form, mixture of stereoisomeric forms, pharmaceutically acceptable salt or prodrug form thereof is a compound of claim 7 or a stereoisomeric form, mixture of stereoisomeric forms, pharmaceutically acceptable salt or pro-drug form thereof. 12. A compound of Formula (2) of claim 5 and stereoisomeric forms thereof; or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof. 13. A compound of claim 12 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R substituents. 14. A compound of claim 12 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R3 is NR6aR78 or OR7. 127871/7 1 . A compound of claim 12 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R4 substituents, and R3 is R6aR7a or OR7. 16. A compound of Formula (1) of claim 5 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Z is CR^. 17. A compound of claim 16 and .: stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R4 substituents. 18. A compound of claim 16 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R3 is R6aR7a or OR?. 19. A compound of claim 18 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R6a is independently selected from: (a) -C] -Ci o alkyi, C3-C10 alkenyl, C3-C] 0 alkynyl, Ci-C] fj haloalkyl with 1 -10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyl, C5-C10 cycloalkenyl, or C6-C]4 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C]-C6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR1 5, SH, S(0)nR1 3, COR1 5, CO2R15, OC(0)R13, NR8COR1 5, N(COR15)2,NR8CONR16R15, NR8C02R13, R16R15, CONR16R1 5, aryl, heteroaryl or heterocyclyl, (b) -H, -aryl, aryl(Ci-C4 alkyl)-, heteroaryl, heteroaryl(C 1-C4 alkyl)-, heterocyclyl or heterocyclyl(C ]-C4 alkyl)-; and R^a is independently selected at each occurrence from: (a) -C5-C10 alkyl, C3-C] 0 alkenyl, C3-C 10 alkynyl, C 1-C10 haloalkyl with 1 -10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyl, C5-C10 cycloalkenyl, or C6-C14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C\-Ce alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR15, SH, 127871/10 S(0)-R13, COR'5, C02R, S, OC(0)R'3, NR8COR15, N(COR15)2, NR8CONR16R , S, NR8C02R13, NR I6R 15, CONR16R15, aryl, heteroaryl or heterocyclyl, (b) -H, -aryl, aryl(Ci-C4 alkyl), heteroaryl, heteroaryl(C C, alkyl), heterocyclyl or heterocyclyl(C,-C4 alkyl); alternatively, NR6SR7" is piperidino, pyrrolidino, piperazino, N-methylpiperazino, morpholino or thiomorpholino, optionally substituted with 1-3 CrC4 alkyl groups. 20. A compound of claim 18 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein RSA and R7* are identical and are selected from: (a) -C1-C4 alkyl or C3-C6 cycloalkyl, each optionally substituted with 1 to 3 substitutents independently selected at each occurrence from Ci-C6 alkyl, C3-C5 cycloalkyl, halo, CpC, haloalkyl, cyano, OR15, SH, S(0)NR13, COR15, COJR15, OC(0)R13, NR8COR15, N(CORL 5)2, NR8C0NR,6R'5, NR*C02R", NR16R15, CONR16R15, aryl, heteroaryl or heterocyclyl, and (b) -aryl or heteroaryl. 21. A compound of claim 18 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R6A . is selected from: (a) -C,-Cio alkyl, C3-C|0 alkenyl, C3-CJ0 alkynyl, C|-Cl0 haloalkyl with 1-10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4-C|2 cycioalkylalkyl, C5-C10 cycloalkenyl; or C«-C,4 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-Q1 alkyl Q-Ce cycloalkyl, halo, C,-C4 haloalkyl, cyano, OR15, SH, S(O)0R13, COR15, C02R15, OC(0)R", NR8COR15, N(COR15)2, NR8CONRLFIRLS, NR8C02R13, NRI 6R15, . CONR,6R15, aryl, heteroaryl, or heterocyclyl, (b) -H, -aryl, aryl(C C4 alkyl), heteroaryl, heteroaryl(C,-C4 alkyl), heterocyclyl or heterocyciyl(CrC4 alkyl); R7* is selected from: -CrC4 alkyl and each such C,-C4 alkyl is substituted with 1-3 substituents independently selected at each occurrence from C,-C6 alkyl, C C6 cycloalkyl, halo, C,-C4 haloalkyl, cyano, OR15, SH, S(0)DR13, COR13, C02R'5, OC(0)R13, NRBCOR]5, N(COR15)2, NR8CONR16R15, NR8C02R13, NR) 6R,S, CONR16R15, aryl, heteroaryl, or heterocyclyl. 127871/7 22. A compound of claim 18 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein one of R6a and R7a is selected from: -aryl, -heteroaryl -heterocyclyl, or -C3-C6 cycloalkyi, each such C3-C cycloalkyi optionally substituted with 1-3 substituents independently selected at each occurrence from Ci-C6 alkyl, C3-C5 cycloalkyi, halo, Cj-Q haloalkyl, cyano, OR»5, SH, S(0)nR COR15, C02 15, OC(0)RJ3, NR8COR15, N(C0R15)2, R8CONR16RI5 NR8C02R I3, NR16R1S, CO R16R15, aryl, heteroaryl or heterocyclyl, and the other of R6a and R?a is unsubstituted C1-C4 alkyl. 23. A compound of claim 18 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R6a and R7a are independently H or C i -Cio alkyl, each such Ci-Cjo alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C] -C6 alkyl, C3-C0 cycloalkyi, halo, C1-C4 baloalkyl, cyano, OR15, SH, S(0)nR13, COR^ 5, C02R] 5, OC(0)R« NR8CORl 5, N(CORl¾, NR8CONR56R] 5, N 8C02 13, NR^R^ CO R16R] 5, aryl, heteroaryl or heterocyclyl. 24. A compound of claim 16 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R^ substituents, and R3 is NR6aR7a or OR?. 25. A compound of claim 24 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R^a is independently selected from: (a) -C1-C10 alkyl. C3-C10 alkenyl, C3-C10 alkynyl, Ci-Cio haloalkyl with 1-10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyi, C4-C] 2 cycloalkylalkyl, C5-C10 cycloalkenyl, or C6-C14 cycloalkenylalkyl, each optionally substituted with ] to 3 substituents independently selected at each occurrence from C \-C6 alkyl, C3-C6 cycloalkyi, halo, C1 -C4 haloalkyl, cyano, OR1 5, SH. S^nR13, COR 1 5, C02R] 5, OC(0)R' 3, NR^OR1 5, N(COR' 5)2, N SCO R16 15, NR8C02R13, NR16R1 5, CONR16R1 5, aryl, heteroaryl or heterocyclyl, (b) -H, -aryl, aryl(Ci-C4 alkyl)-, heteroaryl, heteroaryl(C] -C4 alkyl), heterocyclyl or heterocyclyl(C i-C4 alkyl); R?a is independently selected at each occurrence from: (a) -C5-C10 alkyl, C3-C10 alkenyl, C3-Cj o alkynyl, Cj-Cio haloalkyl with 1-10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyi, C4-C12 cycloalkylalkyl, C5-C 10 cycloalkenyl, or 5-C14 127871/8 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from CpC6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR15, SH, S(0)nR13, COR15, C02R15, OC(0)R13, NR8COR15, N(COR15)2, R8C0NR16R15, NR8C02R13, NR16R15, CO R16R15, aryl, heteroaryl or heterocyclyl, (b) -H, -aryl, aryl(Ci-C4 alkyl), heteroaryl, heteroaryl(Ci-C4 alkyl), heterocyclyl or heterocyclyl(Ci-C4 alkyl), alternatively, NR6aR7a is piperidino, pyrrolidino, piperazino, N-methylpiperazino, morpholino or thiomorpholino, optionally substituted with 1-3 C1-C4 alkyl groups. 26. A compound of claim 24 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R6a and R7a are identical and are selected from: (a) -C1-C4 alkyl or C3-C6 cycloalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from Q-Ce alkyl, C3-C6 cycloalkyl, halo, Cj- C4 haloalkyl, cyano, OR15, SH, S(0)nR13, -COR15, C02R15, OC(0)R13, NR8COR15, N(COR15)2, NR8CO R16R15, NR8C02R13, NH16R15, CONR16R15, aryl, heteroaryl or . heterocyclyl, and (b) -aryl or heteroaryl. 27. A compound of claim 24 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R6a and R7a are identical and are -C1-C4 alkyl, each such C1-C4 alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from Q-C6 alkyl, C3-C6 cycloalkyl, halo, C C4 haloalkyl, cyano, OR15, SH, S(0)nR13 -COR15, C02R15, OC(0)R13, NR8COR15, N(COR15)2, NR8CO R16R15, NR8C02R13, NR16R15, CONR16R15, aryl, heteroaryl or heterocyclyl. 28. A compound of claim 24 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R6a is selected from: (a) -C1-C10 alkyl, C3-C10 alkenyl, C3-C10 alkynyl, CrCio haloalkyl with 1-10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4-C]2 cycloalkylalkyl, C5-C10 cycloalkenyl, or C6-Ci4 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from Ci-C6 alkyl, C3-C6, cycloalkyl, halo, C]-C4 haloalkyl, cyano, OR15, SH, S(0)nR13, COR15, C02R15, OC(0)R13, NR8COR15, N(COR,5)2, NR8CONR16R15, NR8C02R13, NR16R15, CO R16R15, aryl, heteroaryl or heterocyclyl, 127871/7 (b) -H, -aryl, aryl(C] -C4 alkyl), heteroaryl, heteroaryl(C] -C4 alkyl), heterocyclyl or heterocyclyl(Ci-C4 alkyl); and R7a is -Cj-C4 alkyl and each such C1 -C4 alkyl is substituted with 1-3 substituents independently selected at each occurrence from C1-C5 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haioalkyl, cyano, ORIS, SH, S(0)nRi3, CORis, CCfcR1*, 0C(0)R13, NR8C0R15, N(COR'5)2> NR8CONR16R15, NR8CO2R13, NR16R15, CONR16R15, aryij heteroaryl or heterocyclyl. 29. A compound of claim 24 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein one of R6a and R7a is selected from: -aryl, -heteroaryl, -heterocyclyl, or -C3-C6 cycloalkyl, each such C3-C6 cycloalkyl optionally substituted with 1-3 substituents independently selected at each occurrence from Ci-C6 alkyl, C3-C6 cycloalkyl, halo, C]-C4 haioalkyl, cyano, OK^, SH, S(0)nR'3, CO 15 CC^R'S, 0C(0)R'3, NR8COR15, N(COR15)2, NR8C0NR16R15, NRSCC^R^, NRI6R15, CONR16R15, aryl, heteroaryl or heterocyclyl, and the other of R6a and R7a is unsubstituted C]-C4 alkyl. 30. A compound of claim 24 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R6a and R7a are independently H or Ci-Cj fj alkyl, each such C] -C\Q alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C -C^ alkyl, C3-C6 cycloalkyl, halo, C1-C4 haioalkyl, cyano, OR15, SH, S(0)nR13, COR15, CO2R1 5, OC(0)R13, NR8C0R15, N(COR,5)2, NR8CONR] 6R15, NR8C02R13, NRl 6R15, C0NR16R15, aryl, heteroaryl or heterocyclyl. 31. A compound of claim 16 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein -Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R4 substituents, -R3 is NR6aR7a 0r 0R7 nd -R1 and R2 are independently selected from H, C 1 -C4 alkyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl. 127871/8 32. A compound of claim 31 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof . wherein R6a is independently selected from: (a) -Ci-Cio alkyl, C3-Cjo alkenyl, C3-C10 alkynyl, Ci-Qo haloalkyl with 1-10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4-Ci2 cycloalkylalkyl, C5-Ci0 cycloalkenyl, or C^-Cu cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected -at each occurrence from Gi-C6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR15, SH, S(0)nR13, COR15, C02R15, OC(0)R13, NR8COR15, N(COR15)2, R8CONR16R15, NR8C02R13, NR16R15, CONR16R15, aryl, heteroaryl or heterocyclyl, (b) -H, -aryl, aryl(Ci-C4 alkyl)-, heteroaryl, heteroaryl(Ci-C4 alkyl), heterocyclyl or heterocyclyl (CrC alkyl); R7a is independently selected at each occurrence from: (a) -C5-C10 alkyl, C3-C10 alkenyl, C3-Ci0 alkynyl, Cj-Cio haloalkyl with 1-10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4-Ci2 cycloalkylalkyl, C5-C10 cycloalkenyl, or C6-Ci cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from Cj-Cg alkyl, C3-C6 cycloalkyl, halo, C C4 haloalkyl, cyano, OR15, SH, S(0)nR13, COR15, C02R15, OC(0)R13, R8COR15, N(COR15)2, NR8CONR16R15, R8C02R13, NR16R15, CONR16R15, aryl, heteroaryl or heterocyclyl, (b) -H, -aryl, aryl(Ci-C4 alkyl), heteroaryl, heteroaryl(C C4 alkyl), heterocyclyl or heterocyclyl(Ci-C4 alkyl), alternatively, NR6aR7a is piperidino, pyrrolidino, piperazino, N-methylpiperazino, morpholino or thiomorpholino, optionally substituted with 1-3 Ci-C alkyl groups. 33. A compound of claim 31 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R6a and R7a are identical and are selected from: (a) -C]-C alkyl or C3-C6 cycloalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from CpC6 alkyl, C3-C6 cycloalkyl, halo, CrC4 haloalkyl, cyano, OR15, SH, S(0)nR13, -COR15, C02R15, OC(0)R13, NR8COR15, N(COR15)2, NR8CONR16R15, NR8C02R13, NR16R15, CONR16R15, aryl, heteroaryl or heterocyclyl, and (b) -aryl or heteroaryl. 127871/7 34. . A compound of claim 31 and ' , stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R6 and R7a are identical and are -C[-C4 alkyl, each such C1 -C4 alkyl optionally substituted with ] to 3 substituents independently selected at each occurrence from C]-C6 alkyl, C3-C6 cycloalkyl, halo, Cj-C4 haloalkyi, cyano, OR'5, SH, S(0)nRl3, -COR'5, C02R15, 0C(0)R13, NR8COR15 N(CORlS)2; .NR8CONR16R15, NR8C02R13, NRJ6R15, CONR16R15, aryl, heteroaryl or heterocyclyl. 35. A compound of claim 30 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R6a is selected from: (a) -C] -C] o alkyl, C3-CK) alkenyl, C3-C 10 alkynyl, C]-Cl0 haloalkyi with 1 -10 halogens, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyl, C5-C1 0 cycloalkenyl, or C6-C14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyi, cyano, OR1 5, SH, S(0)nR13, COR1 5, CO2R15, OC(0)R13, NR8COR15; NCCO ^),, N ^CC- R^R^ NR8C02R] 3, NR] 6Ri 5, CO R 16R] 5, aryl, heteroaryl or heterocyclyl, (b) -H, -aryl, aryl(C 1-C4 alkyl), heteroaryl, heteroaryl(Ci-C4 alkyl), heterocyclyl or heterocyclyl(Ci -C4 alkyl); R7a is: -C1-C4 alkyl and each such C 1 -C4 alkyl is substituted with 1-3 substituents independently selected at each occurrence from Ci-C6 alky], C3-C6 cycloalkyl, halo, C1-C4 haloalkyi, cyano, OR15, SH, S(0)nRl33 CORI5, C02R15, 0C(0)R135 NR8COR15, N(C0R15)2, NR8CONR16R15, NR8CO2R13.. NR16R153 CONR16R15, aryl, heteroaryl or heterocyclyl. 36. A compound of claim 31 and '. stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein one of R6a and 7a is selected from: -aryl, -heteroaryl, -heterocyclyl, or -C3-C6 cycloalkyl. each such C3-C6 cycloalkyl optionally substituted with 1-3 substituents independently selected at each occurrence from C[-C6 alkyl, C3-C6 cycloalkyl, halo, C 1-C4 haloalkyi, cyano, OR'5, SH, S(0)nR'3, C0R15; CO2R15, OC(0)Rl3, NR8COR15 N(C0R15)2, NR8CONR16R15, NR8CO2R' 3, NR16R15, CONR16R15, aryl, heteroaryl or heterocyclyl. and the other of R6a and R7a is unsubstituted C|-C4 alkyl. 127871/7 37. A compound of claim 31 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R6aandR7a are independently H or C ] -C ] o alkyl, each such C] -C j fj alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C]-C6 alkyl, C3-C6 cycloalkyl, halo, C1-C4 haloalkyl, cyano, OR15, SH, S(0)nRi3, COR15, C02R15, 0C(O)R13, NR8COR15, N(COR,5)2, NR8CONR16R]5, NR8C02R13, NR16R15, CONR16R15, aryl, heteroaryl or heterocyclyl. 38. A compound of claim 31 of Formula (50) FORMULA (50). and ·:-„. -. stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof, selected from the group consisting of: a compound of Formula (50) wherein R3 is -NHCH(n-Pr)2, R4a is CI, R4b is H, R4c is CI, R4d is H and R4eisH; a compound of Formula (50) wherein R3 is -N(Et)(n-Bu), 4a is CI, R4b is H, R4c is CI, R4d is H and R eisH; a compound of Formula (50) wherein R3 is -N(n-Pr)(CH2cPr), R4a ;s CI, R b is H, R4c is CI, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is - (CH2CH20Me)2, R4a is CI, R4b is H, R4c is CI, R4d is H andR4eisH; DM-6864 127871/6 a compound of Formula (50) wherein R3 is -NHCH(Et)(n-Bu), R4a js ci, R4b is H, R4c is CI, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -NHCH(Et)(CH20Me); R4a js ci, R4b is H, R4c is CI, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -NHCH(CH20Me)2, R4a is CI, R4b is H, R4c is CI, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -N(Et)2, R4a is CI, R4b is H, R4c is CI, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -NHCH(CH20Et)2, R a is CI, R4b is H, R4c is CI, R4d is H 4e and R' a compound of Formula (50) wherein R3 is -NHCH(Et)2, R4a is CI, R4b is H, R4c is CI, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -N(Me)(Ph); R4a js CI, R4b is H, R4c is CI, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -N(n-Pr)2, R4a is CI, R4b is H, R4c is CI, R d is H and R4e is H; a compound of Formula (50) wherein R3 is -NHCH(Et)(n-Pr)5 R4a is ci, R4b is H, R c is CI, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -NHCH(CH20Me)2, R4a is Me, R4b is H, R4c is Me, R4d is H and R is Me; a compound of Formula (50) wherein R3 is -NHCH(CH20Me)2, R4a is Me, R4b is H, R4c is Me, R4d is H and R' 4e a compound of Formula (50) wherein R3 is -N(CH2CH20Me)2, R4a is Me, R4b is H, R c is Me, R4d is H and R4e is H; 33053 triazine claims 18-Apr-2005.doc - 187- DM-6864 127871/6 a compound of Formula (50) wherein R3 is -NHCH(Et)(CH20Me); R4a js Me, R4b is H, R4c is Me, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -NHCH(Et)2, R4a is Me, R4b is H, R4c is Me, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -OEt, R4a ;s CI, R4b is H, R4c is CI, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -N(Et)2, R4a 1S Me, R4b is H, R4c is Me, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -N(CH2CN)2, R4a js Me, R4b is H, R4c is Me, R4d is H and a compound of Formula (50) wherein R3 is -NHCH(Me)(CH20Me); R4a [s Me, R4b is H, R4c is Me, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -OCH(Et)(CH20Me)) R4a is Me, R4b is H, R4c is Me, R4d 5 H and R 4e a compound of Formula (50) wherein R3 is -N(n-Pr)(CH2cPr); R4a js Me, R4b is H, R4c is Me, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -NHCH(Me)(CH2N(Me)2), R4a [s Me, R4b is H, R4c is Me, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -N(cPr)(CH2CH2CN)) R4a js Me, R4b is H, R4c is Me, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -N(n-Pr)(CH2CH2CN), R4a is Me, R4b is H, R4c is Me, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -N(n-Bu)(CH2CH2CN); R4a js Me, R4b is H, R4c is Me, R4d is H and R4e is H; 33053 triazine claims 18-Apr-2005.doc -188- DM-6864 127871/6 a compound of Formula (50) wherein R3 is -NHCH(Et)(CH20Me)? R4a is Me, R4b is H, R4c is Me, R^u is H and R C is Me; a compound of Formula (50) wherein R3 is -NHCH(Et)2, R4a is Me, R4b is H, R4c is Me, R4d is H and 5 R4e is Me; a compound of Formula (50) wherein R3 is -N(CH2CH20Me)2, R4a is Me, R b is H, R c is Me, R4d is H and R4e is Me; 10 a compound of Formula (50) wherein R3 is -NHCH(CH20Me)2, R4a is Br, R4b is H, R4c is OMe, R4d is H and R4e is H; a compound of Formula (50) wherein R3 is -NHCH(Et)(CH20Me), R4a is Br, R4b is H, R4c is OMe, R4d is H and R4e is H; 15 a compound of Formula (50) wherein R3 is -N(Et)2, R4a 1S Me, R4b is H, R4c is Me, R4d is H and R4e is Me; a compound of Formula (50) wherein R3 is -NHCH(CH20Et)2, R4a is Me, R b is H, R4c is Me, R d is 20 H and R4e is Me; Where underlined a compound of Formula Γ50 wherein R3 is -NHCHiC^CH^OMeYCH^OMe)^4^ is Me, R4^ is H. specifically disclosed ,s Me. R4^ is H and R4^ is Me; 23.7.97 a compound of Formula (50) wherein R3 is morpholino, R4a js Me, R b is H, R c is Me, R d is H and R4e is H; a compound of Formula (50) wherein R3 is -N(CH2CH20Me)2, R4a is Br, R4b is H, R4c is OMe, R4 is H and R C is H; 30 Where a compound of Formula Γ50 wherein R3 is -NHCHfEt^. is Br, R— is H. R— is OMe. R— is H and underlined specificis H ally disclosed 23.7.97 a compound of Formula (50) wherein R3 is -N(Et)2, R4^ js Br. R— is H. R— is OMe. R— is H and R— is H: 33053 triazine claims 18-Apr-2005.doc -189- DM-6864 127871/6 a compound of Formula (50) wherein Rj is -NPr(c-Pr)) R4a js Me, R >4bD i ■s H u, R D4Cc i ·s Me, R ,4ad is H and Where underlined a compound of Formula (50) wherein R3 is -NHCFKCF OMe)?, R4^ js CN. R— is H. R— is OMe. R— specifically disclosed is H and R— is H; 23.7.97 a compound of Formula (50) wherein R3 is -N(c-Pr)(CH2CH2CN)5 R4A js Me, R4b is H, R4c is Me, R4d is H and R4e is H; 10 a compound of Formula (50) wherein R3 is -NHCH(CH20Me)2, R4a is Me, R4b is H, R4c is Br, R4d is H and R 4e a compound of Formula (50) wherein R3 is ->MCH(CH7QMe)(CH7CH70Me)_R a js Me> R4b jg H R— is Br. R4^ is H and R— is H: 15 a compound of Formula (50) wherein R3 is -NHCFKCF OMe)?, R4^ js Me. R— is H. R— is OMe. R— is Me and R— a compound of Formula (50) wherein R3 is -N(CH7CH7QMe)7, R4-3^ js Me. R— is H. R— is OMe. 20 is Me and R— is H; Where underlined a compound of Formula (50) wherein R3 is -NHCH(Et)2, R4^ js Me. R— is H. R— is OMe. R— is Me specifically dis4e closed and R: 23.7.97 25 a compound of Formula (50) wherein R3 is -N(Et)2, R4^ js Me. R— is H. R— is OMe. R— is Me and R^ is H; a compound of Formula (50) wherein R3 is -NHCH(CH20Me)2, R ^ js CI. R— is H. R— is Me. R— is H and R52 30 a compound of Formula (50) wherein R3 is -NHCH(Et)(CH70Me)i_R4a js CI. R— is H. R— is Me. R— is H and R— is H; a compound of Formula (50) wherein R3 is -N(CH2CH20Me)9, ^3- js CI. R— is H. R— is Me. R— is 35 H and R— is H; 33053 triazine claims 18-Apr-2005.doc -190- DM-6864 127871/6 Me. R4^ is H and R— R4^ is Me and R4^ is H and R^ is H; Where undera compound of Formula (50) wherein R3 is (S)-NHCHCH20Me)(CH CH?OMe_ 4a lined specificR^isClR^isHandR^ ally disclosed 23.7.97 a compound of Formula (50) wherein R3 is -NHCH(CH20Me)(CH?CH70Me) is Cl. R— is H and R— is H; 15 a compound of Formula (50) wherein R3 is -NHCH(Ef)2, R4^ js Me. R— is H. R— is Br. R— is H and R^isH: a compound of Formula (50) wherein R3 is -N(CH2CH20Me)2, R a is Me, R4b is H, R4c is Br, R c* is 20 4e H and R' Where underlined specific ally disMe. R4^ is H and R— closed 23.7.97 25 a compound of Formula (50) wherein R3 is -WCFbCtfrOMe)?, R4-3- }G MG R4b ig R R4c ig C) R4d ig H and R— is H; a compound of Formula (50) wherein R3 is -N(CH2CH20Me)2, R4a js Me, R4b is H, R4c is NMe2, R4d is H and R is H; 30 Where a compound of Formula (50) wherein R3 is -NHCWC^OMeYn-Pr)^4* js Me. R— is H. R— is Me. underlined R^isHandR4^ specifically disclosed 23.7.97 35 is H and R— is H: 33053 triazine claims 18-Apr-2005.doc -191- DM-6864 127871/6 R^ is NMe2. R— is H and R— is H: a compound of Formula (50) wherein R3 is -N(Ef)2. js Me. R^ is H. R— is CI. R— is H and R— is Hi a compound of Formula (50) wherein R3 is -NHCH(Et)2, R^ js Me. R— is H. R— is CI. R— is H and R— is H: 10 H and R— is H; a compound of Formula (50) wherein R3 is -NHCH(CH7QMe)2. R^ js Me. R— is H. R— is CI. R— is H and R^ 15 a compound of Formula (50) wherein R3 is -N(Et)2, R^ js Me. R— is H. R— is Br. R— is H and R— is Hi a compound of Formula (50) wherein R3 is -N(Ef)2, R^ js CI. R— is H. R— is Me. R^ is H and R— is 20 Hi Where underlined a compound of Formula (50) wherein R3 is -NHCH(Et)2, R^ is CI. R^ is H. R— is Me. R— is H and specifically disclosed 23.7.97 25 a compound of Formula (50) wherein R3 is -NHCH(Et)2. R^ js Me. R^ is H. R— is NMe2. R— is H and R^ is H: a compound of Formula (50) wherein R3 is (S -NHCH(CH20Me)(CH2CH20Me)j^a ig Me^ R4b jg R R^ is Me. R— is H and R— is H; 30 a compound of Formula (50) wherein R3 is -NHCWC^OMeyC^C^OMe^-ia. js Me. R— is H. R^ is Me. R^ is Ff and R— is H; a compound of Formula (50) wherein R3 is (S -NHCH(CH20Me)(CH2CH20 e)^4ajg^M^ R4b jg R 35 R^ is CI. R^ is H and R^ is H: 33053 triazine claims 18-Apr-2005.doc - 192- DM-6864 127871/6 R^is Cl.R^isHandR^ a compound of Formula (50 wherein R3 is -N(c-Pr)(CH2CH2CN R-ia is Me. R b jg H R4c {g ^ R4d is H and R— and 4e 10 a compound of Formula (50) wherein R3 is -N(Et)2. R^ js Me. R— is Me. R— is OMe. R— is H and R^isH: 15 R— is H and R— Where underlined specific ally disR^isHandR^ closed 23.7.97 20 a compound of Formula (50) wherein R3 is -NHCH(Ef)2. R^ js Me. R— is Me. R— is OMe. R— is H and R— is H: a compound of Formula (50) wherein R3 is -NKCFbc-Pr) (n-Pr R4J_ js Me. R— is H. R— is CI. R— i H and R^ 25 a compound of Formula (50) wherein R3 is -N(c-Pr) (CFbCFfoCN) R^3- js Me. R— is Me. R— is OMe. R^isHandR^ a compound of Formula (50) wherein R3 is -NHCH (Et^ R^ is CI. R— is H. R— is OMe. R— is H 30 andR 4e a compound of Formula (50) wherein R3 is -N(Et)2, R^ js CI. R— is H. R— is OMe. R— is H and R— is H: 35 a compound of Formula (50) wherein R3 is -WC bCtyOMe^ R^ js CI. R— is H. R— is OMe. R— is H and R— is H: 33053 triazine claims 18-Apr-2005.doc -193- DM-6864 127871/6 a compound of Formula (50) wherein R3 is -N(Et)2. R4^ is CI. R4^ is H, R4^ is CN. R4^ is H and R ^ is H. R4-^ is H and R4^ is H; Where underlined a compound of Formula (50) wherein R3 is -NHCFKCFbOFT^, R4^ js CI. R— is H. R— is CI. R— is H specifically disclosed and R 4 —e is H; and 23.7.97 a compound of Formula (50) wherein R3 is N(CH2CH20Me)2, R4a is Me, R4b is H, R4c is OMe, R4d 15 is H and R4e is H 39. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(n-Pr)2, R4a is CI, R4b is H, R4c is CI, R4d is H and R4e is H. A compound according to claim 38 of Formula (50) wherein R3 is -N(Et)(n-Bu), R4a is CI, R4'3 is H, R4c is CI, R4d is H and R4e is H. A compound according to claim 38 of Formula (50) wherein R3 is -N(n-Pr)(CH2cPr)5 R4a js ci, R4b is H, R4c is CI, R4d is H and R4e is H. 25 A compound according to claim 38 of Formula (50) wherein R3 is -N(CH2CH20Me)2, R4a is CI, R4b is H, R4c is CI, R4d is H and R4e is H. 43. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(Et)(n-Bu)5 R4a js ci, 30 R4b is H, R4c is CI, R4d is H and R4e is H. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(Et)(CH20Me) R4a is CI, R4b is H, R4c is CI, R4d is H and R4e is H. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(CH20Me)2, R4a CI. R4b is H. R4c is CI. R4d is H and R4e is H. 33053 triazine claims 18-Apr-2005.doc •194- DM-6864 127871/6 A compound according to claim 38 of Formula (50) wherein R3 is -N(Et)2s R4a is CI, R4b is H, R4c is CI, R4d is H and R4e is H. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(CH20Et)2 R4a i CI, R4b is H, R4c is CI, R4d is H and R4e is H. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(Et)2, R4a 1S CI, R4b is H, R4c is CI, R4d is H and R4e is H. 49. A compound according to claim 38 of Formula (50) wherein R3 is -N(Me)(Ph)) R4A s c\ R B H, R4C is CI, R4D is H and R4E is H. 50. A compound according to claim 38 of Formula (50) wherein R3 is -N(n-Pr)2, R4A is CI, R4B is H, R4C is CI, R4D is H and R4E is H. 51. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(Et)(n-Pr); R4& JS Q R4B is H, R4C is CI, R4D is H and R4E is H. 52. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(CH20Me)2, R4A is Me, R4B is H, R4C is Me, R4D is H and R4E is Me; 53. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(CH20Me)2; R4A is Me. R4b is H, R4c is Me, R4d is H and R4e is H. 54. A compound according to claim 38 of Formula (50) wherein R3 is -N(CH2CH20Me)2; R4a is Me, R4b is H, R4c is Me, R4d is H and R4e is H. 55. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(Et)(CH20Me); R4a is Me, R4b is H, R4c is Me, R4d is H and R4e is H. 56. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(Et)2, R4a js Me, R4b is H, R4c is Me, R4d is H and R4e is H. 57. A compound according to claim 38 of Formula (50) wherein R3 is -ΟΕΐ; R4a |s ci, R4b is H, R4c is CI, R4d is H and R4e is H. 33053 triazine claims 18-Apr-2005.doc - 195- DM-6864 127871/6 A compound according to claim 38 of Formula (50) wherein R3 is -N(Et)25 R4a is Me, R4 is H, R4c is Me, R4d is H and R4e is H. A compound according to claim 38 of Formula (50) wherein R? is -N(CH2CN)2, R4a is Me. R4b is H, R4c is Me, R4d is H and R4e is H. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(Me)(CH20Me)5 R4a is Me, R4b is H, R4c is Me, R4d is H and R4e is H. 61. A compound according to claim 38 of Formula (50) wherein is -OCH(Et)(CH20Me); 4a js Me, R4b is H, R4c is Me, R4d is H and R4e is H. 62. A compound according to claim 38 of Formula (50) wherein R? is -N(n-Pr)(CH2cPr)) R4a js ^e R4b is H, R4c is Me, R4d is H and R4e is H. 63. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(Me)(CH2N(Me)2); R4a is Me, R4b is H, R4c is Me, R4d is H and R4e is H. 64. A compound according to claim 38 of Formula (50) wherein R3 is -N(cPr)(CH2CH2CN)5 R4a js Me, R4b is H, R4c is Me, R4d is H and R4e is H. 65. A compound according to claim 38 of Formula (50) wherein R? is -N(n-Pr)(CH2CH2CN); R4a is Me, R4b is H, R4c is Me, R4d is H and R4e is H. 66. A compound according to claim 38 of Formula (50) wherein R? is -N(n-Bu)(CH2CH2CN); R4a is Me, R4b is H, R4c is Me, R4d is H and R4e is H. 67. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(Et)(CH20Me)5 R4a is Me, R4b is H, R4c is Me, R4d is H and R4e is Me. 68. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(Et)2, R4a js Me, R4b is H, R4c is Me, R4d is H and R4e is Me. 69. A compound according to claim 38 of Formula (50) wherein R3 is -NiCF^CFbOMe^, R4a is Me, R4b is H, R4c is Me, R4d is H and R4e is Me. 33053 triazine claims 18-Apr-2005.doc - 196- DM-6864 127871/6 70. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(CH20Me)2, R' is Br, R4b is H, R4c is OMe, R4d is H and R4e is H. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(Et)(CH20Me), R4a is Br, R4b is H, R4c is OMe, R4d is H and R4e is H. A compound according to claim 38 of Formula (50) wherein R3 is -N(Et)2, R a is Me, R4b is H, 3 Me, R4d is H and R4e is Me. 10 73. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(CH20Et)2 R4a is Me, R4b is H, R4c is Me, R4d is H and R4e is Me. A compound according to claim 38 of Formula (50) wherein R3 is morpholino^ R4A IS ]ν[6) R4^ is H, R4c is Me, R4d is H and R4e is H. A compound according to claim 38 of Formula (50) wherein R3 is -N(CH2CH20Me)2, R a is Br, R4b is H, R4c is OMe, R4d is H and R4e is H. Where 77. A compound according to claim 38 of Formula (50) wherein R3 is -NHCHfEf)2. R— is Br. R— underlined R4^ is OMe. R4^ is H and R^ specifically disclosed 23.7.97 A compound according to claim 38 of Formula (50) wherein R3 is -N(Ef)2, R— R4^ is OMe. R4^ is H and R4^ A compound according to claim 38 of Formula (50) wherein R3 is -NPr(c-Pr)) R a js Me, R4b 30 H, R4c is Me, R4d is H and R4e is H. Where underlined specificA compound according to claim 38 of Formula (50) wherein R3 is -NHC KCFbOMe)? R4-^ ally disclosed CN. R4^ is H. R4^ is OMe. R4^ is H and R4^ 23.7.97 A compound according to claim 38 of Formula (50) wherein R3 is -N(c-Pr)(CH2CH2CN) R4a Me, R4b is H. R4c is Me. R4d is H and R4e is H. 33053 triazine claims 18-Apr-2005.doc -197- DM-6864 127871/6 A compound according to claim 38 of Formula (50) wherein RJ is -NHCH(CH20Me)2; R' Me, R4b is H, R4c is Br, R4d is H and R4e is H. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(CH2QMe)(CH2CH90Me)_ 4a is Me, R is H. R— is Br. R4^ is H and is H. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(CH?OMe)2, R— Me. R4^ is H. R4^ is OMe, R4^ is Me and R4^ A compound according to claim 38 of Formula (50) wherein R3 is -WCFbCFbOMe)^ R-^ Me. R— is H. R— is OMe. R— is Me and R— A compound according to claim 38 of Formula (50) wherein R3 is - HCH(Et)? R^ js Me. R— is H, R— is OMe. R— is Me and R— is H. 87. A compound according to claim 38 of Formula (50) wherein R3 is -N(Et)2, R— is Me. R— is H. R— is OMe. R— is Me and R— is H. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(CH?OMe)9, R4_- js CI. R4^ is H. R4^ is Me. R4^ is H and R4^ is H. 89. A compound according to claim 38 is CI. R— is H. R— is Me. R— is H and R— is H. 90. A compound according to claim 38 of Formula (50) wherein R3 is -N(CH?CH7QMe)2, R^ is CI. R4^ is H. R^ is Me. R— Js H and R— is H. A compound according to claim 38 of Formula (50) wherein R is -NHCH(CH20Me)(CH2CH2OMe)_R4a is Cl. R4^ js H. R4^ is Me. R4^ is H and R4^ is H. A compound according to claim 38 Me. R— is H. R— is OMe. R— is Me and R— is H. A compound according to claim 38 of Formula (50) wherein RJ is -N(c-Pr)(CH?CH'?CN) R-i^ Cl. R— is H. R— is Cl. R— is H and R— is H. 33053 triazine claims 18-Apr-2005.doc •198- DM-6864 127871/6 94. A compound according to claim 38 of Formula (50) wherein R3 is fS -NHCHrCH 0Me)(CH2CH2QMe}^ 4a ig R4b ig R R4c jg R4d ig H and R4e jg R 95. A compound according to claim 38 of Formula (50) wherein R3 is Where -NHCHiCH 0MeyCH2CH90Me)_R4a js CI. is H. R^ is CI. R^ is H and R^ is H. underlined specifically dis96. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(Et)9,t R4-3- js Me. R— closed 23.7.97 is H. R— is Br. R— is H and R— is H. 10 97. A compound according to claim 38 of Formula (50) wherein R3 is -N(CH2CH20Me)2, R4a is Me, R4b is H, R4c is Br, R4d is H and R4e is H. Where under lined specificR4^ is Me. R4^ is H. R— is Me. is H and R— is H. ally disclosed 23.7.97 A compound according to claim 38 of Formula (50) wherein R3 is -N(CH2CH20Me)2) R4a is Me, R4b is H, R4c is CI, R4d is H and R4e is H. 20 100. A compound according to claim 38 of Formula (50) wherein R-3 is -N(CH2CH20Me)25 R4a js Where Me, R4b is H, R4c is NMe2, R d is H and R4e is H. underlined specifically dis101. A compound according to claim 38 of Formula (50) wherein R- is -NHCH(CH7QMe)(n-Pr^ closed 23.7.97 R4^ is Me. R4^ is H. R— is Me. R4^ is H and R4^ is H. 25 102. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(CH20Et)(Et) R4a j Me. R4b is H, R4c is Me, R4d is H and R4e is H. 103. A compound according to claim 38 of Formula (50) wherein RJ is 30 -NHCH(CH20Me)(CH2CH20Me), R4^ is Me. R4^ is H. is NMe2. R is H and R4^ is H. Where underlined specific104. A compound according to claim 38 of Formula (50) wherein R3 is -N(Et)2, R— is Me. R— is H. ally disclosed R4^ is CI. R4^ is H and R4^ is H. 23.7.97 35 105. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(Et)2, R— is Me. R— is H. R— is CI. R4-^ is H and R4^ is H. 33053 triazine claims 18-Apr-2005.doc ■199- DM-6864 127871/6 33053 triazine claims 18-Apr-2005.doc -200- DM-6864 127871/6 1 18. A compound according to claim 38 of Formula (50) wherein R3 is -N(Et)2, R— is Me, R— is Me, R— is OMe. R— is H and R— 1 19. A compound according to claim 38 of Formula (50) wherein R3 is -N(CHZCHZOMe)(CH2¾OH), R4a is Cl R4b is H R4c ig R4d ig H and R4e jg R 120. A compound according to claim 38 of Formula (50) wherein R3 is -WCH CFbOMe ?^ R-i^ js Me. R^ is Me. R^ is OMe. R^ is H and R^ is H. 10 121. A compound according to claim 38 of Formula (50) wherein R-> is -NHCH(Et)2, ^ is Me. R— is Me, R— is OMe. R— is H and R— is H. A compound according to claim 38 of Formula (50) wherein RJ is -NKCFbc-Pr) (n-Pr) ^ii 15 Me. R^ is H. ^ is Cl. R^ is H and R^ 123. A compound according to claim 38 Me. R— is Me. R— is OMe. R— is H and R— Where 124. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH (Et^J^ - js Cl. R— underlined R^ is OMe. R— is H and R— specifically disclosed 23.7.97 125. A compound according to claim 38 of Formula (50) wherein R3 is -N(Et)9^ R^ js Cl. R— is H. R^ is OMe, R^ is H and R^ is H. 25 126. A compound according to claim 38 of Formula (50) wherein R3 is -N(CH7CH7QMe)2, R^ js is H. R— is OMe. R^ is H and R^ 127. A compound according to claim 38 of Formula (50) wherein R3 is -NHCH(Et)(CH? OMe) R-^ 30 is Cl. R— is H. R— is OMe. R^ is H and R— is H. 128. A compound according to claim 38 of Formula (50) wherein RJ is -N(Ef)2, R— is Cl. R— is H. CN. R— is H and R— 35 129. A compound according to claim 38 of Formula (50) wherein R3 is -N(c-Pr)(CH?CH?CN) R-^ j? Cl. R^ is H, R^ is OMe. R^ is H and R^ 33053 triazine claims 18-Apr-2005.doc -201- 127871/5 Where underlined specific130. ' A compound according to claim 38 of Formula (50) wherein R3 is - HCHrCH70rD2. ~R_— js C ally disclosed R^ is Cl. R^ is H and R4^ 23.7.97 5 131. A compound according to claim 38 of Formula (50) wherein R^ is (CH2CH20Me)2, R4a is Me, R4b is H, R4c is OMe, R4d is H and R e is H. 132. . A compound of claim 3 land stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof,' and pharmaceutically acceptable salt or pro-drug forms thereof, wherein 10 said compound is 4-(bis-(2-methoxyethyl)amino)- 2,7-dimethyl- 8-(2-methyl- 4-methoxyphenyl)- pyrazolo-[ 1 ,5-a]-l ,3,5-triazine . 133. A compound of claim 31 and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof, wherein 15 said compound is 4-(¾is-(2-methoxyethyl)amino)- 2,7-dimethyl- 8-(2,5-dimethyl- 4-methoxyphenyl)- pyrazolo-[l,5-a]-l,3,5-triazine · 134. A pharmaceutical composition according to claim 9, wherein said compound of claim 5, or said stereoisomeric form, mixture of stereoisomeric forms, pharmaceutically acceptable salt or 20 pro-drug form thereof is a compound of claim 16 or a stereoisomeric form, mixture of stereoisomeric forms, pharmaceutically acceptable salt or pro-drug form thereof. 135. A pharmaceutical composition according to claim 9, wherein said compound of claim 5, or said \ stereoisomeric form, mixture of stereoisomeric forms, pharmaceutically acceptable salt or 25 pro-drug form thereof is a compound of claim 24 or a stereoisomeric form, mixture of stereoisomeric forms, pharmaceutically acceptable salt or pro-drug form thereof. 136. A pharmaceutical composition according to claim 9, wherein said compound of claim 5, or said ■ stereoisomeric form, mixture of stereoisomeric forms, pharmaceutically acceptable salt or 30 pro-drug form thereof is a compound of claim 38 or a stereoisomeric form, mixture of stereoisomeric forms, pharmaceutically acceptable salt or pro-drug form thereof. 137. A pharmaceutical composition according to claim 9, wherein said compound of claim 5, or said stereoisomeric form, mixture of stereoisomeric forms, pharmaceutically acceptable salt or 35 pro-drug form thereof is a compound of claim 132 or a stereoisomeric form, mixture of stereoisomeric forms, pharmaceutically acceptable salt or pro-drug form thereof. 127871/9 138. .A pharmaceutical composition according to claim 9, wherein said compound of claim 5, or said stereoisomeric form, mixture of stereoisomeric forms, pharmaceutically ; acceptable salt or pro-drug form thereof is a compound of claim 133 or a stereoisomeric form, mixture of stereoisomeric forms, pharmaceutically acceptable salt or pro-drug form thereof. 139. Use according to claim 1 of a compound according to claim 5 in the preparation of a medicament for treating a disorder the treatment of which can be effected or facilitated by , antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in a mammal, substantially as described in the specification. 140. Use according to claim 139 of a compound according to claim 5 in the preparation of a medicament, wherein said disorder the treatment of which can be effected or facilitated by antagonizing CRF is selected from the group consisting of affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis and hypoglycemia, substantially as described in the specification. 141. Use according to claim 1 of a compound according to claim 24 in the preparation of a medicament for treating a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in a mammal, substantially as described in the specification. 142. Use according to claim 141 of a compound according to claim 24 in the preparation of a medicament, wherein said disorder the treatment of which can be effected or facilitated by antagonizing CRF is selected from the group consisting of affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis and hypoglycemia, substantially as described in the specification. 143. Use according to claim J of a compound according to claim 38 in *· ptepmtioa o CAF, inc]i di¾ b* aol IlB>tBd to ifiordm ^ w by ^ fa g ^ * described in the specificatiorj. *\ »'»"y as 'i substantially as described in the specification. t I '145. Use according to claim ] of a compound accordin to claim 132 in the preparation of a 'medicament for treating & disorder tbe treatment of which can be effected or facilitated by antagoni¾ir)S CKF, including but not limited to disorders induced or facilitated by CRF, in a mammal, substantially as described in tbe specification. ; described in 148. Use according to claim 147 of a compound according to claim 133 in the preparation of a medicament, wherein said disorder the treatment of which can be effected or facilitated by antagonizing CRF is selected from the group consisting of affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis and hypoglycemia, substantially as described in the specification. 149. A compound of claim 32, and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof, wherein: Ar is phenyl substituted with three R4 substituents; R1 and R2 are methyl; R3 is NR^R7", R4 is independently selected at each occurrence from chloro, fluoro and OCH3; R7t is H. 150. A compound of claim 149, and stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof, wherein Ar is selected from the group consisting of 2-chloro-5-fluoro-3-methoxyphenyl, 2-chloro-5-fluoro-4-methoxyphenyl and 2-chloro-5-fluoro-6-methoxyphenyl. 151. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 9 or claim 150. 152. Use of a compound according to claim 149 or 150 in the preparation of a medicament for treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in a mammal, substantially as described in the specification. DM-6864 127871/2 153. Use of a compound according to any one of claims 5, 6, 7, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39-104, 132 or 133 in the preparation of a medicament, substantially as described in the specification. 33053 triazine claims 18-Apr-2005.doc -206-